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Abstract 
Introduction 
Painful cutaneous ulcers are a clinical challenge as the pain can be difficult to control, 
frequently requiring a combination of pharmacological and non-pharmacological measures. 
There is evidence suggesting topical opioid application might be efficacious in the 
management of painful cutaneous ulcers, however this is largely based on case reports.  
 
Methods 
A series of clinical and laboratory studies were undertaken to determine the utility of opioids 
applied topically to painful cutaneous ulcers, these included surveys of hospice admissions to 
determine the prevalence of painful ulcers and the effective dose of topical opioid; a 
randomised, double-blind, placebo-controlled crossover trial design to assess the utility of 
morphine/IntraSite gel mixture, HPLC analysis to determine the mixture’s bioavailability and 
physical stability, and microbiological studies to determine its microbiological stability.  
 
Results 
A survey of 323 hospice admissions over a two-year period identified 125 patients with 221 
ulcers, mostly caused by either pressure (183 ulcers) or trauma (25); 147 (67%) of all ulcers 
were painful. Compared to placebo, morphine/IntraSite mixture was more efficacious; it was 
safe and well tolerated in this population. Morphine applied topically appears to have an 
analgesic effect even at low doses of morphine irrespective of background analgesic 
medication. HPLC analyses suggested morphine and its metabolites might be detectable in the 
plasma of patients with large ulcers, but only at low concentrations. In addition 
morphine/IntraSite gel mixture was physically and, under certain storage conditions, 
microbiologically stable for 28 days allowing the mixture to be prepared and stored before 
use. 
 
Conclusions 
The studies confirmed that painful cutaneous ulcers are a significant clinical problem in 
hospice patients and that morphine/IntraSite mixture can be used safely and effectively in this 
patient group. Bioavailability studies support the possibility that the opioid analgesic effect is 
local rather than systemic, and stability studies show the morphine/IntraSite combination, 
once mixed, can be stored for up to 28 days, allowing the mixture to be prepared and stored 
before use. Given that ulcers can vary in aetiology, size, severity and temporal characteristics 
of pain, an individualised titration protocol is recommended. Further research is required to 
confirm and extend these findings to other ulcers and clinical settings. 
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Chapter 1: Introduction  
1.1 Cutaneous ulcer: scope of the problem 
Skin is the largest organ of the body covering, in an average adult, an area of 1.7m
2
 and 
weighing about 15% of the total body weight (Zaidi & Lanigan 2010). The skin consists of 
epidermis, the dermis, and beneath it the subcutaneous tissue [Figure 1.1].  
 
Figure 1.1 Diagram illustrating a cross section through normal skin (Faller & Scheunke 2004) 
 
 
The epidermis is a stratified squamous keratinized epithelium that in most areas of the body is 
0.1−0.2 mm thick, but on the palms of the hands and the soles of the feet, 0.8−1.5 mm thick. It 
consists of several cell types cells, about 95% are keratinocytes, and the other prominent cells 
are melanocytes, Langerhan cells, and Merkel cells. The epidermis does not have any blood 
vessels and obtains its nutrients via diffusion from the blood vessels of the dermis. The dermis 
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gives skin its resistance to tearing and its plasticity. It consists of a thick network of collagen 
and elastic fibres and contains blood vessels, lymphatics, nerve fibres, connective tissue cells, 
and immune cells. The subcutaneous tissue consists of loose, adipose connective tissue, which 
is subdivided by bands of connective tissue. It connects the skin with the superficial fascia 
covering the body and enables the skin to slide over it. Between the subcutaneous tissue and 
the skin runs a network of arteries and veins, which sends branches as far as the dermal 
papillae of the dermis (Faller & Schuenke 2004). 
 
In normal skin the epidermis and dermis exists in steady-state equilibrium, forming a 
protective barrier against the external environment. Once the protective barrier is broken, the 
complex and dynamic normal process of wound healing is set in motion to restore cellular 
structures and tissue layers. The process of healing can be divided into four phases: (i) 
coagulation and haemostasis; (ii) inflammation; (iii) proliferation; and (iv) wound remodelling 
with scar tissue formation (Velnar et al. 2009). However, the normal process of healing is 
susceptible to interruption or failure remaining in a prolonged inflammatory state 
characterised by elevated levels of pro-inflammatory cytokines, and abundant inflammatory 
cells (especially neutrophils and macrophages) which release high levels of reactive oxygen 
species (Wlaschek & Scharffetter-Kochanek 2005) and multiple classes of proteases (matrix 
metalloproteases, elastase, plasmin) (Trengove et al. 1999). Among the causes of impaired 
wound healing are malnutrition; impaired blood ﬂow and oxygen delivery; impaired 
inﬂammatory and immune responses; infection, wound separation, and foreign bodies; and 
age effects (Guo & Di Pietro 2010). 
 
A cutaneous wound signifies a break in the continuity of tissues covering the body that is 
usually associated with a loss of substance. Deeper injuries that involve the muscle tissue, the 
skeletal system or internal organs are defined as complicated wounds. Wounds are 
17 
distinguished into different types depending on their cause, depth and extent of the defect: 
mechanical or traumatic wounds, thermal and chemical wounds or ulcer wounds. 
 
A cutaneous ulcer is a breach in the epidermis or dermis resulting from trauma or pathological 
change that initiates a process of repair (Collins et al. 2002).  Cutaneous ulcers, which may be 
acute or chronic, are a heterogeneous group with different aetiologies [Table 1.1].   
  
Table 1.1 Categories of cutaneous ulcers 
Cause Examples 
Infections Bacterial, viral, fungal, protozoal 
Vascular Venous, arterial, vasculitis, lymphatic  
Neuropathic Diabetes, peripheral neuropathy 
Haematological Polycythaemia rubra vera, sickle cell anaemia 
Traumatic Burns, cold injury, pressure sore, radiation 
Neoplastic Basal or squamous cell carcinoma, melanoma, metastatic disease 
Others Sarcoidosis, tropical ulcer, pyoderma gangrenosum 
 
 
Risk factors for delayed healing are shown in Table 1.2 (European Wound Management 
Association 2004). Franks et al. (1995) identified ulcer size, ulcer pre-treatment duration and 
limb mobility as three major factors that can delay ulcer healing, the study also demonstrated 
an association between social factors (social class, central heating, being male and being 
single) and venous ulcer healing. Others have also discussed the influence that socio-economic 
factors, through an association with general health, nutritional status and adherence to 
treatment, may adversely affect healing rates (Vetter & Matthew 1999).  
 
In order to distinguish between the possible aetiologies a detailed clinical history should 
include information on the duration of ulcer, previous ulceration, history of trauma, family 
history of ulceration, ulcer characteristics (site, pain, odour and exudate or discharge), limb 
18 
 Table 1.2 Risk factors for delayed wound healing (European Wound Management Association 2004)  
Ulcer duration >6 months 
Ulcer size >10cm
2
 
Reduced mobility 
Severe pain 
Psychological factors 
Male gender 
Poor general health.  
 
 
temperature, underlying medical conditions (for example, diabetes mellitus, peripheral 
vascular disease, ischaemic heart disease, cerebrovascular accident, neuropathy, connective 
tissue diseases (such as rheumatoid arthritis), varicose veins, deep venous thrombosis, 
previous venous or arterial surgery, smoking, medications, and allergies to drugs and 
dressings. Some basic features of the wound should be documented [Table 1.3] and 
appropriate investigations including measurement of blood pressure, weight, and urinalysis 
should be carried out (Grey 2003a). 
 
 
Table 1.3 Elements of a comprehensive wound assessment (McManus 2007) 
Wound size 
Characteristics of wound edge 
Location of wound 
Wound base 
Presence of necrotic tissue, slough, and eschar 
Depth 
Condition of surrounding skin 
Infection 
Pain 
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Regular assessment of patients and their skin is key to maintaining skin integrity or reducing 
skin damage. The assessment and management objectives should be appropriate to the stage 
of the patient’s disease. Collier (2003) suggests four questions that can be helpful in the 
assessment process: 
• What is the aetiology and location of the wound?  
• How should the wound be graded using an objective grading tool?  
• Based on the wound grading, what is the primary treatment objective?  
• What regimen is required to achieve the identified treatment objectives? 
In patients with advanced disease it is desirable to have a comprehensive wound assessment 
tool that supports an individualised plan of care and is linked with quality of life outcome 
measures. 
 
1.2 Cutaneous ulcers in a palliative care setting 
The management of chronic wounds in a palliative care setting is a clinical challenge. A number 
of factors can impede the ability of patients with cancer to heal including the disease process 
itself, the timing and invasiveness of the palliative treatments including surgery, chemotherapy 
and radiotherapy, and patient’s nutritional status (Payne et al. 2008). 
 
In a study of 593 patients with advanced illness, 43 types of wounds were identified and 
grouped into nine categories: malignant, pressure ulcers, iatrogenic, traumatic, diabetic foot 
ulcers, venous leg ulcers, arterial ulcers/gangrene, infections/inflammatory lesions, and 
ostomy related (Maida et al. 2008); the commonest causes in a palliative care setting are as a 
result of trauma (e.g. pressure sores) and neoplasia (Tippett 2005). 
 
1.2.1 Pressure ulcers 
Pressure ulcers are localised areas of tissue destruction occurring when soft tissue is 
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compressed over bony prominences for prolonged periods of time [Figure 1.2]. The prevalence 
in the hospice population ranges from 13 to 47% and the wounds are usually painful unless the 
patient is paraplegic (Langemo 2006; McDonald & Lesage 2006). Pressure ulcers represent a 
major burden of sickness and reduced quality of life for patients and their carers. The financial 
costs to the National Health Service (NHS) are also substantial (Cullum et al. 1995) and it has 
been estimated that preventing and treating pressure ulcers in a 600-bed general hospital 
costs between £600,000 and £3 million a year (Touche Ross 1993); estimates of the cost of 
pressure ulceration to the NHS range from £180m to nearly £2bn a year (Grey et al. 2006b). 
The burden has been acknowledged recently in the Department of Health’s commitment to 
make a proportion of NHS providers’ income dependant on provision of quality and innovation 
through Commission of Quality and Innovation Framework, which for some hospital Trusts has 
included the development and management of pressure sores (NHS Institution for Innovation 
and Improvement 2009).  
 
Figure 1.2 Common sites of pressure ulceration in individuals at risk of ulceration (Grey et al. 2006b) 
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The four main factors implicated in the development of pressure sores are interface pressure, 
shear, friction, and moisture (Grey et al. 2006b). The wound may first present clinically with 
discolouration, tenderness, and changes in consistency or temperature compared to the 
surrounding skin (Fowler et al. 2008). Non-blanchable erythaema is early evidence of abnormal 
perfusion due to pressure-related injury or friction or shearing forces (Vanderwee et al. 
2007b). With deep tissue injury the skin may be purple or maroon, boggy or firm, and warmer 
or cooler than surrounding tissues [Figure 1.3 a, b, c & d]. The area may be painful and may 
develop blood- or serum-filled blisters. As damage evolves, the blister roof dries and an eschar 
develops, in time an open wound can develop of which there are different stages  [Table 1.4]. 
 
Painful pressure sores are a common problem affecting a large proportion of patients in a 
variety of healthcare settings including palliative care settings. The pain may result from 
persistent and recurrent pressure-related ischaemia, trauma, shear, friction and incontinence-
related skin irritation. Hatcliffe & Dawe (1996) undertook an audit of 151 patients in a UK 
hospice and found that 57 patients (37%) had pressure sores; 38 patients (25%) had one sore, 
6 (10%) had two, 8 (5%) had three and 1 (1%) had four. Galvin (2002) retrospectively audited 
pressure ulcer incidence in 542 patients admitted to a specialist palliative care unit over two 
years and found that 26.1% were admitted with pressure ulcers while 12.0% developed 
pressure damage during their stay. Tippett (2005) conducted a prevalence study of chronic 
wounds in over 400 US hospice patients and reported 35% had a skin wound of which pressure 
ulcers were the most common. Reifsnyder et al. (2004) and Reifsnyder & Magee (2005) 
reported retrospective reviews of 980 patients admitted to US hospices and found the 
prevalence of pressure ulcers was 26.9%. Vanderwee et al. (2007a) reported that in a survey of 
5947 patients in 25 hospitals in five European countries (Belgium, Italy, Portugal, UK and 
Sweden), 18.1% were found to have pressure ulcers of which only 9.7% received fully 
adequate preventive care. 
22 
Figure 1.3 Photographic examples of pressure ulcers 
 
a. Superficial pressure sore 
 
 
 
 
b. Pressure ulcer showing extent of undermining 
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 c. Sloughy pressure ulcer 
 
 
 
 
 
 
 
d. Necrotic pressure ulcer 
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 Table 1.4 Pressure ulcer classification (National Pressure Ulcer Advisory Panel 2007) 
Stage Definition Further description 
I Intact skin with non-blanchable redness of a 
localised area usually over a bony 
prominence. Darkly pigmented skin may not 
have visible blanching; its colour may differ 
from the surrounding area. 
The area may be painful, firm, soft, warmer or 
cooler as compared to adjacent tissue. 
Stage I may be difficult to detect in individuals 
with dark skin tones. May indicate “at risk” 
persons (a heralding sign of risk). 
 
II Partial thickness loss of dermis presenting as 
a shallow open ulcer with a red pink wound 
bed, without slough. May also present as an 
intact or open/ruptured serum filled blister. 
Presents as a shiny or dry shallow ulcer 
without slough or bruising. This stage should 
not be used to describe skin tears, tape burns, 
perineal dermatitis, maceration or excoriation. 
 
III Full thickness tissue loss. Subcutaneous fat 
may be visible but bone, tendon or muscle 
are not exposed. Slough may be present but 
does not obscure the depth of tissue loss. 
May include undermining and tunnelling. 
The depth of a stage III pressure ulcer varies by 
anatomical location. The bridge of the nose, 
ear, occiput and malleolus do not have 
subcutaneous tissue and stage III ulcers can be 
shallow. In contrast, areas of significant 
adiposity can develop extremely deep stage III 
pressure ulcers. Bone/tendon is not visible or 
directly palpable. 
 
IV Full thickness tissue loss with exposed bone, 
tendon or muscle. Slough or eschar may be 
present on some parts of the wound bed. 
Often include undermining and tunnelling. 
The depth of a stage IV pressure ulcer varies by 
anatomical location. The bridge of the nose, 
ear, occiput and malleolus do not have 
subcutaneous tissue and these ulcers can be 
shallow. Stage IV ulcers can extend into muscle 
and/or supporting structures (e.g., fascia, 
tendon or joint capsule) making osteomyelitis 
possible. Exposed bone/tendon is visible or 
directly palpable. 
25 
1.2.2 Malignant wounds 
Malignant ulcers may result from local or metastatic disease that occurs on, or just below, the 
skin surface [Figure 1.4 a & b]. The wound may be ulcerative or proliferative and may begin 
with a lesion that does not heal and progresses to become a hard mass fixed to underlying 
structures. The tumour develops its own blood supply, which it may outgrow, resulting in a 
central area of necrosis. After skin breakdown occurs, the colour may range from pink to red, 
violet, brown, or flesh-coloured. Growth may be rapid, with a cauliflower-like lesion or 
ulceration. The necrotic tissue becomes a medium for anaerobic bacteria to proliferate. 
Disrupted microcirculation and impaired coagulation predispose to local bleeding. Sinus tracts 
or fistulas can be associated with deeper wounds. (McDonald & Lasage 2006). 
 
Malignant wounds are most often associated with cancer of the breast, with an incidence 
ranging from 39% to 62%. The other common sites include head and neck, 24%-33.8%; back, 
trunk, or abdomen, 1%-3%; groin or axilla 3%-7.4%; genital, 3%-5.1%; and others, 3.7%-8% 
(Collier 1997; Wilkes et al. 2001; Naylor 2002). 
 
The quality of life of patients with malignant wounds is often severely negatively affected by 
the production of copious exudate (due to the destruction of lymph vessels and nodes), 
malodour (from the high bacterial growth), itching, the constant risk of haemorrhage (due to 
erosion of blood vessels) and pain (Benbow 2009). It is estimated that 5% to 10% of patients 
with advanced cancer will develop a fungating wound (Hasfield-Wolf & Rund 1997), many of 
which will be painful (Hasfield-Wolfe & Baxendale-Cox 1999). 
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Figure 1.4 Photographic examples of malignant ulcers. 
 
a. Fungating breast wound 
 
 
 
 
 
 
b. Squamous cell carcinoma of scalp 
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1.3 A palliative care approach 
The ideal method of providing pain relief is healing of the ulcer but in a palliative care setting 
this is often difficult in benign pressure ulcers and unlikely in malignant ulcers (Alvarez et al. 
2002; Brown 2003; Galvin 2002; Henoch & Gustafsson 2003; Lund-Nielsen et al. 2005). The 
potential for palliative care to improve wound healing and the quality of life for patients and 
families living with chronic wounds is now increasingly recognised (Schulz et al. 2002; Ferris et 
al. 2007; Chrisman 2010).  
 
Palliative care is an approach that improves the quality of life of patients and their families 
facing the problems associated with life-threatening illness, through the prevention and relief 
of suffering by means of early identification and impeccable assessment and treatment of pain 
and other problems, physical, psychosocial and spiritual (World Health Organization 2002). As 
the patient’s health status deteriorates the focus shifts to strategies that prioritise 
symptomatic relief and wound improvement ahead of wound healing (Alvarez et al. 2007); 
central to these palliative strategies is the use of pharmacotherapy. 
 
The palliative care approach encompasses a number of therapeutic interventions that aim to 
promote wound healing, control pain, manage infection, odour, bleeding, exudate, and 
maintain a good quality of life for the patient and caregiver (McDonald & Lesage 2006; Maida 
et al. 2009) [Table 1.5]. The focus in the remainder of this introduction will be on wound pain. 
 
1.3.1 Wound pain 
Chronic wound pain is multifaceted and the pathophysiological processes may involve either 
tissue or nerve injury, which generally speaking can generate two different pain states; 
nociceptive pain from the tissue damage creating the wound and neuropathic pain from 
damaged peripheral nerves at the site of the wound [Figure 1.5].  Nociceptive pain results from  
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Table 1.5 Problems arising from malignant wounds (McDonald & Lesage 2006) 
Problem Nature of impact 
Psychosocial • May include depression, anxiety, poor body image, low self-esteem, and inhibited 
sexuality or intimacy. 
• Bulky dressings can affect self-image and decrease mobility.  
• Patients can become isolated from family and friends because of disfigurement and 
odour. 
Pain • Usually depends on the location of the wound, the depth of tissue invasion and damage, 
the involvement of nerves, the presence of viable tissue with exposed nerve endings, and 
the person's previous experience with pain and analgesia. 
Exudate • Can vary in amount and originates from tumour secretions and increased leakage from 
blood vessels. 
Odour • Odour occurs when tissue is deprived of oxygen and nutrients, becoming necrotic with 
bacterial growth.  
• Organisms commonly causing odour include anaerobes and aerobes.  
• Odour can be a particular problem if the malignant ulcer is close to the bowel or the anus.  
• Odour can cause nausea and reduced appetite, resulting in weight loss and lethargy. 
Bleeding • Bleeding occurs because of abnormal microcirculation within the tumour, erosion of 
blood vessels by malignant cells, and decreased platelet function. 
Itch • Itch is different from the irritation caused by maceration and, although there may be no 
obvious cause, it is thought to be related to the growth of the tumour. Successful 
management can be difficult. 
 
 
normal function of the nervous system caused when a noxious stimulus activates Aδ-fibres and 
C-fibres in either the cutaneous or deep tissues. Nociceptive pain may have a sharp or dull 
quality, is well defined and clearly located. Neuropathic pain is initiated or caused by a primary 
lesion or dysfunction in the nervous system. Neuropathic pain may have continuous and/or 
paroxysmal components and may be associated with so-called positive (e.g. allodynia, 
hyperalgesia, dysaesthesia and paraesthesia) and negative symptoms (e.g. hypoaesthesia, 
anaesthesia, hypoalgesia, and analgesia) that occur spontaneously or in response external 
stimuli (Bennett 2006). In one study, more than 40% of patients with leg ulcers exhibited 
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neuropathic pain symptoms (Briggs et al. 2008).
Figure 1.5 The influences on pain by wound type (modified from Woo et al. 2008)
 
It is often accepted that 
wounds [Figure 1.3d], these are less painful than the more superficial wounds [Figures 1.3 a, b 
& c], however in patients with burns, areas of full thickness burns remained painful despite 
nerve destruction (Atchison et a
order to identify pain in each patient.
 
Pharmacotherapy is the cornerstone of cancer pain management, with the aim of providing 
the greatest pain relief possible
convenient mode of administration. The World Health Organization (WHO) analgesic ladder, 
 
when there is destruction of peripheral nociceptors in the deepest 
l. 1991), individualised assessment is therefore required in 
 
, with the fewest number of adverse effects
 
 
, using the most 
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first published in 1986, provides a simple framework for the pharmacological management of 
cancer pain using a logical stepwise approach (World Health Organization 1986). Presented in 
the form of a three-step ladder, the WHO method recommends a non-opioid for mild pain at 
step 1, an opioid for mild to moderate pain at step 2 and an opioid for moderate to severe 
pain at step 3; analgesia is delivered according to the severity of the pain and not the severity 
of the disease. Treatment "by the individual" is a fundamental principle of the WHO ladder as 
an individual patient's response to a particular analgesic is determined by several factors 
including pain severity, previous analgesia exposure, age of the patient, extent of the cancer, 
and concurrent disease [Figure 1.6].  
 
Wound-related pain is often difficult to manage, in part because it is often poorly responsive 
to opioids (Hanks 1991). Opioid responsiveness is the degree of analgesia achieved as the dose 
is titrated to an endpoint defined either by intolerable adverse effects or the occurrence of 
acceptable analgesia (Mercadante & Portenoy 2001). In wound-related pain this may result 
from several mechanisms including changing nociception associated with ulcer progression or 
the external trauma (e.g. shear forces) it undergoes, the presence of a neuropathic component 
to the pain requiring higher doses of systemic opioid to achieve acceptable analgesia and 
potentially resulting in greater toxicity, and the temporal pattern of the pain which has 
described as cyclic (periodic discomfort), non cyclic (single incident) and chronic (persistent 
discomfort) (Krasner 1995). Furthermore individual patients may have other reasons resulting 
in poor opioid responsiveness not directly related to the ulcer such as age, gender and ethic 
group and the production of opioid metabolites [Figure 1.6].  These factors suggest that 
wound-related pain requires a thorough assessment and that successful treatment of difficult 
wounds requires assessment of the entire patient and not just the wound, yet the evidence 
suggests it is poorly assessed, documented and researched (Duncan & Brooks 2009).  
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In the context of wound pain, analgesia has been administered both systemically and also 
topically to the wound. A systematic review of the literature failed to identify any randomised 
controlled studies to support the utility of systemic analgesia (Evans 
many cases management has focussed on locally applied measures. However the dressing 
changes themselves can be a cause of pain as highlighted in an international survey of 11 
countries (European Wound Management Association 2002). 
 
Figure 1.6 Factors influencing an
A number of dressings are available [Table 1.6] and ideally should offer non bulky comfort 
sized to the wound, gentle adherence, cost
minimisation of shear, friction and pressure, impermeability to bacteria
absorbency of excess exudate to prevent skin excoriation and ease of dressing use by patient 
or care-giver (Grocott 2007; McDonald & Lasage 2006; Reddy et al. 2003; Whitney et al. 2006; 
Robson et al. 2006). A systematic review of the evid
agents on quality of life, and symptoms that impact on quality of life, in people with fungating 
malignant wounds identified only two trials (63 people), one of which provided weak evidence 
that 6% miltefosine solution applied topically to superficial fungating breast lesions (smaller 
than 1 cm) in patients who have received either previous radiotherapy, surgery, hormonal
& Gray 
 
 individual patient’s response to an opioid (Dickman 2010)
-effectiveness, a moist wound healing environment, 
ence of the effects of dressings and topical 
2005), and in 
 
 
, long wear time, 
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 therapy or chemotherapy for their breast cancer, may slow disease progression (Adderley & 
Smith 2007). Furthermore dressing products that are designed to heal acute wounds may not 
have the same effect on chronic, non-healing wounds (Enoch & Price 2004). 
 
In some cases medication applied topically to the wound has been found to be beneficial. A 
systematic review identified six randomised controlled trials showing that 5% Eutectic Mixture 
of Local Anaesthetics (EMLA) lidocaine and prilocaine mixture versus placebo significantly 
reduced the pain intensity during and after sharp debridement of leg ulcers as determined by 
visual analogue scale (VAS) pain score (Briggs & Nelson 2010). Lidocaine patches applied to 
painful areas worn for a maximum of 12 hours daily have been reportedly effective (Evans & 
Gray 2005).   
 
Other analgesics have been applied topically to painful wounds. Ibuprofen, for example, has 
been incorporated into a foam dressing that in the presence of exudate is continuously 
released throughout the entire wear time. Positive results have been reported as case series 
(Flanagan et al. 2006) and crossover case series (Jorgensen et al. 2006) and in three 
randomised controlled studies (Gottrup et al. 2008; Romanelli et al. 2008; Palao i Domenech et 
al. 2008). However a Cochrane systematic review concluded there was no evidence, on the 
basis of two of the randomised trials, that foam dressings containing ibuprofen significantly 
reduce venous leg ulcer associated pain; the trial by Palao i Domenech et al. (2008) was 
published after the review. 
 
Topical anaesthetics such as lidocaine are occasionally used for pain associated with pressure 
ulcers but rarely for the pain associated with malignant skin ulcers. The complex nature of 
these wounds usually requires specialised dressings [Figure 1.6] making it difficult to apply 
anaesthetics directly to them; the same is true of commercially available topical NSAID 
34 
 formulations. This, together with the lack of evidence for these treatments, has led to an 
alternative approach. What dressing can be safely applied to a wide variety of wounds and 
what type of analgesic can be placed within it? 
 
Opioids have also been used in an effort to achieve localised pain relief. Although a recent 
review of topical analgesics included transdermal preparations of both fentanyl and 
buprenorphine as topical opioids, these formulations are applied topically for a systemic rather 
than a local effect (Moody 2010).  In contrast other studies have reported a localised effect. In 
one such study a mixture of 120 mg morphine in 80 grams of a moisturizing cream was applied 
topically for painful back conditions in 26 patients. From 1 mg to 3 mg was applied daily and 
treated with ultrasound to enhance penetration. Most patients (88%) noted up to 40% or 50% 
localized pain relief for four or more hours, and 19% reported relief lasting longer than a day 
(Tennant et al. 1993) However it is the direct application of an opioid directly onto an open 
wound that has gained most interest in an effort to provide local analgesia and minimise 
systemic adverse effects (Back & Finlay 1995; Krajnik et al. 1999). Topically applied morphine, 
for example, has been reported as providing rapid pain relief which lasted usually for seven to 
eight hours with no, or minimal, adverse effects (Krajnik et al. 1999). The theories on the 
possible mechanisms of actions are discussed further in Chapter 2. 
 
1.4 Summary 
Painful cutaneous ulcers as a result of trauma or malignancy are a frequent problem in a 
palliative care setting. They can be extremely debilitating leading to considerable patient 
suffering and morbidity. For some palliative care patients with wounds, treatment of the 
underlying condition will result in full or partial wound healing using best practice wound care. 
For those where chronic wounds persist, integrating the principles of palliative care that 
provide the patient the most comfort in controlling symptoms, such as pain may be beneficial. 
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 Chapter 2: The utility of opioid pharmacotherapy for 
painful cutaneous ulcers 
 
2.1 Discovery and development of opioid pharmacotherapy 
Comprehensive cancer care includes the effective management of pain where 
pharmacotherapy is the cornerstone of treatment, with the aim of providing the greatest pain 
relief possible with the fewest number of adverse effects using the most convenient mode of 
administration. An effective pain control strategy for an individual patient requires knowledge 
of the way in which the cancer, the cancer treatment and the pain therapy interact (Vascello & 
McQuillan 2006). Opioids are commonly used analgesics, in particular morphine (Klepstad et 
al. 2005). 
 
Morphine was first isolated from unripe seed pods of opium poppy, Papaver somniferum in 
1803 by a German pharmacologist Friedrich Sertürner who named it morphium after the 
Greek god of dreams, Morpheus. The opium poppy had been cultivated as early as 3400 BC in 
lower Mesopotamia where the Sumerians referred to it as “Gil,” (“happiness”) (Schiff 2002).  
The farming practice passed to the Assyrians and then the Babylonians who in turn passed 
their knowledge onto the Egyptians; ancient papyrus records reported the use of opium for 
pain relief (Breasted 1930).  
 
The structure of morphine was first determined in 1925 (Gulland & Robinson 1925) and the 
molecule eventually synthesised in 1952 (Gates & Tschudi 1952). Its rigid characteristics led to 
the theory that the analgesic effects are produced by interaction with specific receptors 
(Beckett & Casey 1954). In 1973 using radioactive morphine the drug was found to attach to 
very specific areas of the brain, dubbed “morphine receptors” (Pert & Snyder 1973; Simon et 
al. 1973; Terenius 1973) which triggered a search for the molecule that would endogenously 
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 stimulate that receptor, culminating in the discovery of “endogenous morphines” or 
“endorphins” (Hughes et al. 1975). The existence of multiple opioid receptors had been 
proposed (Portoghese 1965; Gilbert & Martin 1976; Martin et al. 1976) and subsequent 
pharmacological studies led to the classification of opioid binding sites into three receptor 
classes referred to as delta (δ), kappa (κ) and mu (μ) receptors each encoded by separate 
structural genes (Goldstein 1987; Pasternak 1993). The cloning of the opioid receptors and 
subsequent use of recombinant DNA technology has greatly advanced our understanding of 
their structure and function (Minami & Satoh 1995). 
 
Opioid receptors belong to the G-coupled receptor super family of transmembrane proteins 
that are present in both spinal and supra-spinal levels of the central nervous system. There are 
more than 20 types of G-protein and different receptors appear to interact preferentially with 
different types of G-protein (Gudermann et al. 1999). The receptors consist of an extracellular 
N-terminus, seven transmembrane helical twists, three extracellular and intracellular loops, 
and an intracellular C-terminus. The proteins are heterotrimeric consisting of α, β, and γ 
subunits that when activated triggers their immediate phosphorylation, exchanging its bound 
guanosine diphosphate (GDP) for a guanosine triphosphate (GTP), followed by uncoupling 
from intracellular G proteins and sequestration (Carman & Benovic 1998). Both the GTP bound 
α subunit and the combined βγ units can initiate steps in the signalling pathway.  
 
Opioid receptors are present in several regions of the central nervous system that are involved 
in nociception [Table 2.1].  Activation of any of the three opioid receptor subtypes from both 
endogenous and exogenous opioids produces common cellular actions including the inhibition 
of adenyl cyclase, activation of a potassium conductance, inhibition of calcium conductance, 
and an inhibition of transmitter release (Zöllner & Stein 2007). The pharmacodynamics 
response to an opioid depends upon the receptor to which it binds its affinity for that 
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 receptor, and whether the opioid is an agonist or an antagonist.  
 
Table 2.1 Opioid receptors, their ligands, locations, and responses mediated by them (Koneru et al. 
2009) 
Receptor Endogenous ligand CNS Location Response on activation 
μ Endorphins 
Endomorphins 
Brain (laminae III and IV of 
the cortex, thalamus, 
periaqueductal gray), spinal 
cord (substantia gelatinosa) 
μ1-supraspinal analgesia,  
μ2-Respiratory depression, miosis, 
euphoria, reduced gastrointestinal 
motility 
κ Dynorphin A Brain (hypothalamus, peri-
aqueductal gray, claustrum), 
spinal cord (substantia 
gelatinosa) 
Spinal analgesia, sedation, miosis, 
inhibition of antidiuretic hormone 
release 
δ Enkephalins Brain (pontine nucleus, 
amygdala, olfactory bulbs, 
deep cortex) 
Analgesia, euphoria 
 
Opioids may act on either presynaptic nerve terminals or postsynaptic neurones and produce 
their effects through reduced excitability of nerve terminals, attenuation of action potentials 
inhibition of excitatory neurotransmitters and increased transmission of the descending 
inhibitory pathways. Traditionally opioids have been considered to have a site of action in the 
central nervous system, however the analgesic actions of topical opioids were noted in the 
eighteen and nineteenth century. In 1774 William Herberden wrote that patients with 
haemorrhoids should ‘apply a mixture of a dram of the softened extract of opium mixture and 
any simple ointment for pain so excessive so as to require immediate effect (Heberden 1962). 
As the usual adverse effects were not observed, he speculated whether opium acted ‘as a 
topical anodyne’. In 1885 Wood documented that morphine elicited analgesia when 
administered topically to painful sites in the peripheral tissues (Wood 1885). Opioid receptors 
have now been demonstrated on peripheral nerves and lymphocytes (Fields et al. 1980; 
Hassan et al. 1992; Stein 1995; Stein et al. 1995; Zhou et al. 1998) suggesting that opioids may 
have additional peripheral analgesic effects. 
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All classes of opioid receptors have been demonstrated on peripheral nerve terminals, and are 
similar to the population of receptors found in the central nervous system (Stein 1995).  Opioid 
receptors are not obvious in normal tissue but become evident within minutes to hours after 
the start of inflammation. The expression and upregulation of opioid peptides and their pre-
cursors and processing enzymes has been demonstrated in both animals (Sitte et al. 2007) and 
humans (Mousa et al. 2007). Opioid receptor mRNA transcription is apparently upregulated by 
electrical neuronal activity in response to the nociceptive input from the inflamed tissue, as 
this effect can be abolished by a local anaesthetic nerve block (Puehler et al. 2004). Once 
upregulation occurs, opioid receptors are transported peripherally resulting in a higher density 
of opioid receptors at peripheral nerve terminals (Stein et al. 2003; Mousa et al. 2007); this 
stimulation results from the actions of cytokines and nerve growth factor from the inflamed 
tissue. 
 
In addition to dorsal root ganglia and peripheral sensory nerves, opioid receptors have been 
identified on lymphocytes, macrophages and mast cells (Antonijevic et al. 1995; Coggeshall et 
al. 1997); hence analgesia can be elicited by endogenous opioid peptides released from 
immune cells at the site of inflammation (Machelska et al., 2002; Stein et al. 1993). 
Inflammation rapidly stimulates immune cell extravasation and migration into injured tissues 
and in early inflammation; granulocytes (especially neutrophils) are the major opioid-
containing leukocytes, whereas in later stages of inflammation, monocytes or macrophages 
and lymphocytes predominate (Rittner et al. 2008; Stein et al. 2003). Opioid peptide is 
released from the immune cells upon stimulation with corticotropin-releasing factor, 
noradrenaline, tumour necrosis factor alpha, and interleukin-1beta and the immune cells 
return to the local lymph node depleted on peptide (Binder et al. 2004; Czlonkowski et al. 
1993; Sehgal et al. 2011).  
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 Figure 2.1 Endogenous opioid peptides are released by immune cells to reduce inflammatory pain. 
Adhesion molecules expressed on immune cells and inflamed endothelium coordinate the migration 
of circulating immune cells into inflamed tissue. The proinflammatory mediators corticotropin-
releasing factor (CRF) and interleukin-1β (IL-1β), as well as the sympathetic neurotransmitter, 
noradrenaline, stimulate immune cells to secrete their opioid peptides. These peptides activate opioid 
receptors located on the peripheral ends of sensory neurons and effectively reduce inflammatory 
pain. Immune cells, devoid of their opioid contents, then continue their passage to neighbouring 
lymph nodes. 
 
 
Reprinted from Therapeutics and Clinical Risk Management, Volume 1, Kapitzke D, Vetter I, Cabot PJ, 
Endogenous opioid analgesia in peripheral tissues and the clinical implications for pain control pp279-
297, 2005, with permission from Dove Medical Press Ltd 
 
 
The central and peripheral analgesic systems are not independent of one another and there is 
evidence, for example, that the migration of opioid-containing leukocytes into injured tissue 
can be modulated by central mechanisms. Schmitt et al. 2003 demonstrated that analgesic 
doses of intrathecally administered morphine decreased the number of β-endorphin  
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 containing leukocytes in inflamed rat paws. The finding was confirmed by Heurich et al. 2007 
administering epidural analgesia in patients undergoing surgery. It appears, therefore, that 
effective central inhibition of pain reduces the recruitment of opioid-containing cells to injured 
tissues suggesting at least two possible mechanisms (peripheral and central) to respond to 
pain resulting from peripheral injury. 
 
The confirmation that peripheral opioid receptors exist has led to the possibility of specific 
pharmacological targeting of them. The potential advantages of delivering opioids peripherally, 
for example by topical application, includes maximising opioid concentration at the site of 
pain, lower plasma levels with potentially fewer adverse effects and fewer drug interactions. 
Although targeting peripheral analgesics mechanisms may reduce the central adverse effects 
of systemic opioid analgesics, peripherally mediated side effects may remain problematic 
resulting from opioid receptor expression on peripheral nervous system neurons innervating 
peripheral organs such as skin and gastrointestinal tract (Bagnol et al. 1997; Fickel et al. 1997; 
Bigliardi-Qi et al. 2004; Holzer 2004). For example mu-opioid receptors have been found to be 
expressed in the gut from the stomach through to the distal colon where their function in 
thought to include control of visceral pain, regulation of transit time of luminal contents, and 
mucosal transport of fluids and electrolytes. The effect of opioid receptor agonists on gut 
motility and secretion has been utilized clinically in the symptomatic management of diarrhoea 
(Sun et al. 1997). Opioid receptor proteins have also been described in several non-neuronal 
tissues such as vascular and cardiac epithelia although the significance of this is unclear 
(Bildack 2000; Cadet et al. 2000; Mousa et al. 2001; Bigliardi-Qi et al. 2004). 
 
A number of studies have investigated the local analgesic effects of opioids in the clinical 
setting. Studies have examined buccal, dental, perineural, and regional intravenous 
administration, mostly in the postoperative setting and have produced conflicting results 
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 (Cerchietti et al. 2002; Dionne et al. 2001; Racz et al. 1991; Gustafsson et al. 1988); most 
studies have looked at intra-articular opioid administration (Kalso et al. 1997; Gupta et al. 
2001; Kalso et al. 2002). 
 
Kalso et al. (1997) systematically reviewed randomised controlled trials on intra-articular 
opioids and identified 36 studies in knee surgery. Six had both a local anaesthetic control and 
placebo and four showed internal sensitivity, all of which had at least one outcome showing 
efficacy of intra-articular morphine against placebo. Of the six studies comparing intra-articular 
morphine with intravenous or intramuscular morphine or with intra-articular saline without a 
bupivacaine control, four showed greater efficacy for intra-articular morphine; no dose-
response was evident. They concluded that intra-articular morphine might have some effect in 
reducing postoperative pain intensity and consumption of analgesics, although studies had 
significant problems in design, data collection, statistical analysis and reporting.  
 
Gupta et al. (2001) reviewed the literature and performed a meta-analysis of the peripheral 
effects of morphine injected intra-articularly to determine whether does morphine injected 
intra-articularly produced analgesia, was it a dose-dependent effect, and, if so, is the effect 
systemic or mediated via peripheral opioid receptors. Forty-five articles were identified in 
which the effects of morphine were studied in a prospective, randomized manner, and 32 
included a placebo control. Nineteen studies were suitable for meta-analysis that showed an 
improvement in analgesia after morphine compared with placebo, although studies with high 
quality scores showed somewhat smaller improvements. There was no effect on decreased 
analgesic consumption and no clear dose-response effect seen when VAS was used as a 
measure of pain, but it was seen when area under the curve was used as a measure of pain. A 
systemic effect of peripherally injected morphine was not possible to exclude because of the 
very limited data available.  
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 Kalso et al. (2002) identified 25 publications reporting on 28 RCTs in a systematic literature 
review. Twenty-seven comparisons of six different doses (1-10 mg) of intra-articular morphine 
vs. placebo, four comparisons on dose-response and three cross-route comparisons were 
included. Fifteen trials with placebo controls were considered sensitive at any time point, 
immediate (0-2 h), early (2-6 h) and late (6-30 h), whereas ten trials were negative for all 
periods. Ten out of the 12 trials that were sensitive for the late period indicated that intra-
articular morphine provided significantly superior long-term post-operative analgesia. Most 
positive studies had used higher doses (3-5 mg) compared with negative studies that had 
mainly used 1 mg. The two studies using Patient Controlled Analgesia consumption of 
morphine as the primary outcome also showed that intra-articular morphine was superior to 
intra-articular saline. The authors concluded that intra-articular morphine in a dose of 5 mg 
seems to provide relief of postoperative pain for up to 24 hours. 
 
In summary, some of the published studies examining intra-articular opioid administration 
have demonstrated opioid-specific long acting and locally specific analgesic effects, provided 
adequate doses are used. Effective doses were relatively low and produced plasma 
concentrations of opioid incapable of producing a systemic effect, hence adverse effects were 
uncommon. The effects were reversed by intra-articular naloxone. Those studies that failed to 
show an effect often demonstrated a lack of tissue inflammation. 
 
2.2 Topical opioids on cutaneous ulcers: previous studies 
The effects of opioids applied topically to painful cutaneous ulcers have been described in the 
palliative care setting. The aim of this systematic literature review was to identify the evidence 
for their clinical utility at the start of this research project. The review was later extended to 
included current studies in the discussion section of Chapter 5. 
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 2.2.1 Methods for literature review of use of topical opioids on cutaneous ulcers 
Published trials and case series that investigated the utility of topical opioids for painful 
cutaneous ulcers were included. All studies that compared topical opioid analgesics with 
placebo or other opioid analgesics, or both, or other active controls were considered 
regardless of whether single or multiple doses were administered. 
 
An electronic search using Medline, Embase, BNI, CINAHL, CancerLit and the Cochrane Library 
was performed to identify the literature on topical opioids for painful cutaneous ulcers. 
Additional articles were identified from the reference lists of the retrieved papers, relevant 
reviews, and selected journals. Articles published up until December 2001 was included.  
 
A detailed search strategy was developed for each electronic database searched based on the 
search strategy developed for Medline but revised appropriately for each database. The 
subject search used a combination of controlled vocabulary and free text terms based on the 
following search strategy for searching Medline: 
1. opioid or opiate or narcotic or analgesic or morphine or diamorphine or oxycodone or 
hydromorphone or methadone or fentanyl 
2. topical 
3. sore or ulcer or wound 
4. 1 and 2 and 3 
5. Limit 4 to human and adults  
The inclusion criteria for the systematic review were published studies containing primary data 
on the effectiveness of topical applications of opioids in the palliative care setting. To 
determine which regimens were the most effective and practical, evidence for each opioid was 
appraised individually. The primary outcome measure was pain relief and secondary outcome 
measures were time to onset of analgesia, duration of analgesia, and side effects, either local 
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 or systemic. The data collection form also included information on wound aetiology, study size, 
and design to identify which wounds might be most suitable for topical treatment; evidence 
for the impact of associated necrosis, inflammation, infection, and exudate also was sought.  
 
Data from all articles were extracted using a data collection form and the quality of individual 
studies was graded using levels of evidence recommended by the Centre for Evidence-Based 
Medicine and the Oxford Quality Score (Jadad et al. 1996) [Appendix 13.1]. 
 
2.2.2 Results of literature searches 
Electronic and hand searching identified 216 studies [Figure 2.2]. Most papers were excluded 
on reading the abstract because they were beyond the scope of the review (e.g. acute or 
experimental pain, volunteer subjects or children), were duplicates, contained insufficient data 
(e.g. conference abstract), or were review articles. 
 
After reading the abstracts, 12 papers were identified of which seven (recruiting a total of 25 
participants) met the inclusion criteria (Back & Finlay 1997; Krajnik & Zylicz 1997; Krajnik et al. 
1999; Twillman et al. 1999; Flock et al. 2000; Grocott 2000; Paul 2000) [Table 2.2]. Importantly 
all were case reports with no published randomised clinical trials. 
 
2.2.3 Summary of case reports and case series studying topical opioids on ulcers 
Back & Finlay (1995) described three patients with painful skin ulcers; two with pressure ulcers 
and one with a malignant skin ulcer. All patients were receiving systemic opioids (a daily oral 
morphine equivalent dose range of 30-1500 mg) and were given 10 mg of diamorphine added 
to IntraSite gel applied topically to the ulcer once daily. All patients reported being more 
comfortable after the first diamorphine gel application, and the benefit appeared to last 
throughout the day. One patient with a questionable response had the diamorphine omitted 
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 temporarily during which time she reported worse pain, and improved following the re-
introduction of treatment. Two patients were treated for less than a week because of 
deterioration in their general condition; one patient continued the treatment for two months. 
No local adverse effects were noted. 
 
Figure 2.2 Studies on topical opioids and painful ulcers identified in a systematic review of the 
literature (1965-2001) 
 
 
 
Krajnik & Zylicz (1997) described a 76-year-old woman suffering from a non-Hodgkin’s 
lymphoma who presented with a severe tense painful elevated cutaneous lesion in her scalp. 
Pain intensity was 5-7 on a 10-point numerical VAS, despite ibuprofen 400 mg taken three 
times daily.  Unlike Back & Finlay (1995) who chose diamorphine, the authors used 
!
Electronic searching 203 
CANCERLIT    92 
CINAHL    53 
COCHRANE    28 
EMBASE    14 
MEDLINE    12 
BNI       4 
Hand searching   13 
Retrieved for evaluation (n=12)!
Included in the review (n= 7)!
Papers excluded      5 
Review/no primary data      3 
Beyond scope of review      1 
Letter/no primary data      1  
Papers excluded  204 
Beyond scope of review  119 
Duplicates     65 
Abstracts/insufficient data   15 
Review/no primary data      5 
Case reports (n=7) Randomised controlled trials (n=0)
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0.08% morphine in hydrogel (4 g of gel, containing 3.2 mg of morphine), which was applied to 
100 cm
2
 of the scalp under occlusion.  VAS score decreased from 7 to 1 within two hours, 
before increasing back to 6 some 25.5 hours after application. The gel was applied daily for 
seven days with continuing benefit and no adverse effects were noted. Treatment was 
discontinued when the patient developed other pain syndromes and she died seven days later  
 
Krajnik et al. (1999) reported six cases where topically applied opioids were trialled. Three 
patients had cutaneous ulcers where either morphine or diamorphine was used probably 
reflecting the routine clinical practice of the respective authors. A 71-year-old woman with 
renal failure presented with painful necrotic leg ulcers approximately 480 cm
2
. Pain intensity 
was rated 8 using a numerical rating scale (NRS). The wound was dressed with 30-50 ml 0.08% 
morphine gel (24-40 mg morphine) and analgesia occurred after 20 minutes and lasted for up 
to eight hours when the dressing was changed; NRS decreased to 4. After two weeks pain 
intensity increased and the morphine dose increased to 0.16% (48–80 mg morphine per dose) 
and the dressing changed twice daily.  The wound improved with epithelialisation and 
decreased exudate and treatment continued for two months after which the wound 
deteriorated.  A 69-year-old man with carcinoma of the larynx presented with a left supra-
clavicular ulcer (over 6 cm
2
) and severe local pain described as severe burning and rated 9/10 
on the NRS. Morphine gel (0.08%) was applied daily to the ulcerated area. In the first day pain 
decreased to 3 on the NRS and remained controlled (2 or less) for 4 weeks until his death.  A 
62-year-old female with carcinoma of the vulva presented with a fungating right painful groin 
lesion NRS rated 6.  Diamorphine 10 mg mixed with IntraSite gel was applied into the wound 
cavity after which her pain score fell to 2. Dressings continued daily. After 10 days the wound 
appeared infected so the diamorphine was mixed with 1% silver sulphadiazine cream. Her pain 
remained under control for 4 weeks until she died, with pain scores consistently below 4. No 
adverse effects were reported in any of the cases. 
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Twillman et al. (1999) examined the use of either 0.1% or 0.15% weight-to-weight (w/w) 
concentration of morphine infused IntraSite gel in nine patients, eight of whom had open ulcers 
and one a swollen, inflamed bruised scrotum. Doses of morphine were applied directly to 
wounds, usually twice daily. Seven of the nine patients experienced substantial pain relief 
(reported either with verbal descriptors or using NRS), one patient experienced a lesser degree 
of analgesia and another patient without an open ulcer reported no pain relief; interestingly a 
patient with a subcutaneous infiltrate reported by Krajnik et al. (1999) but not described above 
experienced good pain relief despite no break in the skin. The use of morphine was well 
tolerated with no patients reporting systemic or local adverse effects; two patients were 
treated for over a year.  
 
Flock et al. (2000) reported the case of an 82-year-old lady with metastatic ovarian cancer who 
had pain from multiple leg ulcers (stage I-III) of varying sizes. The patient was receiving oral 
analgesics that were initially ineffective and an increased dose lead to systemic adverse 
effects. Like Back & Finlay (1995), the authors chose to use diamorphine gel (0.1% 
concentration w/w equivalent to 1 mg diamorphine/1 mL IntraSite gel) that was applied 
topically to the ulcers every 48 hours. The patient was pain-free within one hour of application 
and remained so for 48 hours until the next dressing change. Subsequently some of the ulcers 
became infected and the IntraSite gel was switched to metronidazole gel (0.1% w/w equivalent 
to 1 mg diamorphine/1 mL metronidazole gel [0.75%]). The patient remained pain-free and the 
leg ulcers started to heal. 
 
Grocott (2000) described a patient with an infiltrating carcinoma of the breast experiencing 
intense cutaneous stinging and irritation neither of which had improved with analgesics nor  
antihistamines. An area approximately 320 cm
2
 was treated daily with 10 mg of diamorphine in 
15 g IntraSite gel. Stinging and irritation were measured using a five point TELER indicators 
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scale for the dimensions of intensity and duration (where 0 is the deficit to be overcome and 4 
and 5 are treatment goals). The doses of diamorphine and hydrogel, together with the 
frequency of application, were titrated over a period of eight days until symptom relief was 
achieved using 40 mg diamorphine divided between two applications; a morning diamorphine 
dose mixed in 30 g of hydrogel and, as reported by Flock (2000) an evening diamorphine dose 
mixed in 30 g of topical metronidazole for odour management. 
 
Paul (2000) assessed four patients with painful malignant and non-malignant skin ulcers for 
pain relief, who then received gel containing fentanyl citrate (25 to 50 µg), applied topically 
once daily. VAS was recorded before and during the study period (range 5 -15 days). Systemic 
adverse effects, regular and rescue analgesia were recorded. All four patients reported a 
reduction in VAS, in two cases the pain was abolished and the need for oral rescue medication 
reduced. No systemic or local adverse effected were reported. 
 
2.3 Discussion 
The evidence for the efficacy of topical opioids identified from this systematic review is 
entirely based on case reports and limited by the small patient numbers. Furthermore, studies 
published in the literature are difficult to compare due to differences in methodologies. For 
example in the identified studies there were differences in the opioid used, the dose(s), the 
frequency of administration, the carrier vehicle, the evaluation of efficacy, safety and 
tolerability, the ulcer pathology and the duration of follow up. The case reports identified in 
the literature review may be confounded by selection and publication bias therefore the 
evidence provided would be considered weaker than that provided by case control studies and 
graded accordingly (Scottish Intercollegiate Guidelines Network 2008) [Appendix 13.2]. 
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Research in a palliative care population is not without its challenges. Recruitment to studies 
can be difficult (Rinck et al. 1997; Kaasa et al. 2006) and attrition rate high during the study 
due to progressive illness or death (McCorkle et al. 1989; Addington-Hall et al. 1992). Although 
a number of measures are available for the assessment of pain (Caraceni et al. 2002), palliative 
care patients may find them difficult to use, particularly if they are weak, debilitated or have 
cognitive impairment (Cohen et al. 1995), furthermore pain may vary during the course of the 
day (Zeppetella et al. 2000; Zeppetella et al. 2001) and the type, size, stage of the wounds and 
frequency of dressing change may all affect efficacy as could the wound’s underlying 
pathophysiology, the degree of inflammation and the perfusion of the tissue.  
 
In most reports topical opioids improved the pain of cutaneous ulcers in patients whose pain 
had previously been refractory to, or had experienced adverse effects from, systemic opioids. 
Most studies demonstrated efficacy by reduction in pain scores and in some cases it was 
possible to reduce or even stop concomitant systemic analgesia. In many cases pain reduction 
occurred quickly. Farley (2011) has described unpublished work suggesting that in-vitro 50% of 
the morphine can be released from the gel in two hours and a steady state achieved after four 
hours providing a possible explanation for the relatively quick onset of action. However as the 
studies identified in the literature review were not blinded it is not possible to exclude a 
placebo effect.  
 
The pain scores used in the identified studies include the NRS and VRS; some used both 
(Twillman et al. 1999) in others the description of numerical VAS makes the actual tool used 
unclear (Krajnik & Zylicz 1997). These measures have not been specifically validated for the 
assessment of wound pain. A five point TELER indicators scale for the dimensions of intensity 
and duration was reported in one study (Grocott 2000). TELER, an acronym for Treatment 
Evaluation by the LE Roux method provides a structure for documenting and reporting clinical 
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outcomes (Le Roux 1993), has been used for assessing malignant fungating wounds and the 
effectiveness of dressings (Grocott 1997). The tool was later updated and validated for use in 
symptom control as well as dressing performance (Grocott 2001). Other validated tools include 
the Toronto Symptom Assessment System for Wounds (Maida 2009). 
 
An arbitrary starting dose of opioid was chosen in the identified case studies and as with intra-
articular opioids, the effective dose of topically applied opioids appears to be relatively low 
(Kalso et al. 2002).  Patients described analgesia despite a wide range of systemic opioid doses. 
In one report a predetermined dose was efficacious in three patients despite a 50-fold 
difference in their daily equivalent systemic morphine dose (Back & Finlay 1995). In most cases 
the starting dose appeared to be effective and in only a few cases was titration required. It is 
possible that patients responding less favourably may have benefited from an increased dose 
of opioid. Further work should establish the role of dose titration and the frequency of 
administration.  
 
It is currently unknown which opioids are best suited to topical administration. Diamorphine, 
morphine and fentanyl were described in the identified studies [Table 2.2], each of which has 
different physicochemical properties that have important pharmacologic implications. Opioids 
are weak bases (pKa for morphine = 8.0, diamorphine = 7.6, and fentanyl = 8.4). In solution, 
they dissociate into ionised and unionised fractions, the relative proportions depend upon the 
pH of the solvent and their pKa. The unionised fraction is more diffusible than the ionised 
form; hence the local factors within the wound affecting pH may influence the efficacy of 
topically applied opioid.  
 
Morphine was used in three studies. The major metabolites of morphine are morphine-3-
glucuronide (M3G) and morphine-6-glucuronide (M6G) (McQuay et al. 1990). M3G does not 
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appear to contribute significantly to the analgesic effect of morphine, whereas the role of M6G 
remains uncertain; M6G administration to healthy volunteers has been shown to reduce pain 
initiated by a variety of noxious stimuli (Penson et al. 2000; Skarke et al. 2003; Romberg et al. 
2004) although a lack of analgesic activity has also been reported (Lötsch et al. 1997). The 
discrepancies between studies may be, partly, due to the range of doses of M6G used in these 
studies, with low doses of M6G being insufficient to induce analgesic effects. Morphine has 
relatively low lipid solubility, a property that could support locally mediated analgesic effect 
following topical administration; bioavailability studies could help confirm this. 
 
Diamorphine was used in three studies reported by centres in the United Kingdom (UK) (Back 
& Finlay1995; Flock et al. 2000; Grocott 2000) .  Although sometimes preferred over morphine 
because of its greater solubility, the rationale for using it for topical administration is 
debatable. There is some evidence of a novel mu-receptor with which diamorphine, but not 
morphine, interact (Rossi et al. 1996). Diamorphine is generally considered to be a pro-drug, 
which in vivo is rapidly de-acetylated to an active metabolite, 6-mono-acetylmorphine (6-
MAM) and then to morphine (Barrett et al. 1992). Furthermore diamorphine is more expensive 
than morphine and not commonly available outside the UK.  
 
Fentanyl was reported in one case study (Paul 2000). It is a synthetic phenylpiperidine 
derivative approximately 100 times more potent and approximately 500 times more lipid 
soluble than morphine; consequently it is rapidly and extensively distributed in the body 
(Shafer & Varvel 1991). The physical characteristic of fentanyl may permit it to cross into the 
systemic circulation following topical administration to a cutaneous ulcer. Bioavailability 
studies would be required to confirm this however the doses used were small (approximately 
systemic equivalent to between 2.5 and 5 mg oral morphine) compared to usual background 
medication taken by this patient group. 
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A number of carriers were used for delivering the opioids of which the hydrogels were the 
most common. IntraSite gel, like other hydrogels, is designed for debridement of necrotic 
tissue and indicated for use in shallow and deep open wounds e.g. pressure sores, leg ulcers, 
surgical and malignant wounds, partial thickness burns, scalds, lacerations and grazes, and also 
for the treatment of granulating cavity wounds (Vernon 2000). The choice of wound dressing 
depends on a number of factors including the wound characteristics, the treatment goals, 
patient/caregivers capabilities and the available resources. The ideal dressing removes excess 
exudate and debris, maintains moisture at wound/dressing interface, permits evaporation of 
excess fluid, eliminates dead space, remains separate from wound bed, minimizes pain and is 
cost effective. IntraSite, therefore, may not be appropriate for all wounds and some parts of 
the body may be difficult to treat under occlusive dressings.  Furthermore the application of 
gel is difficult to the open exudates wounds where much of the drug may be lost or diluted and 
flushed away by the wound fluid.  
 
The potential advantage of topical opioid administration is providing pain relief whilst 
minimising systemic adverse effects. Indeed one study described a patient who developed 
adverse effects with oral opioids but not with topical opioids, the latter also providing superior 
pain control (Flock et al. 2000). Topically applied drugs, however, have the potential to 
produce local adverse effects, either through the drug and/or the carrier. Few local adverse 
effects have been described with topically administered opioids, although itching and skin 
irritation may be associated with the debriding action of the IntraSite gel. Some patients have 
used the treatment safely over the course of many months, suggesting that this is a safe route 
to administer opioids.  
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The ideal method of providing pain relief is healing of the ulcer but this is difficult in benign 
pressure ulcers and unlikely in malignant ulcers. There are data from animal studies suggesting 
that topical opioid administration may impair wound healing by inhibiting the peripheral 
release of neuropeptides (Rook & McCarson 2007) and that the effects may be time-
dependent (Rook et al. 2008). There was no evidence of delayed wound healing in the 
identified studies indeed some commented specifically on wound healing and the potential for 
palliative care to improve wound healing and the quality of life for patients and families living 
with chronic wounds is now being recognised (Schulz et al. 2002; Ferris et al. 2007).  
 
There were no suggestions in the identified studies that patients exhibited signs of tolerance to 
topically administered opioid. Although the follow up periods in most studies were short, in 
two studies patients were followed up for two and 12 months respectively (Back & Finlay 
1997; Twillman et al. 1999), and no signs of tolerance were reported. Although it is generally 
accepted in a palliative care setting that tolerance with systemic opioids is not a significant 
clinical problem (Collin et al. 1993; Grond et al. 1996), there are experimental data suggesting 
tolerance occurs with topical opioids, although this can be reversed by N-methyl D-aspartate 
receptor antagonists (Kolesnikov & Pasternak 1999).  
 
Thus the evidence from this systematic review of previous studies on the use of topical opioids 
for painful ulcers is limited to only seven case studies recruiting a total of only 25 patients. 
Although these studies did suggest that topical opioid application might be a useful option in 
the management of painful skin ulcers there are many questions to address before this 
administration route can become routine medical practice. Such questions include which 
wounds are most likely to respond, which opioid, is preferred, at what dose, and at what 
dosing interval and which, if any, carrier should the opioid be mixed with. 
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Chapter 3: Aims of the Thesis 
There is currently a limited amount of evidence regarding the utility of opioids administered 
topically for the management of painful cutaneous ulcers. A systematic review of the literature 
revealed a few small case studies but they employ different methodologies, opioids, doses, 
administration intervals and carrier vehicles, the evidence is of limited use. Furthermore there 
were differences in the evaluation of efficacy, safety and tolerability of the opioid, the ulcer 
pathology and the duration of follow up for patients studied. Therefore randomised controlled 
trials are required to assess the utility of topically applied opioids for the management of 
painful cutaneous ulcers 
 
The potential benefits of delivering opioids peripherally by topical application include 
maximising opioid concentration at the site of pain, reducing plasma drug levels with 
potentially fewer adverse effects and fewer drug interactions. The presence of opioid 
receptors in the dorsal root ganglia, peripheral sensory nerves, lymphocytes, macrophages and 
mast cells in the presence of inflammation make this theoretically possible.  
 
The null hypothesis is that morphine applied topically to painful cutaneous ulcers does not 
have an analgesic effect. The aims of the research project were to address the hypothesis in 
the following way: 
• Describe the prevalence of the painful ulcers in a palliative care setting;  
• Investigate the efficacy, safety and tolerability of topically applied morphine to painful 
ulcers;  
• Determine the bioavailability of topically applied morphine; 
• Determine the physical and microbiological stability of topically applied morphine; 
• Make practical recommendations regarding the preparation, storage and use of opioids 
applied topically to painful cutaneous ulcers in a palliative care setting.
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Chapter 4: Prevalence of painful cutaneous ulcers in 
patients admitted to a hospice 
 
4.1 Introduction 
A variety of wounds have been identified in patients with advanced illness including malignant, 
pressure ulcers, iatrogenic, traumatic, diabetic foot ulcers, venous leg ulcers, arterial 
ulcers/gangrene, infections/inflammatory lesions, and ostomy related (Maida et al. 2008). 
Most wounds tend to affect the sickest patients, namely, those with advanced illness and 
multiple co-morbid factors.  Furthermore wounds may be associated with reduced life 
expectancy (Maida et al. 2009a). 
 
Risk assessment tools are available that can help identify vulnerable patients and plan their 
care, particularly for the management of pressure ulcers (Pancorbo-Hidalgo et al. 2006). One 
such tool is the Waterlow Score Card [Appendix 13.3] developed for use in all aspects of health 
care (Kottner et al. 2009). One side of the Waterlow Score Card illustrates the risk assessment 
scoring system and the reverse side provides guidance on nursing care, types of preventative 
aids associated with the three levels of risk status, wound assessment and dressings. The 
Waterlow Score Card is a routine part of our own clinical practice as is an assessment of the 
patient’s performance status, using the Eastern Co-operative Oncology Group classification 
(Oken et al. 1982) [Appendix 13.4], also considered to be a risk factor for wound development 
[Table 1.4]. 
 
Wounds are frequently associated with a number of clinical problems including pain, soreness 
and irritation from excoriated skin conditions, pruritus, odour, spontaneous bleeding and 
haemorrhage all of which would be considered in an assessment framework (Grocott 2001; 
Maida 2009). Other information that can have an impact on wound management includes age; 
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social and care environments; psychological perspectives; nutrition; medical diagnosis and 
associated disease processes; drug therapy and history of the wound, is usually also collected 
as part of the assessment process. 
 
Pain is one of the symptoms that patients find particularly distressing (Franks et al. 1994; 
Charles 1995; Price & Harding 1996) and has a negative impact on their quality of life (Price & 
Harding 2004). Pain is a clinical challenge as it can vary from one patient to another and within 
the same patient (Krasner 1995). It may have nociceptive, neuropathic or mixed 
pathophysiological features. Pain may be constant, transient or both; transient pain may have 
specific precipitants such as dressing changes. 
 
The management of pain in chronic wounds depends on comprehensive assessment, reporting 
and documenting patient experience of pain. Assessment should be based on six critical 
dimensions of the pain experience: location, duration, intensity, quality, onset and impact on 
activities of daily living (Price et al. 2007). Despite an increasing acknowledgement of the 
impact of wound pain the literature is limited, particularly in hospice patients. 
 
4.2 Aims of case review 
There are few data describing the characteristics of ulcers in patients admitted to hospices and 
thus the features of cutaneous ulcer-related pain that could then be addressed with topical 
application of opioid. The aim of this study was to describe the prevalence and characteristics 
of cutaneous ulcers in patients on admission to a hospice, with a particular emphasis on the 
presence and characteristics of the associated pain. 
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4.3 Methods 
The clinical notes of all patients admitted to a hospice inpatient unit over a two-year period 
(April 2008 until March 2010) were retrospectively reviewed. The hospice has an eight bedded 
in patient unit that serves approximately 250 000 residents in West Essex and East 
Hertfordshire. Referrals included both cancer patients and patients with advanced non-cancer 
disorders and were received from community health care professionals (e.g. general 
practitioners, district nurses, and clinical nurse specialists), hospital health care professionals 
(e.g. doctors, ward nurses, and clinical nurse specialists) or other hospice, hospital or 
community specialist palliative care services. 
 
The hospice uses multi-professional notes where entries are made by each member of the 
team. The notes have a number of sections dedicated to different aspects of the holistic 
assessment, including skin assessment and presence and characteristics of any identified 
ulcers. During the admission process the presence of ulcers is routinely assessed using the 
wound assessment chart [Figures 4.1 & 4.2]. When staff come into post they undertake 
mandatory training sessions, which includes training on the importance of the accurate 
completion of clinical notes, they then receive further training from a senior member of staff 
as their mentor. The clinical notes are periodically audited for Care Quality Commission 
purposes to ensure completeness and accuracy in all aspects of patient assessment and the 
results disseminated to staff as part of the hospice audit programme. 
 
Patients admitted during the two year time period were identified by IT staff using the hospice 
patient database (iCare) and administration staff then identified the location of the clinical 
notes. I then retrieved and reviewed all the identified clinical notes in order to review and 
record the relevant data. The data were collected using a data extraction form designed for 
the case review [Figure 4.3]; additional information regarding the patients’ analgesia was  
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Figure 4.1 Wound assessment chart within clinical record at St Clare Hospice describing each of the 
four ulcer stages 
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 Figure 4.2 Wound assessment collection form used as part of clinical record at St Clare Hospice
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 Figure 4.3 Ulcer prevalence survey: Data extraction form for patient number 27 identifying three 
painless grade 3 sacral pressure ulcers
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collected from the patient medication chart. To minimise omissions other sections of the 
clinical notes used during the admission process by either the nurses or the doctors were 
reviewed to cross check the information obtained from both the wound assessment and the 
medication charts. Missing data were noted during the collation process and identified during 
the analyses. Where results were analysed statistically non-parametric testing was used and a 
p value of > 0.05 was considered significant. 
 
Formal ethical approval was not sought, but the survey was agreed by the hospice clinical 
governance working group and the hospice Caldicott Guardian, a senior clinician within the 
Hospice responsible for protecting the confidentiality of patient and service-user information 
and enabling appropriate information-sharing (Department of Health 2010).  
 
4.4 Results 
During the study period 323 patients were admitted, of whom 163 (51%) were females. The 
average age of all patients admitted was 70 years (range 25-96) and the most common 
diagnoses were primary cancers of the lung in 54 patients (17%), colon 38 (12%), breast 25 
(8%) and pancreas 24 (7%).  The notes of all 323 patients were examined. In two patients 
where the presence of ulcers was documented in the notes no wound assessment chart was 
completed. In other notes some aspects of the assessment were either absent, incomplete or 
illegible and are identified in the relevant section of the results.  
 
In total, 125 patients (39% of all those surveyed) had cutaneous ulcers documented, the 
average age of this population was 72 years (range 26-93); 65 patients (52%) were male, and 
the most common diagnoses were primary cancers of the lung in 25 patients (18%), colon 11 
(9%), and oesophagus 10 (8%); 4 patients (6%) had advanced non-cancer disease. The median 
(mean ± SD) performance status of all patients surveyed was 2.0 (2.1 ± 1.1); for patients with 
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ulcers the value was 3.0 (3.1 ± 0.7) and those without ulcers 1.0 (1.4 ± 0.7). The median 
(mean ± SD) Waterlow score of all patients surveyed was 17 (17.2 ± 5.2); for patients with 
ulcers the value was 22 (20.7 ± 4.8) and those without ulcers 15 (14.9 ± 4.1). Both 
performance status and Waterlow Scores were significantly higher in the patients presenting 
with ulcers compared to patients without ulcers (z = -13.44, p < 0.001 and z = -8.86, p < 0.001 
respectively). The presence of co-morbidities was also higher in the ulcer group [Table 4.1], 
although this was not statistically significant (χ
2
 = 5.9, p = 0.12). Of the medications identified 
by the Waterlow Score as risk factor for pressure ulcers, corticosteroids and non-steroidal anti-
inflammatories (NSAIDs) were prescribed to a greater proportion of patients presenting with 
ulcers compared to patients without ulcers; this was not statistically significant (χ
2
 = 2.6, p = 
0.3).  
 
A total of 221 cutaneous ulcers were identified. The majority of ulcers were caused by 
pressure 183 (83%); other causes were trauma 25 (11%), malignancy 7 (3%) and vascular 6 
(3%). Most ulcer sites were sacral, 121 (55%); other sites included heel 28 (13%), elbow 24 
(11%) and leg 20 (9%). The average ulcer classification score [see Table 1.4] was 2 and the 
average surface area was 8.2 cm
2
 (range 1-112 cm
2
); malignant ulcers were generally larger in 
size that the other three ulcer aetiologies [Table 4.2].  
 
Not all assessments were fully completed, 39 ulcer classification data points were missing 
(pressure ulcers (32), trauma (6), vascular ulcers (1), malignant ulcers (1)), as were 30 pressure 
ulcers ulcer size data points. The missing data were removed from the denominator when 
calculating percentages [Table 4.2] 
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Table 4.1 Characteristics of patients admitted to a hospice according to whether or not they had 
cutaneous ulcers 
 Patients without ulcers Patients with ulcers 
Number of patients 198 125 
Male 95 65 
Female 97 60 
Average age (±SD) 68 (15) 72 (14) 
Average Performance status (±SD) 1.4 (0.7) 3.1 (0.8) 
Average Waterlow Score (±SD) 14.9 (4.1) 21.5 (4.8) 
Patients with co-morbidities (%)* 30 (15) 70 (56) 
• Diabetes 15 (8) 45 (36) 
• Peripheral vascular disease 12 (8) 19 (15) 
• Chronic infection 5 (3) 4 (3) 
• Incontinence 3 (2) 14 (11) 
Prescribed medication   
• Corticosteroid prescription 63 (32) 78 (62) 
• Cytotoxics 5 (3) 2 (2) 
• NSAIDs 29 (15) 43 (34) 
* Some patients presented with more than one co-morbidity 
 
 
Table 4.2 Duration and physical characteristics of ulcers identified in patients admitted to a hospice 
Ulcer aetiology Pressure Trauma Vascular Tumour 
Number of ulcers 183 25 7 6 
Length of time (weeks) (±SD) 2.4 (1.4) 1 (0.3) 4.4 (2.3) 8.7 (3.9) 
Mean ulcer grade score (±SD) 2.1 (1)* 1.4 (0.5)* 2 (0.8)* 2.3(1.5)* 
Mean ulcer area (cm
2
) (±SD) 7.4(6.6)* 2.4(3.1) 10(6.9) 51(34) 
Ulcer appearance (%)     
• Healthy 11(6) 5 (20) 1(14) 0 
• Epithelialisation 76 (42) 12(48) 0 0 
• Slough 51(28) 5(20) 2(29) 4(67) 
• Necrotic 45 (25) 3(12) 4(57) 2(33) 
Number of painful ulcers (%) 126(69) 11(44) 6(80) 4(67) 
* Values with missing data points 
 
Of the 221 cutaneous ulcers identified, 147 (in 83 patients) were associated with pain [Figure 
4.4]. Most painful ulcers, 126 (86%) were pressure sores, 11 (8%) were related to trauma, 6 
(4%) to tumour and 4 (3%) were vascular. There was some variation in the temporal features 
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of the pain associated with cutaneous ulcers, 116 ulcers (79%) were described by patients as 
having a background pain, 76 (52%) were associated with transient pain and 45 (31%) were 
associated with both background and transient pain. Twenty four patients were able to 
identify factors precipitating transient pain namely, dressing changes [13 patients (8%)], 
pressure [6 (3%)] and movement [5 (3%)]. Of the 147 painful ulcers, 125 (85%) were described 
as either severe or excruciatingly painful; transient pain was usually more severe than 
background pain [Figure 4.5]. 
 
Thirty seven patients presented with a total of 56 painless ulcers (including two patients with 
spinal cord compression where the resulting sensory deficit may have masked any pain 
resulting from the ulcer); eight patients had a mixture of painful (10) and painless (9) ulcers. 
Five patients (presenting with nine ulcers) were too unwell to report whether or not their 
ulcers were painful.   
 
Of the 83 patients with painful ulcers, seven (8%) were prescribed analgesia specifically for the 
pain namely oral paracetamol as required (1 patient), oral paracetamol prescribed regularly 
(1), oral morphine as required (4) and oral oxycodone as required (1). Three patients using 
morphine and the one using oxycodone described their efficacy as partially effective, the 
remainder found analgesia ineffective. 
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 Figure 4.4 Patients admitted to a hospice inpatient with and without cutaneous ulcers, and whether 
or not the identified ulcers were associated with pain
 
 
 
Figure 4.5 Verbal rating score (VRS) 
cutaneous ulcers reported by patients on admission to a hospice
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4.5 Discussion 
Chronic wounds usually occur as a result of local disorders of nutrition in the skin, caused by 
venous, arterial or neuropathic vascular damage or prolonged local pressure or radiation, they 
may also be a symptom of a systemic disease such as infection or malignancy. Almost 40% of 
patients admitted to the hospice had cutaneous ulcers, most of which were grade II pressure 
sores (i.e. partial thickness skin loss or damage involving dermis or epidermis) and their 
distribution was in keeping with the expected pattern namely in areas of bony prominence 
[Figure 1.3]. The average performance status of patients surveyed was 3 (i.e. capable of only 
limited self-care; confined to bed or chair for 50% or more of waking hours) and this together 
with a Waterlow score of 17 emphasises that patients admitted to the hospice were at a high 
risk of developing pressure sores.  
 
Most ulcers were painful and in the majority the severity was rated as either severe or 
excruciating. The variability of wound pain has been described elsewhere and three types 
identified: cyclic (periodic discomfort), non cyclic (single incident) and chronic (persistent 
discomfort) (Krasner 1995); the patients surveyed reported all three pain types.  In order to 
accurately determine the patient’s type of pain a comprehensive assessment is required that 
addresses not only background pain but also the transient exacerbations of pain that were 
more severe than background pain. The exacerbations of pain that occur in the presence of 
controlled background pain are commonly referred to as breakthrough pain (Davies et al. 
2009). Currently there are no validated clinical tools for the assessment of breakthrough pain 
and tools such as the Brief Pain Inventory that assess worst pain, least pain and average pain 
may be helpful (Cleeland 1993). A systematic review identified the McGill Pain Questionnaire, 
the Faces pain scales, and the visual analogue scale as potential tools (Pieper et al. 2009) 
however they do not capture all the elements of cancer pain experienced by the patient 
(Gorecki 2011).  
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The prevalence of malignant ulcers in this survey was 3% and lower than seen in other studies 
where a prevalence rate of approximately 15% has been reported (Maida et al. 2008b; Maida 
et al. 2009). Malignant wounds have been reported to be most prevalent in patients with 
breast cancer where prevalence rates between 30 and 40% have been reported (Lookingbill et 
al. 1993; Wilkes et al. 2001; Maida et al. 2009), although lower prevalence has been described 
(Stotter et al. 1991). Perhaps an explanation of the lower number of ulcers in this survey was 
that the number of patients presenting with breast cancer was only 8% of the survey sample. 
 
Malignant wounds may be classified into four principal classes: nodules and induration, 
fungating, malignant ulcers, and mixed (Maida et al. 2008a; Schultz 2005), in this survey two 
patients had fungating wounds and four had malignant ulcers. Pain is only one symptom 
complicating malignant wounds. For example Maida et al. (2009), found that in a series of 
patients with malignant wounds, most were associated with mass effect (i.e. reduced mobility 
of limbs and spine and difficulties with clothing experienced with fungating wounds), aesthetic 
distress, exudation, odour, pruritus, bleeding, and crusting. The assessment of pain is 
therefore only one element of the wound assessment that requires management, although 
some treatment modalities considered for other symptoms (e.g. radiotherapy and 
chemotherapy) may also improve pain. 
 
Pain from pressure sores has been reported to interfere with patients’ ability to undertake 
daily activities and particular movements, engage in and enjoy socialising; leads to anxiety, 
fatigue, decreased appetite; and contributes to emotional distress (Gorecki et al. 2009). 
Although many of the patients surveyed were experiencing pain from their ulcer, relatively few 
had been prescribed analgesia prior to admission.  Despite the availability of several guidelines 
for cancer pain management (Jacox et al. 1994; WHO 1996; Hanks et al. 2001; Cohen et al. 
2003; Scottish Intercollegiate Guidelines Network 2008), it is clear that many of the patients 
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surveyed did not have adequate pain relief. A systematic literature review of studies using the 
Pain Management Index (PMI) as a tool linking pain severity to intensity/strength of the 
analgesic therapy identified 26 studies within which 43% of cancer patients have a negative 
PMI score suggesting nearly one in two patients were undertreated (Deandrea et al. 2008).  
 
The reasons for under treatment of pain in cancer patients are varied and can relate to either 
the patient (e.g. wanting to be a “good” patient, reluctant to distract the clinician from treating 
the primary disease, may not want to recognise that their disease is progressing, fears of 
becoming addicted or tolerant to analgesics) or health care professionals (inadequate 
knowledge, poor pain assessment, anxiety about regulation of controlled substances, concerns 
about the adverse effects of analgesics and fear of patients becoming addicted or tolerant to 
analgesics) (Ward et al. 1993; Von Roenn et al. 1993), any of which may have played a role in 
the patients surveyed.  
 
The first documentation of wound care can be found in an ancient Egyptian papyrus of 1600 
BC, with a description of the removal of devitalised skin and pus following war injuries (Majuno 
1975). Although the literature on chronic wound management has evolved over the years the 
increased knowledge has not translated into everyday clinical practice. Despite being a key 
clinical indicator, wound pain has been traditionally neglected by health care providers with a 
lack of documentation and treatment. Woo et al. (2008) produced a set of 18 statements 
supported by a literature review that identified 170 articles that met the criteria of temporary 
and persistent wound pain and agreed by a group of experts [Table 4.3]. However producing a 
statement is a relatively simple process; the challenge is its implementation. 
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There may be some confusion of clinical roles when managing patients with chronic wounds 
(Bennett & Moody 1995). Doctors may feel their role is to focus specifically on the underlying 
disease; in the case of malignant wounds there may be a positive impact on pain whereas for 
pressure ulcers this is unlikely. Moreover doctors may consider the management of ulcers to 
be a specific nursing role, despite this the nurse will require the support and advice from 
doctors for prescribing dressings and analgesics. Ideally a group of clinicians, often multi-
professional, with knowledge and expertise of wound care management should be clinically 
responsible for patients. Perhaps greater availability and use of tissue viability clinical nurse 
specialists may help improve the care of patients with chronic wounds (Flanagan 2008). 
 
Table 4.3 Statements for the assessment and management of persistent (chronic) and total wound 
pain (Woo et al. 2008) 
1. Assume all chronic wounds are painful until the patient indicates otherwise 
a. Assess and study chronic wound pain on a regular basis 
b. The patient should be assessed with the same standardised tool at every assessment 
2. Wound pain occurs with activities of daily living, not only at dressing change 
3. Discuss with patients and caregivers the options for wound pain management based on assessment 
results 
4. Consider non pharmacological and pharmacological wound pain management options 
5. Increased wound pain requires reassessment of underlying conditions or aetiologies for treatable 
causes 
a. Increased wound pain may be an important clinical symptom of infection or inflammation 
6. Treat the cause and treat the wound pain with the patient’s active participation 
7. Wound pain often adversely affects activities of daily living and patient well-being; effective 
management may lead to improvement 
8. Prevent and/or minimise anticipatory and procedural wound pain by using appropriate pain 
management techniques 
9. An on-going therapeutic relationship between the inter-professional team and the patient is 
essential for wound pain management 
10. Communicate, educate and implement the wound pain management plan verbally and with 
documentation to he patients, caregivers and the inter-professional team 
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Case studies are descriptive studies usually conducted when little is known about a problem or 
little is known about the occurrence of a known problem (Costantini & Higginson 2007). Case 
studies, such as this retrospective case note review have the advantage of being practical and 
feasible to plan, they are inexpensive, have the ability to use existing records, allow study of 
rare occurrences, and are easier to assess conditions where there is a long latency between 
and exposure and disease. Case studies also have limitations as they rely on accuracy of 
written record or recall of individuals, there may be important data may not be available, and 
bias is difficult to control as there is no blinding or randomisation (Hess 2004), referral bias 
may also be an issue so that the patients surveyed represent those with more complicated 
disease and the findings may be unrepresentative of the population as a whole, as the survey 
does not contain control groups, Furthermore the survey does not take into account other 
methods of managing painful wounds such as dressings, special mattresses or other 
equipment. Hence this case note review is best suited at generating hypotheses that can then 
tested prospectively by other methods and not for establishing cause and effect. 
 
4.6 Summary 
This case note review showed that cutaneous ulcers were a common problem in patients 
admitted to our hospice. Most cutaneous ulcers were pressure ulcers that result from the poor 
general state of health of the patients admitted. The majority of ulcers identified in this survey 
were painful and different patterns of pain were described. Very few patients were prescribed 
analgesia and in those that were, most derived little benefit.
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Chapter 5: Efficacy, safety, and tolerability of opioids 
applied topically to painful cutaneous ulcers 
 
5.1 Introduction 
Cutaneous ulcers have a significant impact on patients in a palliative care setting and their 
management is often inadequate. Cutaneous ulcers may have a variety of causes including 
trauma, pressure, circulatory problems and malignancy; furthermore skin ulcers may become 
infected adding to the management challenge. Pain is one of the symptoms associated with 
cutaneous ulcers, however the evidence presented in Chapter 4 suggests that pain is poorly 
managed. Many patients are not prescribed analgesia and in the minority of patients that are 
it is either ineffective or results in systemic adverse effects. 
 
Topical application of drugs provides a direct, localised effect on a specific area of the skin. 
Topical medications can be delivered via a variety of formulations including creams, ointments, 
gels and lotions. Analgesics such as NSAIDs have been formulated for topical use and 
systematic reviews comparing trial of topical with oral NSAIDs have concluded they were 
equally efficacious (Moore et al. 1996). Importantly, topical application of NSAIDs is not 
associated with serious adverse effects, and therefore provides an effective method of pain 
relief without the gastrointestinal effects seen with the same drugs taken orally. 
 
The premise that opioids exert a local analgesic effect is based on the fact that opioid 
receptors have been found on peripheral nerves and inflamed tissue, and peripheral opioid 
injections for local analgesia, such as intra-articular morphine after knee surgery, have been 
found to be effective in several trials (Kalso et al. 2002).  Evidence from single case reports and 
case series suggests that topical opioids are beneficial in the management of pain associated 
with benign or malignant skin ulcers in palliative care patients (Chapter 2). Topical opioids can 
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be used as an adjunct to systemic analgesia and reduction or cessation of concomitant 
systemic analgesics may be possible. 
 
5.2 Aims of efficacy studies 
The aim of this study was to investigate the efficacy of topically applied morphine in hospice 
inpatients using a randomised, double blind, placebo controlled crossover study design. Two 
trials are reported a pilot study, to determine the feasibility of undertaking such study in a 
hospice inpatient population, and a subsequent larger study. Ethical approval for both studies 
was obtained from the local ethics committee [Appendix 13.5]. 
 
5.3 Pilot study: Methods 
Hospice inpatients were eligible for the study if they had a painful cutaneous ulcer that was 
neither infected nor covered by necrotic tissue and was suitable for once daily treatment with 
IntraSite gel. Patients had to be capable of completing numerical rating score (NRS), and were 
receiving a stable analgesic regimen for at least 48 hours prior to recruitment. For the purpose 
of the study, if the patient had ulcers on more than one site, only one site was chosen for 
topical opioid treatment.  
 
Following written informed consent and, using a table of random numbers, patients were 
randomly assigned to receive either morphine (1 mL morphine sulphate injection 10 mg/mL in 
8 g IntraSite gel) or placebo (water for injection 1 mL in 8 g IntraSite gel). The person obtaining 
consent was blinded to the randomisation sequence. Treatment was applied once daily (in the 
morning), after which the ulcer was covered with a Tegaderm dressing. Patients were treated 
for two days followed by a two-day washout period, after which they were crossed over to the 
alternative treatment. During the six-day study period, no changes were permitted in regularly 
scheduled analgesia; rescue analgesia was available for the patient to use when required. 
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Patients were asked to assess the analgesic effects of each treatment arm by completing an 
11-point NRS score (0 = no pain and 10 = unbearable pain) twice daily, the first score was at 
least two hours after the morning dressing, the second score in the afternoon/early evening. 
Patients and nursing staff also recorded any local or systemic adverse effects experienced or 
observed during the course of the study [see Appendix 13.6].  The average NRS scores for the 
treatment arms for each patient were compared using a Wilcoxon rank test for non-parametric 
data. A P value less than 0.05 was considered to indicate statistical significance. 
 
5.4 Results 
Five patients with advanced malignant disease were recruited for the pilot study and 
randomised to order of treatment. All patients had painful sacral pressure sores ranging in 
surface area from 4.5 to 14 cm
2
. Most patients were already using a regularly scheduled opioid 
for analgesia; one patient was using an oral NSAID. Patients rated their background pain in the 
24 hours immediately prior to starting the study as mild (2 patients), moderate (2) and severe 
(1) [Table 5.1]. 
* Average pain intensity over 24 hours prior to starting the trial 
 
 
Table 5.1 Characteristics of patients recruited to a pilot double blind placebo controlled cross over study 
Patient 1 2 3 4 5 
Sex Male Female Male Female Male 
Age 80 87 78 62 81 
Primary cancer Lung Pancreas Prostate Lung Mesothelioma 
Ulcer area (cm
2
) 4.5 8 7.5 8.25 14 
Stirling score 2 2.4 2.3 2.3 2.4 
Scheduled 
analgesia 
 
Oramorph 
2.5mg  
4 hourly 
MST Continus 
20mg  
12 hourly 
Diclofenac  
50 mg  
8 hourly 
MST Continus 
30mg  
12 hourly 
MST Continus 
30mg  
12 hourly 
Ulcer pain 
intensity* 
Moderate Mild Mild Moderate Severe 
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Table 5.2 Pilot double blind placebo controlled cross over study: Patient numerical rating score 
(NRS) following morphine* and placebo administered topically to painful ulcers and NRS during 
washout period  
Patient 1 2 3 4 5 
Placebo NRS scores      
Day 1 morning 2 1 3.5 5 8 
Day 1 afternoon 5 5 2.5 8 8 
Day 2 morning 2 5 3.5 0 7 
Day 2 afternoon 8 7 3.7 7 2.5 
Mean 4.25 4.50 3.30 5.0 6.38 
 
Washout NRS scores 
     
Day 1 morning 6 0 1 6 7 
Day 1 afternoon 6 5 1 2 4 
Day 2 morning 5 4 4.5 5 4 
Day 2 afternoon 4 8 4 5 5 
Mean 5.25 4.25 2.63 4.50 5.00 
 
Morphine NRS scores 
     
Day 1 morning 2 2 2.5 4 1 
Day 1 afternoon 0 0 1 8 2 
Day 2 morning 0 1 0.25 0 1 
Day 2 afternoon 0 2 0 1 1.5 
Mean 0.50 1.25 0.94 3.25 1.38 
*Patients #1 & 4 received placebo first, patients #2, 3 and 5 received morphine first. 
 
 
Patients completed NRS scores twice daily, in the morning and afternoon during each 
treatment arm and the washout period [Table 5.2]. One patient appeared to have difficulty 
highlighting specific numbers on the NRS with seven of the 12 scores were marked between 
two numbers [Appendix 13.6]. In these instances the value was determined by measuring the 
distance from the lower score and expressing the value as a percentage of the distance in 
between the two scores.  
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The NRS scores were highly variable particularly for the placebo arm and the washout period. 
The median (mean ± SD) NRS score for all patients during placebo, washout and morphine was 
5 (4.67 ± 2.55), 4.75 (4.33 ± 2.03) and 1 (1.46 ± 1.87) respectively. There was a statistically 
significant different between the NRS scores during the two treatment arms (p < 0.01) and the 
scores during opioid treatment and the washout period (p < 0.01). There was no difference 
between the placebo treatment arm and the washout period (p > 0.05).  
 
Some patients appeared to respond better than others. Patients 1 and 3, for example, were 
pain-free on day 2 of morphine treatment, which may imply that the treatment is effective but 
did not have an immediate onset. Patient 5, however, appeared to benefit from placebo, as 
NRS scores fell from 8 to 2.5 in the two-day period, whereas the NRS scores during morphine, 
although low, showed no improvement.  
 
During the trial period patients had their usual rescue medication to take, as they required. 
There was no difference in the patients’ use of rescue medication throughout the trial; the 
mean (± SD) number of daily rescue doses taken was 2.3 (1.4) during placebo, 2.0 (1.6) during 
morphine treatment and 2.1 (1.2) during the washout period (p > 0.1). 
 
Systemic adverse effects were monitored during the study. The number of patient reports (n), 
mean NRS ± SD for nausea during placebo phase was n = 8, 0.78 ± 1.88, washout n = 7, 0.79 ± 
1.13 and during morphine n = 6, 0.5 ± 0.83 and for drowsiness during placebo phase was n = 
13, 3.35 ± 3.04, washout n = 6, 2.75 ± 2.82 and during morphine n = 9, 2.71 ± 2.70. Although 
drowsiness occurred more frequently than nausea there was no difference in each of the 
symptoms during the three phases of the study (p > 0.1).  
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 Most patients reported local symptoms associated with the ulcer. Patients 2, 4, and 5 reported 
localised discomfort while treated with placebo but not with morphine, and patients 1 and 3 
noted itching, burning, and discomfort during t
None of the local adverse effects appeared specifically attributable to morphine. Patients 
reported discomfort, other than pain, on 19 occasions and most commonly during placebo 
treatment days [Figure 5.1]. Thirty s
frequently during placebo treatment when compared to morphine (
differences were found between morphine treatment and washout days 
and placebo treatment and wa
 
Figure 5.1 Local adverse effects reported by 
morphine phases of the pilot study
 
 
Patients were asked at the end of the six treatment 
least amount of pain. Three patients selected the days they were treated with morphine and 
two reported no difference across the six days treatment.
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reatment with both morphine and placebo. 
even symptoms were reported and these occurred more 
χ
2
 = 7.13, p = 0.07); no 
shout days (χ
2
 = 3.87, p = 0.28). 
the five patients during the placebo, washout and 
 
days which days they experienced the 
 
 
(χ
2
 = 2.8, p = 0.42) 
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5.5 Discussion 
This pilot study found that patients with painful pressure sores found morphine to be a more 
effective analgesic than placebo. Furthermore, morphine was generally well tolerated by 
patients, and although local reactions were described during the study, these were mild and 
probably not related to morphine. These findings are consistent with the positive results of 
previous case studies. 
 
Some patients appeared to respond better than others. Patients 1 and 3, for example, were 
pain-free on day 2 of morphine treatment, which may imply that the treatment is effective but 
did not have an immediate onset. Patient 5, however, appeared to benefit from placebo, as 
NRS scores fell from 8 to 2.5 in the 2-day period, whereas the NRS scores during morphine, 
although low, showed no improvement. 
 
NRS scores varied considerably during the course of the pilot study. Patient 3, for example, 
appeared pain-free in the morning of day 2 while on placebo, yet that afternoon was in severe 
pain. This is not totally unexpected as cancer pain intensity can vary during the course of the 
day (Zeppetella et al. 2000). Such variations may complicate assessment and measuring 
multiple NRS scores (worst pain, least pain, and average pain over the preceding 24 hours 
(Cleeland et al. 1994) may be necessary. The potential variation in pain intensity also 
underlines the potential value of a local treatment; as if pain spontaneously subsides systemic 
adverse effects would not be problematic. 
 
The data from the cancer pain literature suggest that NRS is an appropriate measure based on 
its intrinsic properties (Cepeda et al. 2003). The NRS is an example of a uni-dimensional pain 
measurement tool that is well validated in the cancer population and is also commonly used to 
measure pain relief (Caraceni et al. 2002; Hjermstad et al. 2011). Furthermore when compared 
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to the VAS, the NRS has a significantly higher discriminatory capability to distinguishing 
between background and pain exacerbations (Brunelli et al. 2010), which might be applicable 
for patients with pressure pain than occurs or worsens spontaneously, on movement or during 
dressing changes. However frail patient, such as those entered into the study, may fail to 
understand or see how to mark the intended number. Patient 3 for example appeared to mark 
a spot in between two numbers on seven of the 12 assessments, whereas patient 5 did it 
twice. This can cause some confusion and for the purpose of the pilot study the score was 
taken by measuring at what point the patient had marked between the two numbers; a verbal 
rating documented by staff may have proved more accurate (Bijur et al. 2003). 
 
None of the patients surveyed reported systemic adverse effects specifically related to 
morphine, including patient 3, who was opioid-naive. This finding could support a local mode 
of action. A pharmacokinetic evaluation measuring serum morphine and its metabolites 
following topical administration would be required to support a local mode of action. It was 
not possible to run this alongside the pilot study as most patient were taking oral opioids 
which would have made it difficult to distinguish the metabolites from systemic opioid and 
from opioid topically to the wound. 
 
Limited conclusions can be drawn from this pilot study, not only because of the small number 
of patients but also because a single dose was used. It is possible that patients responding less 
favourably may benefit from an increased dose of morphine. A dose titration study would be 
necessary to explore this further. Interestingly, patient 5 had the largest ulcer (three times 
larger than patient 1), and although one could assume that larger ulcers require higher 
analgesic doses, the actual situation is likely to be more complex and requires specific 
investigation. In order to explore these findings further a larger trial was undertaken. 
 
80 
  
5.6 Randomised double blind placebo controlled cross over study 
The pilot study suggested that patients with painful cutaneous ulcers found morphine applied 
topically to the ulcer was a more effective analgesic than placebo. These findings were 
consistent with the positive results from previous case reports. A larger study was therefore 
undertaken using similar methodology 
 
5.6.1 Randomised double blind placebo controlled cross over study: Methods 
This was a single centre randomised, double-blind, placebo-controlled crossover study 
comparing morphine sulphate and IntraSite verses placebo (water for injection) and IntraSite 
applied topically to painful skin ulcers undertaken in a 63-bedded UK hospice inpatient unit.  
 
Patients were eligible for the study if they had been an inpatient at the hospice for at least 48 
hours; were 18 or more years old; were able to give voluntary informed written consent; were 
able to complete a pain score diary; they had an expected prognosis of greater than two 
weeks; were on an analgesic regime that has been stable for at least 48 hours; and that the 
ulcer was painful in the area of skin ulceration, suitable for once daily treatment with IntraSite, 
had any infection treated before entering the study and any layers of necrotic tissue removed 
before the study.  If the patient has ulcers on more than one site, only one site was chosen and 
that site identified at the first assessment.   
 
Patients were ineligible for the study if they had a history of substance abuse; were confused 
or had a reduced level of consciousness, which in the opinion of the investigator could 
preclude participation in the trial; had a concomitant psychiatric disorder; there was a history 
of serious adverse events to strong opioid drugs in the past; there was a history of serious 
adverse events to IntraSite in the past; the maximum diameter of the painful ulcerated area 
greater than 20 cm (to exclude the potential of systemic absorption); the patient had 
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participated in any other clinical trial or research which would interfere with the current study; 
it was the opinion of ward staff attempts to recruit the patient into the study would cause 
undue distress to them or their carers; the patient was pregnant or breast feeding; there was 
clinically significant renal failure. 
 
For subjects satisfying the inclusion criteria and after giving written informed consent, a pre-
trial assessment will be completed which included, identifying the ulcer site; tracing the ulcer 
(this was repeated at the end of the study to determine whether or not there had been a 
change in the ulcer size); determining the ulcer’s aetiology; classification of the ulcer using the 
Stirling method; determining the Waterlow score; determining the patient’s ECOG 
performance status. 
 
Following assessment patients were randomly assigned, using a table of random numbers, to 
receive either morphine (1 mL morphine sulphate injection 10 mg/mL in 8 g IntraSite gel) or 
placebo (water for injection 1 mL in 8g IntraSite gel) topically to their ulcer. The ulcer was first 
exposed by removing the previous dressing and then thoroughly cleaned before either saline 
of morphine was applied to it. Following the procedure the ulcer was covered with a Tegaderm 
dressing. Patients were treated for two consecutive days with one treatment followed by a 
two-day washout period after which they were crossed over to the alternative treatment. 
During the washout period the ulcer was cleaned in the same way but only IntraSite gel was 
directly applied to the ulcer. During the six-day study period, no changes were permitted in 
regularly scheduled analgesia, but their usual rescue analgesia remained available.  
 
During the assessment patients were asked to verbally rate the pain from the ulcer over the 
previous 24 hours using an 11-point NRS (0 = no pain, 10 = worst pain possible) at start of the 
study (baseline) and then every day during the six-day study. Nurses were also asked to 
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identify whether the ulcer was painful whilst being dressed. Patients were asked to record 
adverse effects throughout the study by completing a NRS for common systemic adverse 
effects (or any others they experienced) and asked about local reactions. Nurses were also 
asked to identify local and systemic adverse effects. Patients were withdrawn from the study if 
a serious adverse experience occurred; the staff considered, for safety reasons, in the best 
interest of the subject that he/she be withdrawn; the patient withdrew his or her consent. The 
date and the reason for discontinuation were documented. 
 
Primary outcome was the change from baseline in average pain intensity for each of the two 
treatment periods. Secondary outcome measures included patient preference at the end of 
the trial for either the morphine or placebo treatment days and use of rescue medication 
during the different treatment periods. Sample size was not calculated beforehand, as there 
was insufficient data upon which to base the calculation, however the aim was to recruit fifty 
patients but the study terminated early for administrative reasons. In the analysis, patients 
withdrawing from the study following randomisation were included in an ‘intention-to-treat’ 
(ITT) analysis; ‘per protocol’ (PP) patient outcomes were also included as a comparison. 
Statistical analysis was made using two-tailed non-parametric paired or unpaired test as 
appropriate. A P value less than 0.05 was considered to indicate statistical significance. 
 
5.6.2 Results 
A total of 41 patients were screened between March 2002 and April 2003, of whom 21 were 
enrolled into the study and randomised to order of treatment [Figure 5.2]. The median (mean 
± SD) age of enrolled patients was 78 (77 ± 7), the median (mean ± SD) ECOG and Waterlow 
scores were 3 (3.24 ± 0.54) and 25 (25 ± 5) respectively; most were male [Table 5.3]. Most 
patients presented with pressure ulcers. The median (mean ± SD) for the ulcer surface area 
was 16.5 (10.2 ± 14) and the ulcer grade was 2.3 (2.6 ± 0.5). All but two patients were taking 
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opioids as regularly scheduled medication. The median (mean ± SD) daily morphine dose 
equivalent was 60mg (76.4 ± 57.5). Five patients did not complete the study (deterioration (3), 
protocol violation (2)) but are included in the intention to treat analysis. 
 
Figure 5.2 Study Disposition (CONSORT Diagram) 
 
A total of 109 assessments from a possible total of 126 were made during the course of the 
study. Of the assessments made, 37 (34%) were during morphine treatment days, 37 (34%) 
were during placebo treatment and 35 (32%) were during the washout phase.  
 
The NRS score for patients at pre-trial (baseline), during morphine, washout and placebo 
phases are shown in Table 5.4. All 21 patients randomised to order of treatment are included 
in the ITT analysis; the data for 16 patients who completed the study are also shown. The 
median, upper and lower quartiles, minimum and maximum NRS at baseline and during 
morphine, washout and placebo treatment periods for the ITT population is shown in Figure 
5.3. 
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Figure 5.3 Randomised double 
Median, upper and lower quartiles, minimum and maximum NRS at baseline and during morphine, 
washout and placebo treatment periods
 
The primary outcome NRS c
(baseline (n=11), washout day 2 (n=10)) was significant (Wilcoxon paired test, p = 0.0004); 
furthermore in 16 patients (71%) there was a 
change in NRS was 3.9 (2.9 ± 2.4) range +2 to 
 
 No significant difference was seen between the NRS for placebo day 1 and that of the 
preceding day (baseline = 10, washout day 2 = 11) (p = 0.36) and of these patients, 5 (24%) 
had a ≥ 2 point reduction in NRS; the (mean 
(0.3 ± 1.7) range +2 to -4.
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-7. 
± SD) change in NRS for the placebo group was 0 
 
 (n=21): 
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 The median (mean ± SD) NRS scores for all opioid treatment days and placebo treatment 
days were 3.0 (2.9 ± 1.9) and 5.0 (5.3 ± 2.1) respectively (Mann Whitney U-test, p < 0.0001). 
No significant difference was seen between the two consecutive days washout (Wilcoxon 
paired test p = 0.45), and placebo (p = 0.79); a trend towards significant improvement was 
seen on day 2 opioid treatment compared to day 1 (p = 0.07). 
 
For the ITT population a comparison of baseline and washout day 2 NRS using Wilcoxon 
paired test showed a significant difference (p = 0.04). Dividing the population between 
patients who started with either morphine or placebo showed a median (range) NRS for the 
morphine group at baseline of 7 (4-10) and washout day 2 of 6 (2-7) and comparison 
between the two p = 0.06, whereas for the placebo group the median (range) NRS was 6.5 (5 
-9), the paired washout day 2 was 6 (4-9) and the comparison between the two p = 0.4, 
suggesting that the washout for the morphine group may not have been complete.  
 
For the PP population a paired comparison between the groups showed a median (range) 
NRS for the morphine group (n = 9) at baseline of 6 (4-10) and washout day 2 of 7 (3-7) and 
comparison between the two p = 0.2, whereas for the placebo group (n = 7) the median 
(range) NRS was 6 (5 -9), the paired washout day 2 was 5 (4-9) and the comparison between 
the two p = 0.4 suggesting that washout day 2 could be used as a baseline for the second 
phase of the study as there was no difference this and the NRS at baseline for either group. 
An unpaired pre-washout comparison of morphine and placebo treatment arms from 
baseline was statistically significant to first time and second time points (Mann Whitney U 
Test p = 0.0001 and p = 0.0005 respectively), and for all observations combined (p = 0.0001). 
  
Most patients (69%) preferred the analgesia on morphine treated days to placebo treated 
days. There was no difference in the patients’ use of rescue medication during the two 
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 treatment arms, the mean (± SD) number of daily rescue doses taken were 1.9 (1.7) during 
placebo and 1.8 (1.5) during morphine and 2.1 (1.8) during the washout period. (p  > 0.1).  
During the trial period patients had their usual rescue medication to take, as they required. 
There was no difference in the patients’ use of rescue medication throughout the trial; the 
mean (± SD) number of daily rescue doses taken was 2.1 (1.1) during placebo, 2.3 (1.7) 
during morphine treatment and 2.3 (1.8) during the washout period (p > 0.1). 
 
Systemic adverse effects were monitored during the study. The number of patient reports 
(n), mean NRS ± SD for nausea during placebo phase was n = 14, 0.49 ± 0.69, washout n = 19, 
1.23 ± 1.80 and during morphine n = 16, 0.57 ± 0.77 and for drowsiness during placebo 
phase was n = 24, 1.27 ± 31.71, washout n = 18, 1.14 ± 1.91 and during morphine n = 21, 
1.11 ± 1.39. Although drowsiness was reported more common than nausea there was no 
difference in each of the symptoms during the three phases of the study (p > 0.1). 
 
Patients reported local symptoms associated with the ulcer on 174 occasions during the 
course of the study [Figure 5.4]. None of the local adverse effects appeared specifically 
attributable to morphine, adverse effects were reported more frequently, during placebo 
treatment when compared to morphine and of borderline statistically significant (χ
2
 = 7.7, p 
= 0.06); no significant differences were found between morphine treatment and washout 
days (χ
2
 = 2.68, p = 0.44) and placebo treatment and washout days (χ
2
 = 3.51, p = 0.32).  
 
During the course of the studies the nurses dressing the ulcers documented local and 
systemic adverse effects [Figure 5.5], as with patient reports, none of these specifically 
attributable to morphine and there was no difference comparing placebo to morphine 
treatment days (χ
2
 = 0.39, p = 0.94), morphine treatment and washout days (χ
2
 = 0.72, p = 
0.87) and placebo treatment and washout days (χ
2
 = 0.1, p = 0.99).  
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 Figure 5.4 Local adverse effects during the placebo, washout and morphine phases of the 
randomised controlled study 
Figure 5.5 Nurses reported dressing related pain, local reactions or systemic adverse during the 
placebo, washout and morphine phases of the randomised controlled study 
 
 
At the end of the study the median (mean ± SD) 
changed from the start of the study (z = 0.87, p = 0.38); there was no difference in the ulcer 
grade at the end compared to the start of the study. 
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 5.6.3 Discussion 
Like the pilot study, this study suggested that patients with painful pressure sores found 
morphine to be a more effective analgesic than placebo. Morphine 10 mg appeared 
effective across a wide range of background opioid dose, for example one patient was opioid 
naïve whereas another was taking the daily equivalent of 240 mg oral morphine.  It is 
possible that patients responding less favourably to topical opioids may have benefitted 
from an increased dose of morphine or more frequent applications during the course of the 
day. The same may also be true for ulcer size, for example patient 9 with an ulcer of 22.4 
cm
2
 demonstrated small differences in NRS scores and reported no preference between the 
different treatment days. However the ulcer sizes of patients reporting a preference for 
morphine (second study) varied almost tenfold (4.5-38 cm
2
).  
 
In order to preserve benefit of randomisation all randomised participants were included in 
the ITT analysis, which is widely recommended as the preferred analysis strategy because it 
avoids bias associated with non-random loss of participants (Hollis & Campbell 1999; 
Herman et al. 2009). Data were missing for five patients randomised to order of treatment 
but did not complete the study. To account for these missing outcomes the “last observation 
carried forward” was used, where missing values were replaced by the last known value 
before the patient dropped out of the study. Although a simple and widely used process, it 
has been suggested that this method can introduce bias (Molnar et al. 2008) and has been 
criticised as no allowance is made for the uncertainty of imputation (Ware 2003; Streiner 
2002; Lane 2008).  
 
Missing data could result in the ITT analysis underestimating the potential benefit of the 
treatment and other analyses, such as a PP analysis, may be considered and are therefore 
included in the results. Indeed the ITT analysis in this study appeared to show a carry over 
93 
 effect of morphine, and not placebo, to the washout days as relatively small NRS values 
were being carried forward to account for missing data; this was not seen in the PP analysis. 
Given the difficulties with assumptions made in the various analytical methods the CONSORT 
checklist has dropped the specific request for ITT analysis in favour of a clear description of 
exactly who was included in each analysis (Moher et al. 2010). 
 
Opioid receptors have been demonstrated in peripheral sensory nerves and are activated by 
either endogenous or exogenous opioids allowing the possibility to provide localised 
analgesia, avoiding systemic analgesia thus minimising systemic adverse effects. The 
distinction therefore is drawn between this local effect associated with topical application 
and the more widely recognised systemic analgesic effect associated with transdermal 
delivery of opioids such as fentanyl. No systemic adverse effects specifically attributable to 
morphine were reported, including three opioid naïve patients, supporting the possibility of 
a local mode of action. 
 
Morphine applied topically to painful ulcers was generally well tolerated by patients, 
although mild local reactions were described during the study. In this, and most other 
studies, the opioid has been mixed with IntraSite gel, a hydrogel designed for debridement 
of necrotic tissue and for wounds that are granulating and epithelialising. When in contact 
with the wound, IntraSite absorbs excess exudates and produces a moist environment at the 
surface of the wound. Although generally well tolerated, it is possible that the local 
symptoms described by patients in both studies were due to IntraSite gel (propylene glycol, 
is a potential irritant and sensitising agent), as the local reactions were reported during both 
morphine and placebo treated days. 
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 The pain from cutaneous ulcers is often complex with features of both nociceptive and 
neuropathic pain. In the past it was felt that neuropathic pain was non responsive to opioids 
(Amer & Meyerson 1988) and the concept of opioid-responsive and opioid-non-responsive 
pain were often equated with nociceptive and non-nociceptive pain (Hanks 1991; Hanks & 
Forbes 1997). The subsequent finding that both central and peripheral neuropathic pain can 
respond to opioids (Dellemijn 1990; Rowbotham et al. 2003), has led to the concept of 
opioid responsiveness, defined as the degree of analgesia obtained following the escalation 
of the dose to the point of analgesia or intolerable adverse effects (Portenoy et al. 1990). In 
some cases it appears that although the neuropathic pain is opioid responsive, systemic 
adverse effects limit titration to an effective dose (Eisenberg et al. 2006); topical 
administration of opioids avoids this potential systemic problem. 
 
The major advantage of the crossover design used in these studies was that it allowed within 
subject comparison between treatments (each subject serves as their own control) by 
removing the between subject variability from the comparison. The sample size was not 
calculated beforehand as we had insufficient data upon which to base the calculation. Using 
the data from the second study that indicated the change in pain score was normally 
distributed with a standard deviation 1.9, 12 subjects would be required to achieve a 90% 
power for detection of a clinically meaningful NRS difference of 2 at the 5% level of 
significance. As 16 patients were studied, the power was greater than 90%. 
 
There is a growing literature on the utility of opioids applied topically to painful cutaneous 
ulcers. Since undertaking the systematic review for this project (Chapter 2) an updated 
review using the same search strategy undertaken in September 2010 identified a further 14 
studies, eleven case reports (Ballas 2002; Abbas 2004; Ashfield 2005; Durán et al. 2005;  
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 Gallagher et al. 2005; Platzer et al. 2005; Porzio et al. 2005; Tran & Fancher 2007; Zeppetella et 
al. 2007; van Ingen et al. 2008, Barker 2009) and three randomised controlled trials (Flock 
2003; Vernassiere et al. 2005; Jansen et al. 2009) [Table 5.5], recruiting a total of 112 patients; 
a further 26 patients were recruited in the aforementioned efficacy studies. 
 
Flock (2003) recruited 13 hospice patients with grade II or III pressure ulcers that were 
randomly assigned to two randomised double blind treatment arms: three days of IntraSite gel 
followed by three days of diamorphine gel (a 0.1% w/w mixture of diamorphine in IntraSite 
gel), or vice versa, with two days washout period. Treatment was applied once daily and all 
pre-trial medication was continued. Ulcer pain was assessed before and one and 12 hours after 
gel application by nursing staff using a five point VRS (none, mild, moderate, severe or 
overwhelming); nurses checked local and systematic adverse effects once daily. 
 
Seven patients completed the study and pain scores improved significantly at one (p = 0.003) 
and at 12 hours (p = 0.005) after diamorphine gel application compared with baseline. Six 
patients each had improved pain scores both one and 12 hours after diamorphine gel 
application. Four were pain free after one hour and three after 12 hours. One patient 
experienced symptoms of opioid toxicity, including drowsiness, nightmare, hallucinations and 
myoclonus during the course of the study, however her dose of transdermal fentanyl had been 
increased the day before recruitment and symptoms resolved once the fentanyl dose was 
reduced. The study recruited similar patients and used similar methods to those employed in 
our studies although the opioid was different. Given the evidence that diamorphine degrades 
to morphine and 6-monoacetylmorphine, both of which may have contributed, in some part, 
to the analgesia.  
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 Not all randomised trials have reported positive results. Vernassiere et al. (2005) recruited 26 
patients with painful chronic skin ulcers ≤ 150 cm
2
 to a controlled double-blind randomised 
study. Patients received either 10 mg of morphine hydrochloride or water mixed with 15 g of 
IntraSite gel at a fixed time daily for five days. Pain was assessed using NRS before, 
immediately after, one hour and 12 hours after treatment. All patients received opioids for 
mild to moderate pain and had access to rescue treatment. During the five days of treatment 
there was no statistically significant difference between the two groups’ assessment of pain 
relief: patients on the morphine group assessed the overall analgesic efficacy at 5.5 over five 
days, versus 5.6 for patients in the placebo group. Systemic tolerance was noted to be good. 
Although the opioid and hydrogel were similar to that used in our study the methodology was 
different, including randomisation, opioid administration method and assessments. 
Furthermore there was a significant difference in the pre-treatment pain scores in the two 
treatment arms (p = 0.03). The two groups were treated separately without cross over and the 
final morphine group included nine patients whereas the placebo group had five patients; the 
process of randomisation was also unclear. The concentration of morphine tested was half 
that used in our pilot and extended studies. 
 
Jansen et al. (2009) reported a in a double-blind, placebo-controlled, three-way crossover pilot 
study involving nine patients to assess the efficacy of topically applied 0.5% morphine in 
hydrogel for painful arterial leg ulcers. All patients had a baseline NRS of at least 5. The three 
treatments randomised on three consecutive days were morphine hydrogel plus a 
subcutaneous placebo infusion, placebo gel plus a subcutaneous infusion of 5 mg morphine 
over six hours and a placebo gel plus a subcutaneous placebo infusion. Each treatment lasted 
one day and pain was assessed during the first 24 hours after application of the hydrogel and 
the start of the subcutaneous infusion. There was a statistically significant difference between 
average baseline pain scores and those reported during treatment, but this difference was not 
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 clinically significant. The three treatments did not differ in terms of the pain relief provided 
suggesting that topical application of morphine does not have a clinically relevant analgesic 
effect in patients with painful arterial leg ulcers.  
 
The available data suffer from limitations common in palliative care studies namely small 
patient numbers and high attrition rates, the latter often due to the unpredictable nature of 
malignant disease and poor estimates of life expectancy (McWhinney et al. 1994; Kinzbrunner 
et al. 1995; Rinck et al. 1997; Smeenk et al. 1998). The patients recruited to our study were 
generally elderly (average age 77) and had poor performance status (average ECOG 3.1 i.e. 
capable of only limited self-care, confined to bed or chair for more than 50% of waking hours) 
and were therefore typical of many hospice admissions. Other challenges include patient 
vulnerability, obtaining informed consent, conflict between research and clinical roles and 
difficulties faced by patients in evaluating the risks and benefits of research and in particular 
the burden of research upon the participant. Not all these problems are unique to palliative 
care and have been successfully addressed in other areas of medical research (Cassarett & 
Karlawish 2000). 
 
5.6.3.1 Other reports of topical opioid application to cutaneous wounds 
In addition to the chronic wounds identified in the systematic review, morphine has been 
applied to chronic venous ulcers, and acute wounds including burns, oral mucositis, the pain of 
photodynamic therapy, and in children with epidermolysis bullosa; results have been variable. 
 
Venous leg ulcers affect 1% in the adult population and up to 5% in the population over 65 
years of age (Gottrup & Karlsmark 2005). When they become painful, venous ulcers often limit 
patient mobility and simple daily activities, furthermore dressings and dressing changes can 
further increase discomfort. A randomised, placebo-controlled, crossover pilot study (Bastami 
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 et al. 2011) where 21 patients were randomly assigned to receive either morphine or placebo, 
failed to show an overall statistically significant difference between the two groups. In a 
systematic literature review of randomised controlled trials evaluating locally applied therapies 
to relieve venous leg ulcer pain (Briggs & Nelson 2010), although one study had been identified 
(Vernassiere et al. 2005), also identified in the review included in this chapter, it included 
people with both leg and pressure ulcers and could not therefore be included; no other studies 
were found to support the use of topically applied opioids for either background or dressing 
related pain. 
 
The pain from burns is one of the most distressing symptoms and yet difficult to manage. 
Common treatment options include oral or parenteral opioid although topical opioid have also 
been tried. In a double-blind, placebo-controlled study with four patients morphine-infused 
silver sulfadiazine cream reported lower average (range) pain ratings than placebo, 2.1 (0-7) 
vs. 5.6 (2-8) compared to placebo (p = 0.001), and had a lower average oral morphine 
consumption per half day, 42.9 mg vs. 55.3 mg (p = 0.07).  In a separate placebo-controlled 
three-treatment randomised controlled trial, 59 patients were randomly allocated to receive a 
dressing containing IntraSite gel and morphine sulphate, IntraSite gel and water or the 
conventional Jelonet dressing (Welling 2007). No significant differences were observed 
between the pain scores or comfort ratings of the three treatments.  
 
Oral mucositis is one of the most common and debilitating adverse effects of radiotherapy 
and/or chemotherapy and despite many treatment strategies, no gold standard exists 
(Clarkson et al 2010). In a two-phase study, 10 patients were first randomized to receive 15 ml 
of either 1‰ or 2‰ morphine solution followed by an efficacy an open safety phase with 22 
patients; in addition morphine serum concentrations were measured in five patients. The first 
phase suggested a dose-response relationship for topical morphine as 2‰ morphine solution 
101 
 showed better pain relief than those with 1‰ (p = 0.02). Therefore in the second phase, 
patients received 2‰ morphine solution and reported time to good (≥ 50%) or to complete 
(100%) pain relief was 28 (± 12) minutes after the first mouthwash, and the duration of relief 
was on average 216 (± 25) minutes. Six patients needed supplementary analgesia after, on 
average 1.18 (± 0.8) days. No systemically active detectable concentrations of morphine were 
found; very mild-mild intensity burning/itching sensation was reported as a local adverse 
effect.  The same group enrolled 26 patients with WHO ≥ Grade 2 painful mucositis, randomly 
assigning them to either as 2‰ morphine mouthwash or a mixture of equal parts of lidocaine, 
diphenhydramine, and magnesium aluminium hydroxide (Cerchietti et al. 2003). When 
compared to the alternative mixture, morphine resulted in significantly lower pain intensity 
and duration (p = 0.03, p = 0.04 respectively), fewer local adverse effects (p = 0.007) and none 
of the morphine patients required step three opioids.  Furthermore there was a significant 
difference in duration of severe functional impairment (P = 0.017). In another randomised 
double-blinded crossover trial, patients suffering from radiotherapy- and/or chemotherapy-
induced oral mucositis, patients were assigned to either the as 2‰ morphine solution or a 
placebo mouthwash (Vayne-Bossert et al 2010). Duration of pain relief following morphine was 
123.7 minutes suggesting a possible analgesic effect of topical morphine in line with previous 
studies. None of the studies cited above were identified in the systematic review of 
interventions for treating oral mucositis for patients with cancer receiving treatment (Clarkson 
et al. 2010) 
 
Morphine gel has been tried on the management of pain resulting from photodynamic 
therapy, a well-established treatment for actinic keratoses and basal cell carcinomas where 
frequently adverse effects are pain and post-treatment erythema and oedema. In a 
randomised, double-blind, placebo-controlled study involving 28 patients with either actinic 
keratoses or basal cell carcinomas, 3% morphine gel failed to show significant pain relief when 
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 compared with placebo gel (p > 0.23) (Skiveren et al. 2006). The authors suggest that hat 
opioid receptors may not be involved in the pain induced by photodynamic therapy. 
 
Most identified studies have been in adults, however the use of topical morphine has been 
described in children with epidermolysis bullosa, a hereditary bullous disorder of the skin, in 
which minimal trauma causes chronic, severe and extremely painful blistering (Watterson et 
al. 2004). The cases of a 13 and a 16 year girl were reported where 10 mg morphine sulphate 
was mixed with 15 g of IntraSite gel and a dose of morphine equivalent to 0.2 mg/kg was used. 
Ulcer pain assessed using a VAS fell in both patients at one hour. The 16 year old was opioid 
naıve but noted no adverse effects after using the morphine gel. Both patients continued to 
use the gel with good effect for between one and five months 
 
In summary these data are variable and have employed different opioid concentrations, 
carriers, and administration frequencies. On the whole, however, these results are less 
encouraging that the studies identified in the systematic review 
 
The long term effects of topically applied opioids require further investigation. There are 
recent data from animal studies suggesting that topical administration of opioids may impair 
wound healing by inhibiting the peripheral release of neuropeptides and reduce inflammation 
(Rook et al. 2007; Rook & McCarson 2009), although these effects may be time-dependent and 
if demonstrated in patients may require strategies such as the timing of the administration and 
the addition of adjuvant drugs to optimise topical opioid administration (Rook et al.2008). 
Conversely other animal studies have suggested that opioids can accelerate wound healing by 
up-regulating nitric-oxide synthase (Poonawala et al. 2005). The duration of our studies were 
short and may not have been sufficient to demonstrate some of the longer term adverse 
effects of opioids, furthermore the potential for palliative care to improve wound healing and 
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 the quality of life for patients and families living with chronic wounds is also recognised (Schulz 
et al. 2002; Ferris et al. 2007). 
 
Other long-term effects of opioids include immune suppression (Vallejo et al. 2004). The 
relationship between pain and the immune system is well described, in particular how the 
inflammatory response is amplified by migration of leucocytes in the inflamed tissues by the 
production of cytokines, chemokines, growth factors and a fall in pH (Rittner et al. 2008). The 
short duration and design of this study do not allow any conclusions to be drawn on the 
immune suppressive effects of topically applied opioids. 
 
The prolonged application of opioids can sometimes lead to tolerance (Furlan et al 2008). 
Although this is often a concern in chronic non-cancer pain management it is considered less 
of a clinical problem in the palliative care setting (Collin et al. 1993; Zech et al. 1995; Grond et 
al. 1996). There are experimental data that suggest long term exposure of peripheral opioid 
receptors to opioids may result in tolerance however the presence of inflammation appears to 
reduce this effect (Zöllner et al. 2008). As with immune suppression the duration and design of 
this study did not allow it to draw any conclusion on tolerance. 
 
5.6.4 Summary 
Two randomised, double blind, placebo controlled, crossover studies are described that are 
consistent with the previous open studies in the literature that have reported an analgesic 
effect when morphine has been applied topically to painful cutaneous ulcers. The patient 
numbers in both studies are small and these data, therefore, should be interpreted cautiously. 
In particular, it is not possible to draw conclusions about the type, grade, and area of ulcer that 
responds best to topical opioid application, as other published randomised controlled studies 
with different methodologies have reported different outcomes. The duration of the studies 
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 was short and it was not possible to determine whether tolerance is a feature in topical opioid 
administration. Furthermore the conclusions cannot be applied to necrotic and infected ulcers 
as they were excluded from the study, nor the use of a carrier other than IntraSite gel.  
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 Chapter 6: Bioavailability of morphine applied topically to 
cutaneous ulcers 
 
6.1 Introduction 
Morphine is the most commonly used opioid applied to painful cutaneous wounds, although 
other opioids, including diamorphine, oxycodone, hydromorphone and fentanyl have been 
used. The rational for the use of topical opioids is that their site of action is local and not 
systemic. To confirm this would require evidence of the limited systemic absorption when the 
opioid is applied topically to a cutaneous wound. Despite the increased use of topical opioids, 
there are no pharmacokinetic studies evaluating this route in palliative care patients. A 
challenge with such a study may be the low plasma morphine and metabolite concentrations 
resulting from topical administration, requiring a sensitive analytical method such as liquid 
chromatography with electrochemical detection. 
 
Chromatography is the collective term for a set of laboratory techniques used for the 
separation of mixtures. It involves a sample (or analyte) being dissolved in a mobile phase (gas 
or a liquid). The mobile phase is then forced through an immobile, immiscible stationary 
phase. The phases are chosen such that components of the sample have differing solubility 
within each. A component which is quite soluble in the stationary phase will take longer to 
travel through the column than a component which is less soluble in the stationary phase but 
very soluble in the mobile phase. As a result of these differences in mobility, sample 
components will become separated from each other as they travel through the stationary 
phase. 
 
In 1906 the Russian chemist and botanist Mikhail Semyonovich Tswett devised an absorption 
method for separating the pigments of green leaves (Berezkin 2001). He was able to identify 
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 six pigments by grinding leaves in petroleum ether and allowing the liquid to trickle down a 
glass tube filled with powdered chalk or alumina. He named the process chromatography 
(colour development) and the technique, although not widely used in his own lifetime, has 
since become essential in analytical laboratories (Gehrke et al. 2001).  
 
Three types of chromatography are routinely used: 
• Column chromatography where the stationary phase is a solid adsorbent placed in a glass 
or stainless steel column, the analytes is loaded on top of this column and the mobile 
phase is a solvent poured or pumped through on top of the loaded column. As the solvent 
flows down the column, the components of the analyte distribute between the adsorbent 
and the solvent, thus separating the components of the mixture. 
 
• Thin Layer Chromatography where the stationary phase is an adsorbent fixed to an 
aluminium, glass, or plastic plate and the analyte is loaded near the bottom of the plate. 
The plate is placed in a reservoir of solvent so that only the bottom of the plate is 
submerged. As the solvent moves up the plate it causes the components of the analyte to 
distribute between the adsorbent on the plate and the moving solvent. 
 
• Gas Chromatography where the stationary phase is a high-boiling point liquid packed into 
a long, narrow glass or metal column and the analyte is loaded into the beginning of this 
column; the mobile phase is an inert gas which continuously flows through the column. 
The components of the analyte distribute between the stationary liquid and mobile gas 
phase moving through the column.  
 
High-performance liquid chromatography (HPLC) is a chromatographic technique that utilises 
different types of stationary phases, a pump that moves the mobile phase and mixture  
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Figure 6.1 Diagram to illustrate the components of an HPLC system: the sample containing materials 
A, B, C, D and E is injected into the column, the separated solutes are detected as they emerge from 
the columns by a sensitive detector, and the detector signal is recorded to give a quantifiable record. 
 
 
through the column, and a detector to provide a characteristic retention time for the analyte 
[Figure 6.1]. It is a form of liquid chromatography that utilizes smaller column size, smaller 
media inside the column, and higher mobile phase pressures. With HPLC, a pump (rather than 
gravity) provides the higher pressure required to move the mobile phase and analyte through 
the densely packed column (Knox 1978). In reversed-phase HPLC compounds are separated 
based on their hydrophobic character. The stationary bed is hydrophobic in nature, while the 
mobile phase is a polar liquid. Structural properties of the analyte molecule play an important 
role in its retention characteristics. In general, an analyte with a larger hydrophobic surface 
area results in a longer retention time whereas polar analytes reduce retention as they are 
well integrated into the more polar mobile phase.  
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 6.2 Aims of bioavailability study 
The aim of this study was to determine the bioavailability of morphine and its metabolites, 
morphine- 6-glucuronide (M6G) and morphine-3-glucuronide (M3G), using HPLC, following the 
topical application of morphine sulphate mixed in IntraSite gel to cutaneous ulcers in hospice 
inpatients. 
 
6.3 Methods 
This was a randomised, open label cross over study; ethical approval for the study was 
obtained from the local ethics committee.  Six adult hospice patients were recruited into the 
study. Patients were eligible if they had skin ulcers (larger than 2 cm in diameter and 0.5 cm in 
depth) that were neither infected nor covered with necrotic tissue. Patients were required to 
be morphine, codeine, diamorphine or hydromorphone naïve; fentanyl and tramadol were the 
only opioids permitted, as they and their metabolites do not interfere with the HPLC assay for 
morphine.  
 
Following written informed consent, patients received either morphine sulphate in IntraSite 
gel applied topically to their ulcer or morphine sulphate administered subcutaneously over 
four hours, followed by the alternate treatment (topical or subcutaneous); the two treatments 
were separated by a washout period of one day. The order of treatments was randomised 
using a table of random numbers. 
 
The topical morphine mixture was prepared by thoroughly mixing morphine sulphate injection 
BP 10 mg (Celltech Pharmaceuticals, Berkshire, UK) with IntraSite gel 8 g (Smith & Nephew 
Healthcare Ltd, Middlesex, UK) in a sterile galipot; this dose of morphine was chosen as it is 
commonly used in clinical practice. The ulcer was first cleaned with sterile water, after which 
the morphine mixture was applied directly to the wound and then covered with a Tegaderm 
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 dressing. The opioid was kept in contact with the wound for 24 hours. Venous blood samples 
were taken from an indwelling cannula immediately prior to the application of morphine, and 
then at 1, 2, 4, 6, 8, 10, 12, and 24 hours afterwards.  
 
The subcutaneous morphine infusion was prepared by diluting morphine sulphate 10 mg in 
water for injection to a volume of 10 mL in a plastic syringe. The syringe was then attached to 
a syringe driver (Graseby MS16a) and connected to an infusion set with the butterfly needle 
inserted in the upper forearm. The infusion set was primed with the morphine solution and 
the whole amount delivered over four hours. Venous blood samples were collected 
immediately prior to starting the infusion and then at 1, 2, 4, 6, 8, 10, and 12 hours after 
commencement. All blood samples were separated by centrifugation (1000g for 10 minutes) 
within 30 minutes of collection and the plasma then stored at -40
o
C until analysis. 
 
6.3.1 Pharmacokinetic assessment 
Morphine, M3G, and M6G (all Sigma chemicals, Poole UK) were analysed using a previously 
reported method (Joel et al 1988), involving sample clean-up using C8 cartridges (1 cc/100 mg 
Varian, Anachem, Luton, Beds) followed by reverse-phase HPLC with electrochemical and 
fluorescence detection. Extraction cartridges were conditioned with methanol (1.5 mL), 10 
mM sodium dihydrogen phosphate, pH 2.1 with 10% acetonitrile (1.0 mL) and water (1.5 mL). 
Plasma (0.75 mL) was buffered with 500 mM ammonium sulphate, pH 9.3 (2.25 mL), and 2.5 
mL of this mixture loaded onto the cartridge. The cartridge was then washed with 5mM 
ammonium sulphate, pH 9.3 (5.0 mL), and water (0.2 mL). Morphine and its metabolites were 
eluted with 10 mM sodium dihydrogen orthophosphate pH 2.10 with 10% acetonitrile (0.80 
mL). 
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 Separation was achieved using an Apex 5 μ C18 column (Jones Chromatography, Hengoed, 
Wales) fitted with a 2-cm Apex ODS 10 μm precolumn. Morphine and M6G were detected by 
electrochemical detection and M3G by fluorescence detection. Approximate retention times 
for M3G, M6G, and morphine were 4, 5.5, and 10 minutes respectively, with lower limits of 
quantitation (LLQ) of 3 nM/L (1.1 ng/mL) for morphine, 2 nM/L (1 ng/mL) for M6G, and 40 
nM/L (20 ng/mL) for M3G. Between-run variability for this assay at 100, 800, and 3500 nM/L 
M3G and 10, 80, and 350 nM/L morphine and M6G is less than 10%.  
 
Pharmacokinetic parameters for morphine, M3G and M6G were derived using non-
compartmental methods in Kinetica (Innaphase Corp, Philadelphia, PA). The area under the 
concentration time curve (AUC) was calculated using the trapezoidal method as the sum of 
linear areas up to the maximum concentration and logarithmic areas from Cmax to the last 
time point (tn). AUC was extrapolated out to infinity using the concentration at the last time 
point and the elimination rate constant (λz). Cmax and tmax were the measured values. The 
elimination half-life was calculated as 0.693/ λz, the apparent clearance (CL) as dose divided by 
AUC0- INF and the apparent volume of distribution as dose divided by the product of AUC0-INF x 
λz.. The bioavailability of morphine, and apparent bioavailabilities of M3G and M6G, after 
topical morphine were calculated as AUC0-tn, TOPICAL/AUC0-tn, INFUSION X 100. 
 
6.4 Results 
6.4.1 Patients 
Three male and three female hospice in-patients entered the study [Table 6.1]. Most patients 
had advanced cancer and all but one were receiving regular analgesia. The mean (range)  
surface area of the ulcers was 20.4 cm
2
 (4.5-60); one ulcer was of malignant aetiology, the 
remainder were benign. Morphine, M6G and M3G were below the LLQ in all samples prior to 
the administration of subcutaneous or topical morphine. 
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*MS= Multiple sclerosis; COPD = Chronic Obstructive Pulmonary Disease 
 
6.4.2 Subcutaneous morphine 
Mean plasma concentrations of morphine, M6G and M3G in all six patients after subcutaneous 
morphine are shown in Figure 6.2. Morphine was detected in the first post-treatment sample 
(1 hour) in all patients and was still detectable in four patients at 12 hours. Peak morphine 
concentration was measured at four hours in five patients and at two hours in the remaining 
patient (56.5 nmol/L at two hours vs. 50.0 nmol/L at four hours). M6G was first detected at 
one hour in five patients and at two hours in one patient, and was still detectable in all 
patients at 12 hours. M3G was detected at one hour in one patient, two hours in four patients, 
and three hours in the remaining one patient. As with M6G, M3G remained detectable in all 
patients at 12 hours. Peak metabolite concentrations occurred between four and eight hours  
(median tmax was four hours for M6G and four and a half hours for M3G).  Pharmacokinetic 
parameters for morphine, M6G and M3G are shown in Tables 6.2 & 6.3. 
  
Table 6.1 Morphine bioavailability study: patient and ulcer characteristics 
Patient Sex Age Diagnosis Ulcer size  Analgesia  
1 M 87 Ca Colon 13 cm
2
 Paracetamol 1g prn 
2 M 61 MS*  9 cm
2
 Paracetamol 1g prn 
3 M 80 Ca prostate  5 cm
2
 Fentanyl-TTS 25mcg/h,  
Diclofenac 50mg tds,  
Paracetamol 1g qds 
4 F 73 Ca breast 23 cm
2
 Tramadol 100mg tds,  
Ibuprofen 400mg tds 
5 F 70 COPD* 14 cm
2
 None 
6 F 67 Ca Lung 60 cm
2
 Paracetamol 1g qds,  
Tramadol 200mg bd 
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 Figure 6.2 Plasma morphine, M6G and M3G concentration in 6 patients after 10 mg subcutaneous 
morphine infused over 4 hours (mean + SD).  
 
Figure 6.3 Plasma morphine and M6G concentrations in patient 6 after 10 mg topical morphine in 
IntraSite gel. 
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Table 6.3 Pharmacokinetics of morphine and its glucuronides following 
subcutaneous and topical administration of morphine sulphate  
 Morphine M6G M3G 
Subcutaneous morphine (n=6)    
Cmax (nmol/L) 72.6 ± 22.5 60.2 ± 6.6 303 ± 36 
tmax (hr) 4 (2-4) 4 (4-8) 4.5 (4-8) 
AUC0-tn (nmol/l.hr) 326 ± 90 450 ± 88 2339 ± 262 
AUC0-INF  (nmol/L.hr) 356 ± 105 588 ± 82 3652 ± 850 
Apparent CL (mL/min) 1295 ± 267 - - 
Apparent Vd (L) 281 ± 52 - - 
Elimination t½ (hr) 2.5 ± 0.3 4.8 ± 0.9 6.5 ± 2.6 
    
Topical morphine (patient 6 only)    
Cmax (nmol/L) 9.4 9.5 - 
tmax (hr) 1 4 - 
AUC0-tn (nmol/l.hr) 56 82 - 
Bioavailability % (AUC0-tn) 19.6 20.5 - 
Values are mean ± SD except tmax, which is median (range) 
 
 
6.4.3 Topical Morphine  
Morphine, M3G and M6G were detected in the plasma of only one patient (Patient 6) after 
topical application of morphine sulphate, this patient had the largest ulcer (60 cm
2
) compared 
to an average of 12.8 cm
2
 in the other five patients.  Both morphine and M6G were first 
detected at one hour, were still detectable at 12 hours but were <LLQ by 24 hours. Morphine 
Cmax was in the first post-treatment sample (one hour), while M6G Cmax was at four hours. 
Trace amounts of M3G, below the LLQ, were detected between four and ten hours. 
Pharmacokinetic parameters for morphine and M6G are shown in Tables 6.2 & 6.3, with 
bioavailabilities of 19.6% and 20.5% respectively. 
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 6.4.4 Adverse Events 
During the topical application of morphine neither patients nor nursing staff reported any 
systemic or local adverse events. During subcutaneous administration of morphine one patient 
(Patient 2) reported drowsiness.  
 
6.5 Discussion 
Several different methods of assaying morphine have been reported in the literature including 
gas-liquid chromatography (Wasels et al. 1989; Brose et al. 1991), radioimmunoassay (Lee et 
al. 1991; Chapman et al. 1994; Chapman et al. 1995), thin layer chromatography, (Loh et al. 
1973; Wang et al. 1986), gas chromatography particularly coupled to mass spectrometric 
detection (Leung 1994; Wasels and Belleville. 1994; Fryirs et al. 1997; Bogusz et al. 1996). This 
study used HPLC where morphine, M3G, and M6G were analysed using a previously reported 
method (Joel et al. 1988) and as described elsewhere (Pawula et al. 1993; Watson et al. 1996; 
Meng et al. 2000; Penson et al. 2000; Stuart-Harris et al. 2000; Penson et al. 2001; Penson et 
al. 2002). 
 
The pharmacokinetics of morphine, M6G, and M3G have been described following oral, 
subcutaneous, and intravenous administration of morphine in healthy volunteers and patients. 
One volunteer study has described the pharmacokinetics of morphine hydrochloride in 
solution delivered from an occlusive reservoir applied to de-epithelialised skin (Westerling et 
al. 1994). The bioavailability of morphine from this route and formulation was 75%, with stable 
morphine concentrations maintained for 11 hours. 
 
The aim of this study was to determine whether morphine sulphate in IntraSite gel was 
absorbed systemically when applied to ulcerated skin. In five of the six patients, morphine and 
its metabolites were undetectable, suggesting limited, if any, systemic absorption. In one 
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 patient, who had the largest pressure sore, morphine and M6G were detected, with a 
bioavailability of 20%. The majority of cutaneous ulcers in clinical practice are smaller than that 
seen in patient 6 [Table 4.2], but it appears that if large ulcerated areas are treated topically, 
systemic absorption of morphine can occur. However, a bioavailability of 20% is unlikely to 
result in excessive systemic adverse effects given the relatively small daily dose of morphine 
applied topically with concentrations of less than 10 nmol/L across the study period, and the 
fact that most patients with advanced disease are also likely to be on oral opioids. 
 
The subcutaneous infusion route was included to determine the relative bioavailability of 
topical morphine. The estimate of total plasma morphine clearance after subcutaneous 
infusion in this study is slightly lower than that previously derived in healthy subjects (Stuart-
Harris et al. 2000) (1295 vs. 2125 mL/min), resulting in an increased AUC 0-t (356 vs. 205 
nmol/L·hr). This was likely due to the effects of age and on-going disease in our study group. 
 
IntraSite gel, a ready-mixed hydrogel containing water, propylene glycol, and 
carboxymethylcellulose, is widely used in the management of skin ulcers in the palliative care 
setting. When placed in contact with the wound, IntraSite gel absorbs excess exudates and 
produces a moist environment at the surface of the wound (Vernon 2000). These fluid 
handling properties may influence the pharmacokinetics of opioids when they are mixed with 
IntraSite gel and applied to skin ulcers. As hydrogels differ in the amounts of fluid they release 
or absorb (Thomas & Hay 1995), the degree of absorption of drugs from these gels may also 
vary. 
 
Several opioids have been applied topically to ulcers, including diamorphine, morphine, and 
fentanyl. We have investigated the bioavailability of morphine, as it appears to be the most 
commonly used in published reports. The advantages of morphine over other opioids are that 
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 it is widely available, is cheaper than most other opioid preparations, and is available in liquid 
form, which is easy to mix with a hydrophilic vehicle. Sampling of different parts of a morphine 
IntraSite gel mix prior to commencing the study, prepared as described in the methods of our 
study, showed that the mixture had a fairly homogeneous morphine concentration (variability 
in concentration <20% for four samples); others using HPLC have reported that homogeneity 
of the mixture was obtained after three minutes of mixing (Vernassiere et al. 2005). 
Furthermore the morphine/IntraSite gel mixture has been shown not to degrade over time, 
whereas diamorphine mixed with IntraSite gel showed some degradation to 6- 
monoacetylmorphine, and then morphine under the same conditions (see chapter 7). 
 
6.6 Summary 
When applied topically to ulcers in IntraSite gel, morphine is not absorbed except when there 
the ulcer has a large surface area. Reported analgesic effects after topical morphine are, 
therefore, likely to be mediated locally rather than systemically. 
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 Chapter 7: Physical stability of opioids in IntraSite gel  
Introduction 
Stability is the capacity of a drug substance or drug product to remain within the established 
specifications to maintain its identity, strength, quality and purity throughout the re-test or 
expiration dating period (ICH 2003). The purpose of stability testing is to provide evidence on 
how the quality of a drug substance or drug product varies with time under the influence of a 
variety of environmental factors such as temperature, humidity, and light, and to establish a 
re-test period for the drug substance or a shelf life for the drug product and recommended 
storage conditions (ICH 2003). It is an essential factor of quality, safety and efficacy of a drug 
product. For example a drug may become less effective as it undergoes degradation or may 
yield toxic by-products that can be harmful to the patient. 
 
Opioids commonly used in a palliative care setting include morphine, diamorphine, oxycodone 
and hydromorphone. Recent studies have suggested that if applied directly to painful ulcers 
that have a local analgesic effect. In many cases the opioids have been mixed with IntraSite gel 
(Chapter 2). 
 
Morphine is the main pharmacologically active 
ingredient of opium extracted from the poppy Papaver 
somniferum. The chemical structure of morphine is that 
of a phenanthrene alkaloid, consisting of rings that are 
structurally rigid and would be chemically inactive were 
it not for the two hydroxyl groups at C3 and C6 (Resine 
& Pasternak 1996), the same two hydroxyl groups 
make it relatively water soluble and poorly lipid 
soluble. Morphine degrades in aqueous solution to 
 
 
Figure 7.1 Chemical structure of 
morphine 
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 pseudomorphine (a morphine dimer formed at the C7 
position), morphine-N-oxide and possibly to 
apomorphine (Vermeire & Remon 1999).  
 
Diamorphine is an opioid derivative synthesised from 
morphine by the addition of two acetyl groups at C3 
and C6 making the molecule highly lipid soluble. It is 
generally considered to be a pro-drug without intrinsic 
activity (Inturrisi et al. 1984). Diamorphine hydrolyses 
to 6-monoacetylmorphine, and then to morphine, with 
potential morphine degradation products formed 
thereafter (Payne & Tempest 1988). Diamorphine has 
been widely used as the parenteral opioid of choice for 
cancer pain in the UK, but not elsewhere. 
 
 
 
 
 
   
 
 
Figure 7.2 Chemical structure of 
diamorphine            
 
 
Oxycodone is a semi-synthetic opioid derived from the 
opium alkaloid thebaine that has been in clinical practice 
since 1917. It is structurally related to morphine and 
widely used to manage cancer pain (Poyhia et al. 1993), 
although there is evidence to suggest oxycodone and 
morphine produce analgesia through different 
populations of opioid receptors (Smith et al. 2001). 
Oxycodone N-oxide and pseudooxycodone have been 
reported degradation products. 
 
 
 
 
Figure 7.3 Chemical strucutre of 
oxycodone 
 
Hydromorphone is a semi-synthetic derivative of  
 
120 
 morphine with similar pharmacokinetic and 
pharmacodynamic properties that has been in clinical 
practice since the 1920s (Sarhill et al. 2001). It is a 
hydrogenated ketone of morphine, structurally the C6 
hydroxyl group of morphine has been substituted with 
a carbonyl group and the double bond at the C7-8 
position has been removed.  Hydromorphone N-oxide, 
hydroxylated hydromorphone and 
pseudohydromorphone have been reported 
degradation products. 
 
 
 
 
IntraSite gel is a colourless transparent aqueous gel, which contains 2.3% of a modified 
carboxymethylcellulose polymer together with propylene glycol (20%) as a humectant and 
preservative. When placed in contact with a wound, the dressing absorbs excess exudate and 
produces a moist environment at the surface of the wound, without causing tissue maceration 
(Vernon 2000).  
 
IntraSite gel may be applied to many different types of wound, including leg ulcers, pressure 
sores, surgical wounds and extravasation injuries. It is of particular value in the treatment of 
dry, sloughy, or necrotic wounds, promoting rapid debridement by facilitating rehydration and 
autolysis of dead tissue. In the management of granulating wounds, IntraSite gel has been 
shown to prevent desiccation, and thus facilitates re-epithelialisation. Although there are no 
known contra-indications to the use of IntraSite as a topical wound dressing, the material is 
not ideally suited for application to wounds that are exuding very heavily. 
 
 
Figure 7.4 Chemical structure of 
hydromorphone 
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 7.2 Aims of physical stability studies 
The aim of this study was to determine whether morphine, diamorphine, oxycodone and 
hydromorphone are stable when mixed with IntraSite gel at room temperature in the dark, at 
room temperature under normal day/night conditions and at 4°C in the dark, over a period of 
28 days, and thereby determining the feasibility of extending expiration dates after mixing. 
 
7.3 Materials 
The pharmaceutical preparations of morphine sulphate and diamorphine hydrochloride were 
obtained from Arum Pharmaceuticals Ltd. Hydromorphone hydrochloride, 
pseudohydromorphone and hydromorphone-N-oxide (all dry powder) were obtained from 
Napp Pharmaceuticals Research Limited (Cambridge, UK).  Morphine, morphine-N-oxide, 
pseudomorphine and naloxone were obtained from McFarlan Smith (Edinburgh, UK). 
Oxycodone hydrochloride was obtained as a dry powder, from Sigma Aldrich (Poole, Dorset, 
UK). This was used to determine the linearity of the standard curve. The pharmaceutical 
preparation of oxycodone (Oxynorm) was obtained from Napp Pharmaceuticals Research 
Limited (Cambridge, UK), for use in the both gel recovery and the stability studies.  The 
formulation contained 10 mg active drug substance (oxycodone hydrochloride), citric acid 
monohydrate, sodium citrate, sodium chloride, sodium hydroxide, dilute hydrochloric acid and 
water for injection. Oxynorm was packaged in 1 mL ampoules. IntraSite gel was obtained from 
Smith & Nephew Healthcare Ltd (Hull, England). Sodium dodecyl sulphate (99% GC grade) and 
apomorphine were obtained from Sigma Aldrich (Poole, Dorset, UK).  Sodium dihydrogen 
orthophosphate 1-hydrate (analar HPLC grade), acetonitrile (HPLC grade), othophosphoric acid 
85% (HPLC grade) and sodium hydroxide pellets (99%) were purchased from Merck (Enfield, 
UK) and 6-monoacetylmorphine (6-MAM) was provided by Dr Wynn Aherne, Institute of 
Cancer Research Sutton, Surrey, UK.  
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 7.4 Methods 
7.4.1 Analysis of opioids by HPLC 
The studies were conducted using a Perkin Elmer series 200 HPLC system. The 
chromatographic conditions for the study were developed from a previously published method 
known to resolve morphine and its degradation products (Joel et al. 1988; Ribeiro et al. 2004). 
The mobile phase consisted of 10 mM sodium dihydrogen orthophosphate 1-hydrate and 0.8 
mM sodium dodecyl sulphate with 25% acetonitrile (ACN).  The pH of the solution was 
adjusted by drop wise addition of sodium hydroxide or orthophosphoric acid.   The solution 
was then filtered using a Millipore solvent filtering system with 0.45 μm Millipore filter papers 
and a vacuum pump. Chromatic separation was achieved by using a Hyperclone HPLC 5 μM 
ODS (C18) column, 150 mm X 4.6 mm diameter. Flow rate and run time were set at 1.5 mL/min 
and 50 minutes respectively. Detection was by UV absorbance at 210 nm.  
 
The pH of the buffer was adjusted to pH 2.0, 4.0, 6.0 or 8.0, and the system left to stabilise for 
two hours. The samples were then re-injected at each pH.  Retention times and separation of 
the compounds were observed. The mixed solution of analytes spiked with compounds to act 
as possible internal standards (naltrexone or naloxone), was also used to optimise the ACN 
content in the mobile phase, and the flow rate.   
 
Morphine and its known degradation products were used in establishing the run time for the 
method.  As the study drugs are structurally related to morphine, it was expected that similar 
degradation products would be formed.  The expected retention times for degradation 
products were estimated from the retention time relationship of morphine to morphine N-
oxide and pseudomorphine.  These data were used to determine the run time length.  
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 7.4.2 Gel Homogeneity 
Seven grams of IntraSite gel was expelled from the dosing pack into 25 mL sterile plastic 
containers. The respective opioid was then added and mixed for one minute using a sterile 
glass rod.  As a standard comparison seven grams of phosphate buffer was weighed out on the 
balance into a 25 mL sterile plastic container. The opioid was then added and mixed by 
vortexing. Between 200-300 mg of gel was removed from the container using a sterile metal 
spatula and weighed. The sample was then diluted gravimetrically 1:10 with phosphate buffer.  
Ten samples from each gel were prepared in this manner.  All were mixed by rotation for one 
hour at room temperature. Eight samples were obtained from the ‘buffer’ containers, with 
200-300 mg of the sample being removed by Pasteur pipette then treated in the same way as 
the ‘gel’ samples. 
 
All samples then underwent a second volumetric 1:10 dilution with phosphate buffer (as used 
in the mobile phase) in 1.5 mL eppendorf tubes.  Duplicate second dilutions were made from 
all 10 of the gel samples. All samples were mixed for three seconds using the vortex mixer.  Gel 
samples were also centrifuged at 4
o
C and 3000 rpm for five minutes before HPLC analysis. The 
final mobile phase consisted of 10 mM sodium dihydrogen phosphate, 0.8 mM sodium dodecyl 
sulphate (SDS) at pH 4.0, 71% buffer with 29% ACN.  Mobile phase flow was 1.5 mL/min with a 
run time of 20 minutes.  
 
7.4.3 Gel Stability 
Triplicate preparations were made and stored at room temperature in day/night conditions 
(16 hour/8 hours respectively) on a laboratory bench out of direct sunlight but approximately 
1.5 m from a fluorescent lamp that was illuminated between the hours of 9am and 5pm; in a 
fridge at 4
o
C in the dark and, at room temperature in the dark.  
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 The study gels were removed from their place of storage. Using a sterile metal spatula 200-300 
mg of gel was removed, placed into a labelled sterile plastic container and weighed. Gel 
samples were then treated as described in the recovery method. The gels were sampled on 
day 0 (baseline), 2, 4, 7, 10, 14, 21 and 28. 
 
Samples containing drug and breakdown products were removed from the freezer and left to 
defrost at room temperature, before being mixed for three seconds with the vortex.  These 
samples did not undergo any further dilution and were analysed at the beginning and end of 
the run.  Standards were injected before the gel samples and quality control samples were 
inter-dispersed throughout the run. Extraction efficiency from the gel was calculated from the 
following: 
Extraction efficiency =  Mean peak height of duplicate gel samples  x  100%   
Mean peak height of all standard ‘buffer’ samples 
 
Retention times were confirmed on the computer system.  The software package then drew 
baselines for each peak, which were inspected and amended if necessary.  A summary report 
of the retention time and peak heights was generated by the package and the data underwent 
further analysis using Microsoft Excel.  Concentrations of the compounds of interest in both 
quality control and samples were determined from the known concentration and peak heights 
of the standards using the following formula: Response factor = 1/[Σ (peak height/ 
concentration)]/1 
  
 A summary of the data were plotted and analysis of variance carried out using Minitab, 
controlling for storage condition, day, and sample replicate.  As multiple ANOVAs were 
performed a p-value of 0.01 was taken as statistically significant.   
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 7.5 Results 
7.5.1 Stability of morphine in IntraSite gel 
Chromatograms of mixed standards, morphine and diamorphine samples are shown in Figure 
7.5. A total of 63 samples containing morphine sulphate were analysed. The mean extraction 
efficiency of morphine from gel was found to be almost 100%. No evidence of 
pseudomorphine or morphine-N-oxide was observed in any of the samples up to 28 days 
irrespective of the temperature and whether or not samples were exposed to light. The 
morphine concentration appeared to fall during the first 10 days of storage [Figure 7.6]. The 
fall appeared greatest in the samples exposed to light (30%), compared to samples kept in the 
dark (5%) and samples at 4°C (20%). After this initial period the measured morphine 
concentration remained unchanged to 28 days. As the fall in morphine concentration was not 
accompanied by a rise in known degradation products, poor sample mixing was a possible 
explanation. The study was therefore repeated employing more rigorous mixing and additional 
time points within the protocol. 
 
Figure 7.5 Stability study No. 1: Chromatogram of mixed standard, morphine and diamorphine 
samples. Naltrexone used as internal standard 
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Figure 7.6 Stability study No. 1: Morphine stability in IntraSite gel at room temperature (dark and 
dark/light cycle) and at 4°C (Mean ± SD). 
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 the repeat study a total of 72 samples containing morphine sulphate were analysed. The 
repeat analysis confirmed no evidence of pseudomorphine or morphine-N-oxide in any of the 
samples up to 28 days irrespective of the temperature and whether or not samples were 
exposed to light [Figure 7.7]. The morphine concentration was again variable during the first 
five days of storage, after which recovered drug concentration stabilised [Figure 7.8]. Including 
all the data in an analysis on variance found no effect of storage conditions on morphine 
concentration (p > 0.5), but a significant time effect (p = 0.001).  A similar analysis including 
data from day 8 onwards found no effect of storage time (p = 0.250), suggesting the time 
effect was due to variability in recovered morphine concentration across the first five days 
when mixing of the samples might have been incomplete. After this initial mixing period the 
measured morphine concentration remained unchanged to 28 days. 
 
Figure 7.7 Stability study No. 2: Morphine stability at room temperature, day 28. Naltrexone used as 
internal standard 
Peak Height (μV) 
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 Figure 7.8 Stability study No. 2: 
dark/light cycle) and at 4°C (Mean ± SD) between 0 and 28 days.
  
7.5.2 Stability of diamorphine in IntraSite gel
The mean extraction efficiency of 
the 63 diamorphine samples showed that diamorphine hydrochloride was degraded to 6
MAM, and then to morphine. The rate and degree of degradation was related to the sample 
temperature. At room temperature the percentage 6
on day 28, 30.2 (0.6), whereas at 
[Figure 7.9]. No morphine degradation products were detected in any diamorphine sample
As with the first morphine stability samples there appeared to be a fall in diamorphine 
concentration which was smaller than that seen with morphine and cou
for by the concentration of degradation products. It 
this fall was directly related to diamorphine or whether the degradation to morphine 
subsequently lead to a fall in the latter’s concentration gi
morphine was present than expected. The study was therefore repeated with more vigorous 
mixing and additional time points within the protocol.
Morphine stability in IntraSite gel at room temperature (dark and 
  
 
diamorphine from gel was found to almost 100%. Analysis of 
-MAM (± SD) on day 7 was 7.1 (0.4) and 
4°C the percentages were 3.2 (3.5) and 4.5 (
was not possible to determine whether 
ving the impression that less 
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 Figure 7.9 Stability study No. 1: Stability of diamorphine hydrochloride in IntraSite gel stored at 4°C 
(A), at room temperature in the dark (B) and dark/light (C); (Mean + SD) 
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 Figure 7.10 Stability study No. 2: 
at room temperature in the dark (B) and dark/light (C)
Stability of diamorphine hydrochloride in IntraSite gel
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 Figure 7.11 Stability study No. 2: 
in IntraSite gel stored at different temperature and light conditions; 
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 Figure 7.12 Stability study No. 2: Diamorphine stability at room temperature (Days 1 and 28).  
Naltrexone used as internal standard 
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 Analysis of the 72 diamorphine samples in the second stability study confirmed that 
diamorphine hydrochloride degraded first to 6-MAM, and then to morphine (ANOVA for 
storage time p < 0.001). The rate and degree of degradation was related to the storage 
conditions (ANOVA p < 0.001 for diamorphine, morphine and 6-MAM), with samples stored at 
room temperature showing a greater accumulation of 6-MAM with time than samples stored 
at 4°C (ANOVA p < 0.001) [Figures 7.10 & 7.11]. No morphine was detected in any sample 
stored at 4°C. Although the difference was small, recovered 6-MAM and morphine 
concentrations were consistently higher in samples stored at room temperature in the 
day/night light compared to dark  (ANOVA p = 0.001 for 6-MAM and morphine). There was no 
difference in diamorphine concentration between these two storage conditions (p = 0.11). By 
day 28 this resulted in 6-MAM and morphine concentrations of 0.367 ± 0.018 mg/mL and 
0.019 ± 0.001 mg/mL respectively in samples stored at room temperature in the dark and 
0.381 ± 0.007 and 0.021 ± 0.002 mg/mL for those exposed to light. No further morphine 
degradation products were found [Figure 7.12]. 
 
7.5.3 Stability of oxycodone in IntraSite gel  
Chromatograms of mixed standard are shown in Figures 7.13. The mean extraction efficiency 
of oxycodone from gel was found to be 96% ± 4.4% and reproducibility across the 10 samples 
was 4.6%, representing intra-assay precision. Oxycodone concentrations appeared to show 
variability in all gels until day 7, after which time sample concentrations were more stable. 
Concentrations within the oxycodone gel were higher than expected.  As in the other opioid 
studies starting concentrations of oxycodone varied between triplicate preparations stored 
under the same conditions and much of the variability occurred within the first few days 
[Figure 7.14]. There was no evidence of degradation products at the estimated times 
calculated from morphine degradation up to day 28 in any of the gels containing oxycodone, 
regardless of storage conditions.  An unknown peak was detected at a position not expected of 
134 
 a degradation product and appeared to increase with time as shown in Figure 7.15. This 
unknown peak was also apparent in quality control samples and standards but was not 
apparent in the 0 standard or buffer [Figure 7.16] suggesting that it was related to the drug. 
 
An analysis of variance was performed to determine whether there was any significant change 
in the percentage concentration of the analytes from day 0 concentration between triplicate 
samples (p <  0.001), over time (p = 0.042) and across storage conditions (p = 0.117).  A 2-way 
ANOVA was then performed to look at the effect of sample replicate and day for each 
condition. The variation in percentage of starting concentration over time was found to be 
significant in the gel stored at room temperature in the dark (p = 0.002) and suggested in the 
gel stored at 4°C in the dark (p = 0.027); there was no significant difference when the gel was 
stored at temperature in day/night condition (p = 0.559).  There was a significant change in 
percentage concentration between the triplicate preparations stored at room temperature in 
the dark (p < 0.001) and room temperature in day/ night condition (p < 0.001), however no 
significant variation between the triplicate store at 4°C in the dark (p = 0.08). 
 
7.5.4 Stability of hydromorphone in IntraSite gel  
Hydromorphone concentration appeared to be variable up until day 4, irrespective of storage 
condition.  After this time concentration across all of the gels became stable.  Theoretical 
concentration of the drug in the gel was expected to be 1.25 mg/mL and the majority of 
samples were found to fall between 5% and 10% of this concentration.  The mean extraction 
efficiency of hydromorphone from gel was found to be 92% ± 5.0% with reproducibility across 
10 samples of 5.5%, representing intra-assay precision. If this is taken into account it could be 
expected that the concentrations may be up to 8% higher, taking them close to the theoretical 
concentration. Data were plotted as measured hydromorphone concentration for each storage 
condition showing that much of the variation within the assay occurs within the first few days 
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 [Figure 7.17].   
Figure 7.13 Chromatogram showing separation of the analytes for the oxycodone assay. Naloxone 
used as internal standard 
Peak Height (μV) 
 
Time (minutes) 
 
 
Figure 7.14 Graph of Oxycodone concentration over time in gels stored at each condition; (Mean ± SD)   
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Figure 7.15 Chromatogram showing unknown peak in the oxycodone gel sample stored at room 
temperature in day/night conditions. (day 0 and day 4 contain internal standard, Naloxone at 3.5 
minutes). 
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Figure 7.16 Chromatogram showing unknown peak in the oxycodone 1.2 mg/ml QC sample on day 0, 
4, 10, 21 & 28 (day 0 and day 4 contain internal standard, Naloxone at 3.5 minutes).  
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 An analysis of variance was performed to determine whether there was any significant change 
in the percentage concentration of the analytes from day 0 concentration between triplicate 
samples (p = 0.132), over time (p= 0.864) and across storage conditions (p = 0.396) showing 
there was no significant change in percentage of day 0 concentration over the study period 
regardless of time, storage condition or triplicate sample. 
 
No known degradation peaks were observed in any gel samples, on any day of the study 
regardless of storage condition. Figure 7.18 shows a sample of chromatograms from one 
triplicate stored at the day/ night condition at room temperature, on days 0, 4, 10, 21 and 28.  
While no known degradation products were seen, a peak of unknown origin was detected in all 
chromatograms [labelled in figure 7.18].  This peak appeared to increase with time with its 
peak area found to be approximately 3.3% of the hydromorphone peak area in gels from day 
28. The peak was not detected in the Day 0 standard or phosphate buffer 
 
Figure 7.17 Graph of hydromorphone concentration over time in all storage conditions. 
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 Figure 7.18 Chromatograms of hydromorphone 2.0 mg/ml standard on day 0, 4, 10, 21 and 28.   
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7.6 Discussion 
Stability testing is a routine procedure performed on drug substances and products. The design 
of the formal stability studies for the pharmaceutical product should be based on knowledge 
of the behaviour and properties of the active substance, and from stability studies on the 
active substance and on experience gained from pre-formulation studies and investigational 
pharmaceutical products (World Health Organization 2006). 
 
Five types of stability are generally recognised: 
• Chemical: Each active ingredient retains its chemical integrity and labelled potency, within 
the specified limits. 
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 • Physical: The original physical properties, including appearance, palatability, uniformity, 
dissolution, and suspendability are retained. 
• Microbiological: Sterility or resistance to microbial growth is retained according to the 
specified requirements. Antimicrobial agents that are present retain effectiveness within 
the specified limits. 
• Therapeutic: The therapeutic effect remains unchanged. 
• Toxicological: No significant increase in toxicity occurs. 
This study addressed the chemical stability of the opioid-IntraSite gel mixtures. 
 
Stability studies determine the drug substance or product’s degradation as a result of exposure 
to a variety of conditions, such as temperature, humidity, light, orientation and packaging 
materials over an extended time frame. According to the ICH, significant change in drug 
product is a 5% change in the measured concentrations from its initial value, and any 
degradation product exceeding its acceptance criterion. Where the data show so little (< 5%, 
degradation), and variability the requested shelf life is granted (ICH 2003). 
 
 
7.6.1 Morphine 
The stability of morphine in aqueous solutions had been extensively investigated and it was 
generally accepted that oxygen from air, sunlight, UV irradiation, iron and organic impurities 
could promote the degradation of morphine (Yeh & Lach 1961; Vermeire & Remon 1999). 
However several published reports have demonstrated that solutions of morphine sulphate for 
intravenous infusion appear to be relatively stable, irrespective of opioid concentration, 
storage temperature, storage container, whether or not they were protected by light and 
whether in combination with other drugs. (Vecchio et al.1988; Grassby & Hutchings 1993; 
Trissel et al. 2002a; Xu et al. 2002; Trissel et al. 2002b).  
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In our first study a fall was seen in morphine concentrations, which was not accompanied by a 
rise in the degradation products pseudomorphine or morphine-N-oxide. Possible explanations 
included precipitation or evaporation of morphine; poor mixing of the sample and that as 
molecules move with time they become more thoroughly mixed and concentrations become 
more uniform, and adherence of the drug to the containers. Poor mixing was assumed and 
although the second study showed some variation in morphine concentration during the initial 
five days, probably because of incomplete mixing, thereafter morphine appeared stable 
throughout the 28 days irrespective of the temperature and whether or not samples were 
exposed to light.  
 
7.6.2 Diamorphine 
Aqueous solutions of diamorphine are less stable than solutions of morphine. Degradation of 
diamorphine has been shown to occur at different concentrations, and at different 
temperatures and the percentage fall is directly related to initial concentration and 
accompanied by a corresponding increase in 6-MAM and to a lesser extent morphine 
(Poochikian & Cradock 1979; Poochikian et al. 1983; Barrett et al. 1992; Omar et al. 1989). 
Diamorphine is generally considered to be a pro-drug, which in vivo is rapidly hydrolysed by 
plasma cholinesterases and other blood and tissue esterases to active metabolites, although 
the presence of a novel mu receptor with which diamorphine, but not morphine, interact has 
been described (Rossi et al. 1996).   
 
This study showed that the degradation of diamorphine occurred in vitro and was seven times 
greater at room temperature compared to 4°C. This would imply that diamorphine should be 
stored at low temperature and protected from light although the degradation products are 
active metabolites in themselves. Indeed if diamorphine is solely a pro-drug it appears illogical 
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 to use it in this way. In addition to requiring metabolism to active metabolites it is not 
commonly available in all countries and more expensive i.e. assuming a 1.5 potency ratio 
between morphine and diamorphine (Scottish Intercollegiate Guidelines Network 2008) 10 mg 
diamorphine hydrochloride injection (£3.59) vs. 15 mg morphine sulphate injection 1ml (72p) 
(British National Formulary 2011). 
 
7.6.3 Oxycodone 
A number of assays have been developed for the analysis of oxycodone in plasma and in vitro 
when combined with other drugs (Kapil et al. 1992; Wright et al. 1998; Brogle et al. 1999; 
Gebauer et al. 2001; Turnbull et al. 2002; Hines & Pleasance 2009), but there are no stability 
data for oxycodone in IntraSite gel.  
 
The data collated from this study found that the data were far more variable than those for the 
other opioids, a finding that may again be attributed to difficulties in achieving uniform mixing 
of the drug within the gel as occurred in the first morphine assays, or the finding might be 
related to the physico-chemical structure of the opioid interacting with the gel.  The gradual 
stabilisation may have occurred secondary to a change in properties of the gel over time as 
observed during the period of the study or due to inadvertent mixing each time the gel was 
sampled.  Results showed a statistically significant day effect on concentration in the gel stored 
at room temperature in the dark and suggested a day effect on concentration in the samples 
stored at 4
o
C in the dark.    
 
An unknown peak was detected in all gels irrespective of storage condition and appeared to 
grow with time. As no known degradation products could be obtained to run with the samples, 
it was assumed that a degradation pattern of a similarly structured drug, morphine would 
occur (Gebauer 2001).  Estimations of the expected retention times were based on the pattern 
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 seen in morphine degradation, however the peak did not occur at any of these estimated 
times.  This peak was also detected in quality control and standard samples that were stored at 
-40
o
C and therefore unlikely to have degraded.   
 
A previous study (Gebauer 2001) showed oxycodone to be stable for up to a year when stored 
under refrigeration in pre-packaged syringes.  The large variability within this study, coupled 
with significant changes in concentration of drug over a 28 day study period suggest that 
further work is required before comparison with other studies can be made.   
 
7.6.4 Hydromorphone 
The stability of hydromorphone has been demonstrated in several published studies either 
alone, with other drugs and in a variety of delivery systems (Walker et al. 1991; Hildebrand et 
al. 2001; Trissel et al. 2002c; Nassr et al. 2003; Khondkar et al. 2010). 
 
In this study hydromorphone was found to be stable, with no significant change in starting 
concentration regardless of storage condition, time or replicate.  A small peak of unknown 
origin, not eluting at a position expected for known degradation products of hydromorphone 
was however, detected at a retention time of two minutes. This peak was present in all gel 
samples regardless of storage condition and appeared to increase in size over time, with a 
peak area on day 28 of approximately 3.3% of hydromorphone peak area.  It is pertinent that 
this peak was also present in the quality control and standard samples. These samples were 
made up on day one and stored in aliquots at -40
o
C so is unlikely that this peak results from an 
unknown degradation product.  Hydromorphone concentration over the study stabilised at a 
concentration lower than the expected theoretical concentration of 1.25 mg/mL.  This finding 
is not explained by the formation of degradation products but may be accounted for by slightly 
reduced extraction efficiency from the gel. 
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7.7 Summary 
The results of this study suggest that morphine and hydromorphone remain stable when 
mixed with IntraSite gel for up to 28 days, whereas diamorphine degrades to 6-MAM and then 
to morphine, which then remains stable. The results for oxycodone were too variable, perhaps 
due to contamination, to recommend its use without further testing. The results are limited to 
the methods employed in the study and do not offer information on the stability of the same 
opioids in different concentrations, prepared using different salts or formulations, prepared in 
a different way, at different temperatures or stored for longer periods of time. 
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 Chapter 8: Microbiological stability of morphine in 
IntraSite gel  
8.1 Introduction 
A sterility test is a test that critically assesses whether a sterilised pharmaceutical product is 
free from contaminating microorganisms. The term sterility means no surviving organisms 
whatsoever; there are no degrees of sterility and no level of contamination that is considered 
negligible, insignificant or acceptable (Denyer & Hodges 2004).  
 
When preparing drug mixtures a number of potential sources may be problematic including 
water (e.g. gram-negative groups: pseudomonas, xanthamonas, flavobacterium) and air (e.g. 
mould spores: penicillium, aspergillus, bacterial spores: bacillus species, yeasts). The risk of 
contamination is more likely in non sterile than in sterile products and in multiple use 
formulations compared to single unit dose systems. A number of steps may be helpful to 
prevent contamination to the formulation during storage including the use of suitably 
designing the containers (ideally single dose), adhering to proper storage conditions and 
adding an antimicrobial substance as preservative. 
 
IntraSite gel is an amorphous hydrogel consisting of water (> 60%), glycol (10-30%) and 
absorbent polymer (< 10%), developed for the debridement of necrotic tissue and the 
absorption of slough and exudate; IntraSite gel is available as a single use ‘Applipak’ capsule 
thus reducing the risk of contamination [Figure 8.1]. The capsule is sterilised by steam and 
advice from the manufactures, Smith & Nephew Healthcare Ltd, is that it should be stored in a 
cool dry place when it will have a three-year shelf life; once opened the capsule should be 
stored in a cool dry place and used within one week. HPLC methods have determined that 
morphine-IntraSite gel mixtures may be physically stable for up to 28 days (Chapter 7); 
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 however it has not been shown whether the mixture is microbiological
period of time. 
Figure 8.1 IntraSite Gel Capsule (
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 for baseline microbiological analysis (Day 0) and the remaining 45 were randomly divided 
equally between three test storage conditions. Each of the three samples sets were randomly 
labelled 1 to 15 and then stored in their respective conditions (room temperature in the dark, 
room temperature under normal day/night conditions and 4
o
C in the dark) and sent for 
microbiological analysis in groups of five; day 7 (samples 1-5), day 14 (samples 6-10) and day 
28 (samples 11-15). 
 
Microbiological analysis was undertaken at the Royal London Hospital Microbiology 
Department, where in order to isolate specific microbial contaminants a number of processes 
were used to detect the presence of: 
1. Non-specific organisms: Blood, MacConkey incubated at 37oC in CO2 for 48hrs; 
2. Acinetobacter, coliforms or Pseudomonas: Blood and MacConkey agar at 37oC in CO2 for 
48hrs; 
3. Staphalococcus Aureus or Group A Streptococci: CNA agar at 37oC in CO2 for 48 hrs; 
4. MRSA: MRSA selective media at 30oC for 18 hours; 
5. Aspergillus and other fungi or yeasts: Sabouraud’s media with chloramphenicol. 
  
Once the samples were received each IntraSite gel capsule and appropriate culture plates were 
identified with a unique bar coded number. A 1 µL sterile disposable loop was inserted into the 
IntraSite gel capsule and the material inoculated onto a Blood agar, MacConkey agar, and a 
Sabouraud’s agar plate. The inoculum was spread with a sterile loop for discrete colonies. 
Plates were then incubated at 37
o
C in CO2 in accordance with established laboratory 
procedures. Culture plates were examined at 24 hours and if no growth obtained were re-
incubated for a further five days before discarding. Any growth was identified and the results 
recorded on a Winpath a Laboratory Information Management System. 
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 8.4 Results 
Of the 50 samples sent for microbiological analysis no growth was identified in any of the 
samples at days 0, 7 and 14. One colony of Corynebacterium coyleae was identified in one of 
the five gel samples stored at room temperature in both light and dark conditions and tested 
after 28 days storage, but not in any of the other storage conditions [Table 8.1]. 
 
Table 8.1 Results of microbiological analysis of morphine sulphate mixed with IntraSite gel at stored in 
three storage conditions: samples tested at Days 0, 7, 14 and 28 
 
Day Fridge Room temperature (dark) Room temperature (light/dark) 
0 No Growth No Growth No Growth 
7 No Growth No Growth No Growth 
14 No Growth No Growth No Growth 
28 No Growth No Growth One colony of Corynebacterium coyleae 
 
 
8.5 Discussion 
Sterility is an important component of any preparation intended for contact with broken skin, 
particularly when the threat of infection exists, as in the case in chronic cutaneous wounds.  A 
sterility test should assess whether a product is free from contaminating microorganisms by 
incubation of either the whole or a part of that product with a nutrient medium. (Denyer & 
Hodges 2004). The results of this study suggest that the mixed samples prepared in a ward 
type environment remained microbiologically stable for up to 14 days in any of the three 
storage conditions, and up to 28 days if stored in the fridge or at room temperature in the 
dark. A colony of Corynebacterium coyleae was isolated in one of the gel samples stored at 
room temperature for 28 days in both light and dark suggesting if samples are to be stored for 
more than 14 days prior to use, this should not be at room temperature.  
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 Corynebacterium coyleae was first described in isolates from clinical samples in 1997 and 
named after Marie Coyle for her contribution to the clinical microbiology of Coryneform 
bacteria (Funke et al. 1997). Corynebacterium coyleae are Gram-positive rod-shaped aerobic, 
non-motile bacteria and one of the largest genera within the Actinobacteria that currently 
embraces over 50 species, most of which are innocuous (Collins et al 2004); the most notable 
human infection is diphtheria, caused by Corynebacterium diphtheriae [Table 8.2]. 
Corynebacterium coyleae is an environmental organism and although generally considered to 
be harmless has been isolated in clinical samples associated with sepsis (Fernández-Natal et al. 
2008). 
Table 8.2 Select Corynebacterium species associated with disease (Rogers et al. 2011) 
Organism Associated disease 
C.diphtheriae (toxogenic) Respiratory diphtheria 
Cutaneous diphtheria 
Pharyngitis 
C.diphtheriae (non-toxogenic) Endocarditis 
C. ulcerans Respiratory diphtheria 
Zoonotic infections 
C. jeikeium Septicaemia, endocarditis 
Wound infections 
Catheter/shunt infections 
C. amycolatum Septicaemia 
Respiratory tract infections 
Urinary tract infections 
Wound infections 
Catheter/shunt infections 
C. urealyticum Urinary tract infections (pyelonephritis, cystitis) 
Wound infections 
Septicaemia, endocarditis 
C. pseudotuberculosis Abscess formation 
Lymphadenitis 
Ulcerative lymphangitis 
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 Hydrogel dressings are most commonly supplied as an amorphous, cohesive topical application 
that can take up the shape of a wound. They are designed to provide and maintain a moist 
wound environment and by increasing moisture content, hydrogels have the ability to help 
cleans and debride necrotic tissue (Jones & Milton 2000). Nine amorphous hydrogel 
preparations are listed in the British National Formulary, five of which, including IntraSite gel, 
contain propylene glycol (British National Formulary 2011).  Propylene glycol is a chemically 
inert molecule that acts as a humectant preventing the gel from drying out and improving its 
handling, however it may also help preserve the sterility of the dressing due to its 
bacteriostatic properties. Research undertaken by Smith and Nephew reported the effect of 
IntraSite Gel and Purilon gel on microbial proliferation. The two gels were each inoculated with 
Stapholococcus aureus, Psudomonas aeruginosa or Candida albicans and, in contrast to 
Pruilon, IntraSite Gel showed bacteriostatic and fungistatic activity in-vitro against all three 
different test organisms (Harrow 2011.). The same bacteriostatic features had already been 
identified in other areas of experimental and clinical practice (Bazzicalupo et al. 1951; Bahn & 
Michalsen 1961). The presence of propylene glycol in IntraSite gel may have therefore 
contributed to the relative stability of samples stored in the fridge and at room temperature in 
the dark 
 
In considering the results one should determine whether the absence of contamination in 
other samples was a consequence of using unsuitable media or that the sampling process was 
not random and bias was introduced into the methodology. A wide spectrum of 
microbiological testing was used and randomisation of samples took place in three stages of 
the preparation process, which will have improved the reliability of the results. The next step 
would be to adopt the procedures laid down by the European Pharmacopoeia that provides 
details on sample size, specific media employed, sampling, control samples and re-testing 
(European Pharmacopoeia 2002). 
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 The microbiological stability considered in combination with the physical stability results 
presented in Chapter 7 suggest that morphine IntraSite gel mixtures can be prepared in 
advance, but carefully stored, increasing the convenience of this treatment option, particularly 
for patients with painful cutaneous ulcers managed at home.  If the sterility of the product is to 
be ensured, the sterilisation, aseptic filling and closing operations must be adequately 
validated. In order to improve the microbiological stability of the morphine IntraSite mixture 
and ensure a longer shelf life, a sterilisation process should occur after the constituents have 
been mixed. Sterilisation processes may involve elevated temperature, reactive gas, 
irradiation,  or through a microorganism proof filter (Soper & Davies 1990). IntraSite gel is 
sterilised with elevated temperature using steam whereas morphine is irradiated, furthermore 
heat sterilisation of morphine is not recommended. The sterilisation process is thus a 
compromise between achieving optimum antimicrobial activity and maintaining product 
stability, hence if the mixture were to be sterilised, selecting the method is important as there 
is a potential risk of product damage that could result in reduced therapeutic efficacy and 
stability, requiring a new set of efficacy and stability studies in this new formulation. 
 
8.6 Summary 
The results of this study suggest that a mixture of morphine and IntraSite gel prepared using 
aseptic technique in a ward type environment remains microbiologically stable for up to 14 
days in any of the three storage conditions, and up to 28 days if stored in the fridge or at room 
temperature in the dark. The results are limited to the methods employed in the study and do 
not offer information on the stability of the same opioid prepared using different methods or 
for longer periods of time. 
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 Chapter 9: Opioids applied topically to painful cutaneous 
ulcers: results of introducing a titration protocol into 
clinical practice 
 
9.1 Introduction 
Cutaneous ulcers are a heterogeneous problem that can vary in aetiology, pathophysiology 
and chronicity (Maida et al. 2008). In many cases healing of these wounds is not possible and a 
palliative approach is required to help manage the multiplicity of problems associated with 
them. 
 
Palliative care is an approach to improve quality of life through impeccable assessment of 
symptoms within a holistic framework. Any given individual will have their own disease course, 
consequences and coping strategies, the only way to ensure appropriate and adequate 
management is to a adopt an individualised approach. This principle applies equally to 
pharmacological and non-pharmacological treatment modalities. 
 
Several pharmacological strategies may be appropriate for the management of pain in patients 
with cancer based on an assessment of the individual patient characteristics, co-morbidities, 
and other treatments that may influence drug absorption, pharmacokinetics, and 
pharmacodynamics. For example during the titration of background pain using opioids, 
supplemental doses of opioids are advised, the dose of which is based on the patient’s 
background dose (Hanks et al. 2001). However when background pain is controlled but 
patients experience breakthrough pain, the optimum dose of analgesic can be difficult to 
predict and therefore most safely determined by titration (Davies et al 2009; Caraceni et a. 
2012). Given the heterogeneity of cutaneous ulcers and the variability of the pain that they are 
associated with (Krasner 1995) the same principle of analgesic titration may apply to the use of 
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 topically applied opioids. 
 
There has been interest in the use of topically applied opioids to cutaneous wounds in our 
hospice. In addition to a few publications, one of the nursing staff undertook a review on the 
treatment of painful ulcers as part of her palliative care degree following which the clinical 
team agreed to introduce a clinical protocol for the management of ulcers in order that the 
problem was assessed and managed in a systematic manner. This management protocol was 
introduced into hospice clinical practice in May 2007 with the agreement of the hospice clinical 
governance committee and the in-patient unit manager. Central to this protocol was the 
titration of topically applied opioids (usually morphine) based on the patient’s assessment of 
ulcer pain and their decision as to whether or not a change in opioid dose was required.  
 
9.2 Aims of case note review 
The aim of this study was to review the titration protocol introduced into clinical practice in 
May 2007 to determine whether or not topical morphine application was effective, if so at 
what dose(s), whether there was relationship between the effective topical morphine dose 
and the patient’s background medication, and the length of time required for the patient to 
determine an effective dose of topical opioid. 
 
9.3 Methods 
A retrospective case note review of patients admitted between 1st April 2009 and 31st March 
2010 and assessed for topical opioid administration was undertaken. Hospice IT staff identified 
patients admitted in the study period using the hospice patient database (iCare), 
administrative staff identified the location of the clinical notes and I then retrieved and 
reviewed all the identified clinical notes in order to review and record the relevant data. 
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 The titration protocol introduced two years previously was standard nursing practice on the 
hospice inpatient unit and staff were trained when it was first introduced; new staff since May 
2007 were trained on the use of the protocol as part of their induction. In accordance with the 
titration protocol the painful ulcer was first assessed in terms of grade, surface area, aetiology, 
pain severity and suitability for a once daily dressing using IntraSite gel; the effectiveness of 
previous analgesia (if prescribed) for the ulcer was also documented [Figures 9.1 & 9.2].  
 
When the dressing change was due, the ulcer was first exposed by removing the previous 
dressing and then thoroughly cleaned with saline to remove any exudate, debris, slough or 
contaminants. Morphine mixed with IntraSite gel was applied directly to the wound, after 
which the ulcer was covered with a Tegaderm dressing. An aseptic non-touch technique was 
used throughout the procedure to prevent the introduction of potentially pathogenic micro-
organisms into the wound. Education, training and assessment in the aseptic technique are 
provided to all persons undertaking such procedures and the technique is standardised across 
the organisation. 
 
Following the initial assessment the protocol was initiated. The starting dose of morphine was 
5 mg; 10 mg was offered if the patient rated the pain as either severe or excruciating using a 
VRS. If during the titration process the morphine-IntraSite mixture became too fluid to be 
reliably retained in the wound, switching to diamorphine was considered, which as a powder 
could be dissolved in small volumes of normal saline. The starting dose of diamorphine was 
based on the previous dose for morphine assuming a relative potency of 1.5 (i.e. 45 mg 
morphine was equivalent to 30 mg diamorphine) based on recommended oral opioid 
conversion charts (Scottish Intercollegiate Guidelines Network 2008).  
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 Pain intensity was reviewed daily at the dressing change, when patients were asked to rate the 
pain from the ulcer in the last 24 hours since the last dressing change using a five point verbal 
rating scale (no pain, mild, moderate, severe or excruciating). Patients were then asked 
whether they wished the dose of analgesia to increase, decrease, or remain unchanged; 
increases or decreases were made in 5 to 10 mg steps depending on pain severity. Titration 
was deemed successful when patients no longer requested changes in their dose of morphine 
and the dose remained stable for at least two consecutive days.  
 
The data from the titration protocol clinical documentation sheet was entered onto a data 
collection form together with information from the patient’s medication chart to confirm the 
doses of morphine prescribed, and over what period of time. To minimise omissions all other 
sections of the clinical notes used during the admission by either nurses or doctors were 
reviewed to cross check the information obtained from both the wound assessment and the 
medication charts. Missing data were noted during the collation process and identified during 
the analyses. Data were entered on a Microsoft Excel database and means compared using 
parametric or non-parametric, as appropriate. In the statistical analysis p < 0.05 was deemed 
to be statistically significant.  
 
Formal ethical approval was not sought, however the case note review was agreed by the 
hospice clinical governance working group and the hospice Caldicott Guardian, a senior 
clinician within the Hospice responsible for protecting the confidentiality of patient and 
service-user information and enabling appropriate information-sharing (Department of Health 
2010).  
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 Figure 9.1 Topical opioid treatment protocol: front sheet with instructions for clinical staff when 
considering topical opioid treatment for painful cutaneous ulcers 
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 Figure 9.2 Topical opioid treatment protocol: clinical documentation sheet to record ulcer 
characteristics, pain severity, analgesia effectiveness and whether patient chooses to change opioid 
dose 
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 9.4 Results 
During the survey period 175 patients were admitted to the hospice, the average age (range) 
age was 70.3 years (28-97) and 89 (51%) were female. The notes of all patients were reviewed 
and there were no missing data. Of the 175 patients admitted, 55 patients (32%) had painful 
ulcers and were considered by the clinical staff for topical opioid analgesia; 21 of the 55 
patients (38%) were excluded from the protocol because of having either necrotic ulcers (15) 
or infection (6). The remaining 34 patients participated in the protocol; 20 (59%) were male 
[Table 9.1], the average age  (range) of patients enrolled was 69 years (38-89). Seven patients 
withdrew during the titration protocol because of deterioration (3 patients), confusion (3) or 
pain worsening (1). Of the 27 evaluable patients 14 (52%) were male and their average age 
(range) was 69 years (38-89) [Table 9.2]. All but one ulcer was of benign aetiology and the 
mean (± SD) surface area was 13 (9) cm2. All but four patients were taking opioid analgesia; 
the average (± SD) morphine equivalent daily dose was 121 (179) mg. 
 
All patients reported that they experienced background pain from their cutaneous ulcers that 
was mild (2 ulcers), moderate (11), severe (9) or excruciating (5). Seventeen ulcers had 
transient exacerbations of pain that were described as severe (6) or excruciating (11) and 
usually brought about by movement (12), friction (8), dressing change (7) or a combination of 
these factors 
 
Six patients (22%) reported that they had been prescribed analgesics specifically for the pain 
caused by the cutaneous ulcer, namely morphine (3 patients), paracetamol (3), oxycodone (2), 
NSAIDs (2) all on ‘as required basis’; three patients were prescribed two analgesics. Patients 
reported the effectiveness of their analgesia as completely effective (1 patient), partially 
effective (4) and ineffective (2). 
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 Table 9.2 Changes on pre and post titration morphine dose  
Patient Starting dose (mg) Final dose (mg) Days to final dose Days at final dose 
1 5 15 3 5 
2 5 10 2 5 
3 5 10 2 4 
4 5 10 2 3 
5 5 5 Withdrawn  
6 5 15 3 6 
7 10 10 1 9 
8 5 10 2 4 
9 10 10 Withdrawn  
10 5 5 1 16 
11 5 25 29 12 
12 5 10 2 19 
13 5 5 1 6 
14 5 10 2 12 
15 5 10 2 6 
16 5 5 Withdrawn  
17 5 10 3 14 
18 5 5 Withdrawn  
19 10 20 11 12 
20 5 15 3 4 
21 5 5 Withdrawn  
22 10 10 1 8 
23 5 10 2 8 
24 5 10 Withdrawn  
25 5 5 1 7 
26 10 10 1 4 
27 5 10 2 13 
28 5 20 4 6 
29 5 20 6 11 
30 5 5 1 4 
31 5 10 2 5 
32 5 10 Withdrawn  
33 10 60 14 8 
34 5 15 3 5 
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 Patients who had determined an effective dose of topical morphine were titrated for a 
median (mean ± SD) of 9 (11 ± 8) days (range 4-40). All but one patient were titrated solely 
with topical morphine; patient 33 was switched to diamorphine during the titration as the 
gel become too fluid. The median (mean ± SD) successful morphine equivalent dose 
achieved through titration was 10 mg (12.2 ± 9.8) range 5-60 mg [Figure 9.3] and the median 
(mean ± SD) time to titration was 2 days (4 ± 5.9). If the three patients with the longest 
titration periods are removed (for reasons see later) the median (mean ± SD) successful 
morphine dose achieved through titration was 10 mg (10 ± 4.1) and the time to titration was 
2 days (2.2 ± 1.2). There was no simple relationship between the successfully titrated dose of 
topical morphine and the dose of background opioid, (correlation coefficient r = -0.07, t = 
0.35, p > 0.05), [Figure 9.4]. 
 
Following titration, efficacy was rated as partial in 14 patients and complete in 13 patients. 
Topically applied morphine appeared to have a beneficial effect on both background and 
transitory pain. Converting the VRS to a five point NRS where 0 = no pain and 4 = 
excruciating pain, the median (mean ± SD) pre-treatment background pain was 3 (2.6 ± 0.8) 
compared to 0 (0.4 ± 0.6) post treatment (Wilcoxon signed rank test p < 0.01). Of the 17 
patients experiencing transitory pain the median (mean ± SD) pre and post-treatment pain 
scores were 4 (3.7 ± 0.5) and 1 (1.2 ± 0.8) respectively (p < 0.01) [Figure 9.5]. Three patients 
no longer reported transitory pain, 14 reported improvements in the frequency of episodes 
(3 patients), pain severity (5) or both (6). 
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 Figure 9.3 Review of clinical protocol for the titration of topically applied opioids: Morphine doses 
that patients deemed successful 
 
 
Figure 9.4 Review of clinical protocol for the titration of topically applied opioids: 
between successfully titrated topical morphine dose and patients’ regularly scheduled opioid 
analgesia (r = -0.07, p > 0.05)
 
 
 
D
a
y
s
 a
t 
e
a
c
h
 d
o
s
e
 
  
Successful topical morphine dose (mg)
 
Relationship 
 
 
164 
 Figure 9.5 Review of clinical protocol for the titration of topically applied opioids: Pre and post 
titration pain mean NRS (± SD)
Three patients (11%) had a more protracted titration period [Figure 9.6] wh
compared to the other patients did not appear to be related to ulcer aetiology, pain severity, 
background analgesia or ulcer surface area. Patient 11 was initially titrated to morphine 15 
mg and remained at this dose for over two weeks before furt
morphine 20 mg for eight days and then finally 25 mg for 12 days. Patients 19 showed a 
similar pattern at first morphine 15 mg and then morphine 20 mg. Patient 33 also appeared 
to require increases after a few days at each do
60 mg effective for eight days after which time he was discharged home. These patients may 
have exhibited tolerance to the topically applied opioid dose although the changes may have 
been as a resulting in incr
 
 
 
 for background and transient pains. (*p < 0.05)
her increases were required to 
se, before finding the equivalent of morphine 
eased ulcer pain and requiring additional analgesia.
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 Figure 9.6 Review of clinical protocol for the titration of topically applied opioids: Morphine doses 
for patients requiring the longest titration periods
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 Topically applied opioids appeared to be well tolerated in this patient group. Pruritus was 
reported in five (19%) patients and burning in three (11%). No systemic adverse effects were 
documented although most patients were on regular opioid analgesia [Table 9.1] that would 
have made specific contribution of topical opioids to any systemic adverse effect difficult to 
determine. 
 
9.5 Discussion 
Successful management of pain requires a comprehensive assessment, good 
communication, education and reassurance of the patient and family, and efforts to 
encourage the participation of patients and caregivers in the treatment plan.  Integral to this 
plan is the appropriate use of medication that should be administered at the right time at 
the right dose and for the right patient. In the case of painful chronic wounds where the  
pathophysiological processes are variable between one patient and another and within the 
same patient over time, titration of analgesia against an ongoing assessment offers a 
relatively safe, highly individualised and systematic approach of achieving appropriate 
management. 
 
Most patients in this review were able to find a successful dose of opioid that was 
efficacious and well tolerated. Furthermore the dose was reached within a relatively short 
time. Although some patients appeared to have more variable requirements through a 
process of re-assessment and ongoing titration they too were able to determine a dose that 
suited them. 
 
One of the features of wound pain is its variability and three types have been described: 
cyclic (periodic discomfort), non cyclic (single incident) and chronic (persistent discomfort) 
(Krasner 1995). The opioid-IntraSite mixture appeared to be effective for both persistent (or 
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 background) and periodic (or transient) discomfort with patients reporting significant falls in 
pain scores for both pain types. The duration of analgesia provided by the topical 
administration of opioids appeared to last the 24 hours between dressing changes, which 
has been reported elsewhere (Krajnik et al. 1999).  It is possible that some patients may 
have managed with less frequent dressing changes. A possible way of testing this would be 
to apply the two treatments and measure the “time to exit” for each, a method applied 
elsewhere (Galer et al. 1999) If analgesia does last for several days, this would increase the 
attractiveness of this treatment option, as provided the reduced frequency was appropriate 
for the nature of the wound, it would be more convenient for the patient and help reduce 
nurse workload. 
 
There did not appear to be a simple relationship between the effective dose of topically 
applied opioids and the patients around the clock medication. A similar finding has been 
found in other pain states including cancer breakthrough pain (Zeppetella & Ribeiro 2006; 
Zeppetella 2011).The ability to predict the appropriate dose would make this a more 
convenient treatment method as patients could be started on pre-determined effective 
dose. Despite this, most patients were controlled with 10 mg morphine applied daily which 
suggests that this is a reasonable starting dose that can, following reassessment, be 
decreased to 5 mg if adverse effects are experiecned, or increased in a step-wise fashion as  
required until successful analgesia is achieved.  
 
In the UK morphine is available as a solution. In most patients 10 mg morphine doses 
contained within a 1 mL ampoule were used. If higher doses are required the increase in 
volume can make the mixture more difficult to retain within the wound and contained by 
the dressing, although morphine is also available in 1 mL ampoules at concentrations of 15, 
20 and 30 mg/mL allowing for some flexibility of dosing. Diamorphine, which is available as 
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 an anhydrous powder, is much more soluble than morphine and was therefore used for 
patient 33 who required higher doses of opioid. Diamorphine degrades first to 6-MAM, and 
then to morphine and although an equivalence ratio of 1.5 was assumed (Scottish 
Intercollegiate Guidelines Network 2008), there are not data to support this. Moreover the 
potency ratios of oral opioids can be variable and depend on both patient and pain related 
factors (Mercadante & Portenoy 2001). Hence for patient 33 a morphine equivalent dose of 
60mg is assumed but it may have been either lower or higher. The benefit of a titration 
process informed by re-assessment allows for a flexibility of dosing that is responsive to the 
patient’s needs. 
 
The combination of morphine and IntraSite gel is an unlicensed use of a controlled drug. 
There has been recent concern regarding whether nurses are authorised to prescribe 
unlicensed medicines, which could be a barrier to the use of morphine mixed and IntraSite 
gel for painful ulcers. Following clarification by the Medicines and Healthcare products 
Regulatory Agency (MHRA), it was confirmed that mixing two licensed medicines, where one 
is not a vehicle for administration of the other, falls within the definition of manufacture and 
results in a new, unlicensed product being administered (Medicines and Healthcare products 
Regulatory Agency 2008). The person undertaking this preparation, unless an exemption 
applies, must hold a manufacturer’s licence, although the MHRA recognise that palliative 
care requires special consideration (Medicines and Healthcare products Regulatory Agency 
2009). In the case of morphine and IntraSite gel, the gel is a vehicle for administration and 
the mixture, therefore, is not considered a new, unlicensed product and can be prepared by 
nursing staff when required without seeking a manufacturer’s licence. 
 
Storage of the mixture will be required in accordance with the statutory regulations. 
Schedule 2 drugs such as morphine should be kept in a locked cabinet that should conform 
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 to British Standards and be attached to the fabric of the building. The specifications with 
which safes, cabinets and rooms must comply are given in detail in the Misuse of Drugs 
Regulations 2001. 
 
Limitations of this survey are similar to the case review described in Chapter 4 and although 
the review has the advantage of being practical, feasible to plan, inexpensive, and uses 
existing records, it relies on the accuracy of written records or recall of individuals and bias is 
difficult to control as there was no blinding or randomisation, which has been done in the 
titration process of other pain states (Portenoy et al. 1999). Furthermore although three 
patients had a lengthy titration process it is not possible to draw conclusion on opioid 
tolerance, immune suppression or effect (either positive or negative) on healing and how 
the ulcer had changed over time. Patients were selected for this treatment method if the 
wound was appropriately managed with IntraSite gel and although a positive effect was 
found, it is not possible to extrapolate these finding to necrotic or infected ulcers where the 
use of IntraSite is not indicated. 
 
9.6 Summary 
Most hospice in-patients with painful cutaneous ulcers were successfully and safely titrated 
to a successful dose of topically applied morphine-IntraSite mixture  using a clincial titration 
protocol. Morphine-IntraSite mixture  appeared to be effective in most patients, the 
effective dose low (usually 5-10 mg), unrelated to the backgound opioid dose and was 
usually determined within two days of starting titration. 
170 
 Chapter 10: Discussion 
Painful cutaneous ulcers are a heterogeneous group of wounds that represent a significant 
burden to patients, a clinical challenge for health care professionals and a threat to the 
health-care economy and resources. Venous ulcers, for example, may be as a result of 
longstanding venous hypertension leading to hypoxia in areas of venous congestion in the 
lower extremities, diabetic ulcers occur as a result of neuropathic impairment of 
musculoskeletal balance as well as immune compromise from leukocyte dysfunction and 
peripheral vascular disease, pressure ulcers from pressure induced tissue necrosis over a 
bony prominences, and malignant ulcers arise from primary or secondary cancerous 
growths. Common to all of these processes is a prolonged inflammatory state comprising a 
continuous physiological process involving a number of chemical mediators. One of the 
processes is the migration of opioid receptors to the peripheral nerve endings and has 
provided the rationale for the direct application of opioid to the wound in the same way the 
body releases endogenous opioid via the immune system. 
 
There are a number of advantages to the application of topical opioids. For example, they 
are inexpensive, appear safe, provide localised analgesia, may be systemic, oral or parenteral 
opioid sparing, give the patient control, and there is little, if any, potential for abuse and 
addiction (Tennant 2010).  Questions however remain to be answered including: 
• What are the most efficacious opioid and at what dosages?  
• What are the most advantageous carrier and method of application?  
• Which pain types are most amenable to topical opioid therapy?  
• What degree and duration of analgesic effects might be expected?  
• In which circumstances could topical opioids completely replace the need for systemic 
opioids or other analgesics?  
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• What is the potential, if any, for developing tolerance or hyperalgesia during prolonged 
use of topical opioids?  
A Cochrane review is currently being planned to provide an overview of the analgesic 
efficacy and associated adverse events of topical analgesics (including opioids) for the 
treatment of acute and chronic pain in adults (Moore et al. 2010) and may be helpful in 
answering some of these questions. 
 
The results of the studies reported in this thesis are limited to the methods employed in 
each study. For example the efficacy studies cannot be applied to necrotic and infected 
ulcers, as these ulcers were excluded from the study, nor the use of carriers other than 
IntraSite gel. Furthermore the physical and microbiological stability studies do not offer 
information on of the same opioid prepared using different methods or for longer periods of 
time. Nonetheless the results do provide some support in the palliative care setting for the 
utility of topically applied morphine for painful pressure ulcers that are neither necrotic nor 
infected and suitable for treatment with IntraSite gel, and therefore does not support the 
null hypothesis set out at the beginning of this thesis (see Chapter 3). The results also 
support the possibility of the opioids having a local action and the practical application of 
preparing morphine IntraSite gel mixtures in advance rather than just prior to the dressing. 
 
Some aspects of the thesis were more challenging than others. The biochemical 
bioavailability and stability studies and the microbiological stability studies were relatively 
straight forward. Generally recognised methods were employed based on previous work and 
the results, I feel, stand up well to other work in the literature within the limitations of the 
methods employed, e.g. dose drug.  Other aspects of the thesis that were limited by the 
challenges of undertaking clinical trials in a frail population with multiple co-morbidities, in 
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 particular the efficacy study, which was terminated early because I moved from St Joseph’s, 
where the study was carried out, to St Clare Hospice. The ITT efficacy data suggest that there 
was a carryover effect of morphine through to the washout period whereas the PP 
population did not Furthermore although separate analysis of the pre-washout morphine 
and placebo arms compared to baseline was strongly significant in favour of morphine this 
should be taken with caution as the lower number of observations reduced the power of the 
study. A higher number of patients and a longer washout period may have helped clarify 
some of the findings. I have attempted o repeat the randomised double blind study in a 
larger population collaborating with other palliative care units in both the UK and abroad, 
and working with the Herts and Essex Comprehensive Local Research Network (CLRN), but 
have been unable to do so. The most promising option was the dermatology speciality at the 
CLRN and given the opportunity I would wish to explore this further in the future. 
 
The effective dose of morphine in IntraSite gel requires further investigation and although 
most patients appeared to respond to low doses, this was determined using a retrospective 
chart review method that has certain limitations. Ideally a prospective randomised double 
blind study would give more information. All patients could be randomly assigned to begin 
treatment with either 5 or 10mg morphine in IntraSite gel daily both preparations being 
identical in appearance and both the patient and the investigator blind to this starting dose. 
The dose of morphine would then be increased or decreased on successive days in 5mg 
steps; the 5mg starting dose could be reduced to 2.5mg. The decision to titrate or maintain 
the dose for another day was made following the assessment that evaluated response to the 
morphine/IntraSite mixture with the patient Some titration trials have built in a separate 
randomisation to include an ‘ignore request’, i.e. a certain number of requests to increase 
the dose are ignored and unbeknown to patient and investigator the dose remains 
unchanged (Portenoy et al. 1999). This second randomisation and blinding procedure, 
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 together with the double-blind random assignment to a starting dose, reduces the likelihood 
that the patient or investigator would know either the dose or whether it represented a true 
increase. The titration process continues until the patient finds a successful dose or is 
deemed to be a non-responder. I feel such a trial would help clarify the issue of the most 
effective dose. 
 
It is assumed that opioids exert their effect by activating peripheral opioid receptors to 
produce analgesia by inhibiting the excitability of sensory nerves, the release of excitatory 
neuropeptides, or both. Because these effects occur in the periphery, they are devoid of 
central opioid side effects, such as respiratory depression, sedation, or dysphoria (Machelska 
& Stein 2002). Opioids produce analgesia by increase potassium and decrease calcium 
currents through interactions with G-proteins in the CNS (Law et al. 2000) and inhibiting 
calcium currents in the dorsal root ganglion (Atkins & McCleskey 1993). However other 
mechanisms of action could be implicated in peripheral analgesia and contribute to the 
results seen in the efficacy studies and our on-going clinical practice.  
 
Methadone, for example, has been shown to have weak NMDA receptor antagonistic activity 
(Chizh et al 2000; Callaghan et al. 2004)) that may account for some of its effectiveness in 
neuropathic pain states and contribute to the improvement seen in opioid induced 
hyperalgesia resulting from opioid switching. Peripherally the NMDA system may interact 
with other systems including adenosine, which is released locally at sites of cellular trauma, 
and acts on specific cell-surface purinergic receptors (termed P1 receptors) near its site of 
release to exert its effects (Kowaluk 1998). 
 
Morphine and other opioids have been shown to modulate immune responses by central 
and peripheral mechanisms; opioids share many properties of cytokines, the principal 
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 mediators of the immune function. While exogenous opioids mediate immunosuppression, 
endogenous opiates exert opposite actions; acute and chronic opioid administration is 
known to have inhibitory effects on humoral and cellular immune responses including 
antibody production, natural killer cell activity, cytokine expression, and phagocytic activity 
(Vallejo et al. 2004). One of the possible mechanisms is through hypothalamic-pituitary-
adrenal axis leading to increased glucocorticoid production (Zhang et al. 2011) that in turn 
could have an analgesic effect.  
 
Finally opioids have been shown to induce oxidative stress resulting in generation of free 
radicals and lipid peroxidation (Zhou et al. 2000), which may be an important where 
expression of growth factors and new vessel growth can be initiated via inflammatory 
reactions or oxidative metabolites. Morphine has been shown in vitro to have antioxidant 
activity (Gülçın et al. 2004), which could interfere with the oxidation process during 
inflammation by reacting with free radicals, chelating, catalytic metals, and also by acting as 
oxygen scavengers. 
 
The pathophysiology of peripheral injury and inflammation is complex and includes the 
release of numerous chemical mediators including K+, H+, bradykinin, substance P, 
prostanoids, and cytokines, in addition to the expression of opioids receptors peripherally. It 
is unlikely that these systems work in isolation and our understanding of the inflammatory 
processes are limited by the lack of data rather than the potential of the human body. With 
respect to the opioids receptor contribution to the inflammatory processes, it may be 
possible to explore this further by determining whether topical analgesia can be reversed by 
the application of naloxone as has been demonstrated with intra-articular opioids 
 
 
175 
  
Treatment options often fall in and out of favour, and over the last 25 years I have been 
involved in some that have done just that. For example, since I published the initial case 
series reports of nasal and buccal fentanyl for the management of breakthrough pain 
(Zeppetella 2000; Zeppetella 2001), the use of transmucosal fentanyl has turned into a major 
therapeutic area where a number of products exist. On the other hand, the use of nebulised 
morphine for the management of breathlessness (Zeppetella 1997) has failed to show a 
consistent benefit and is a treatment I no longer use. My view on the topical application of 
morphine has evolved over the last ten years. Clearly painful ulcers are difficult to treat, the 
cause of the pain is multifactorial and dynamic and the treatment should be multimodal. 
Non-pharmacological treatments (e.g. special mattresses) should be tried, reversible causes 
(e.g. infection) addressed and adequate analgesia should be prescribed. But in some patients 
who have tried and not benefitted from these measures and continue to experience 
inadequate analgesia or have troublesome adverse effects and the wound is suitable for 
IntraSite dressing, topical application of morphine, as described in this thesis, can be offered.  
 
At the start of this process I was unsure about the utility of topical opioids for painful 
cutaneous ulcers in our hospice patients, but now, under the right clinical circumstances and 
whilst we await the publication of further evidence, I would have no hesitation in offering 
this treatment option to them. 
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 Chapter 11: Conclusions 
1. Cutaneous ulcers were found to be common in a patients admitted to a hospice. Most 
were as a result of pressure and the majority were painful. Patients were seldom 
prescribed analgesia specifically for the pain resulting from cutaneous ulcers. 
 
2. The evidence from a systematic review of the literature was that the efficacy of topical 
opioids was largely based on case reports; controlled studies are few and results limited 
by small patient numbers. In published reports the opioids applied topically appeared to 
be well tolerated with little or no local or systemic adverse effects reported.  
 
3. Small randomised controlled studies of hospice in-patients with painful cutaneous ulcers 
suggested that morphine applied topically was an effective method of producing local 
analgesia, was well tolerated by patients, and was not associated with systemic adverse 
effects. A review of a titration treatment protocol that had previously been introduced 
into clinical practice suggested that most patients with painful cutaneous ulcers 
responded to low doses of topically applied morphine and that there was no simple 
relationship between the effective dose of topically administered morphine and the 
dose of regularly scheduled systemic analgesia. 
 
4. When applied topically to cutaneous ulcers, morphine was not absorbed in the majority 
of patients, suggesting any analgesic effect was mediated locally rather than 
systemically. However, in ulcers with a large surface area, systemic absorption may 
occur, however unlikely to result in excessive systemic adverse effects given the 
relatively small daily dose of morphine applied topically and the fact that most patients 
with advanced disease are also likely to be on oral opioids. 
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5. Stability studies indicate that morphine/IntraSite and hydromorphone/IntraSite gel 
mixtures are stable for up to 28 days irrespective of the temperature and whether or not 
samples were exposed to light. Diamorphine/IntraSite gel mixture breaks down to 6-
MAM, then morphine and no other degradation products are measurable. 
Oxycodone/IntraSite gel mixture show variability in all gels until day eight after which 
time concentration of the samples was more stable; no known degradation products are 
measurable. Morphine/IntraSite mixture was shown to be microbiological stable for up 
to 28 days if stored in the fridge or at room temperature in the dark. 
 
6. It is not possible to draw conclusions about the type, grade, and area of malignant or 
non-malignant ulcer that responds best to topical opioid application. Therefore larger 
prospective, randomised studies are recommended to determine which ulcers respond 
best to the treatments. Furthermore the effects of topically applied opioids on immune 
suppression, tolerance and wound healing require further exploration. 
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 Chapter 12: Summary of recommendations for the 
management of painful cutaneous ulcers with topically 
applied morphine 
 
12.1 Introduction 
The WHO ladder provides a simple framework for the pharmacological management of 
cancer pain using a logical stepwise approach. The aim is prevent background pain and 
relieve breakthrough pain by selecting the appropriate analgesic drug, dose and 
administration route. It is an individualised approach where the patient is titrated to the 
optimum dose that delivers maximum benefit and tolerable adverse effects. When adverse 
effects become problematic a switch of administration route may be considered; one 
potential clinical challenge when this occurs is in the management of painful cutaneous 
ulcers. 
 
Topical opioids may be considered for the management of painful cutaneous ulcers (e.g. 
open pressure sores, malignant ulcers, and fungating tumours) in palliative patients where 
opioids by other routes have proved ineffective or limited by adverse effects. The work 
presented provides evidence predominantly for this approach in the management of painful 
pressure ulcers. A systematic approach is recommended where through a sequence of sets 
the patient’s management is individualised [Figure 11.1]. 
 
12.2 Assessment 
The mainstay of pain assessment is the patient self-report; however, family caregivers are 
often used as proxies for patient reports, especially in situations in which communication 
barriers exist, such as cognitive impairment or language difficulties. A variety of tools have 
been designed to assess pain in cancer e.g. the Brief Pain Inventory (Cleeland 1984), the goal 
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 of which is to characterize the pain and determine its impact on the patient.  Assessment 
follows the usual clinical model of history, examination and relevant investigations and 
should consider the physical effects/manifestations of pain, the functional effects  
(interference with activities of daily living), the psychosocial factors (level of anxiety, mood, 
cultural influences, fears, effects on interpersonal relationships, factors affecting pain 
tolerance and the spiritual aspects. 
 
12.3 Assess for and minimise risk factors 
A number of factors may impair the healing response resulting in chronic wounds including 
local infection, hypoxia, trauma, foreign bodies, or systemic problems such as diabetes 
mellitus, malnutrition, immunodeficiency, or medications. In some cases it may be possible 
to address these specifically, in others, such as malignant wounds, the goal is palliation. 
 
12.4 Indications of topical morphine 
Painful cutaneous ulcers in palliative care patients where opioids or other analgesics by 
alternative routes have proved ineffective or have been limited by adverse effects. 
 
12.5 Preparation of topical morphine/IntraSite mixture 
Sterile technique is recommended and two methods are suggested 
1. Using a sterile needle and syringe withdraw 10 mg morphine from an ampoule and 
inject into an 8 g IntraSite gel capsule. Shake well for three minutes. Label capsule 
morphine/IntraSite gel mixture 0.125%. Use as soon as practical and discard any 
remaining mixture immediately after use. Alternatively store in a dry cool place in 
accordance with the organisation’s Medicine Management policies and procedure for 
controlled drugs. 
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 2. Squeeze the contents of an IntraSite gel capsule into a clean container and add 10 mg 
morphine (10 mg/mL). Mix thoroughly for three minutes. Label container 
morphine/IntraSite gel mixture 0.125% and use as soon as practical as no 
microbiological stability data exist. Discard any remaining mixture immediately after use. 
 
12.6 Storage 
If prepared on ward or in the patient’s home use as soon as practical. If the mixture is 
prepared using method 1, it can be stored in the fridge for up to 28 days (Chapter 8). The 
mixture contains a controlled drug and should be handled in accordance with the relevant 
policies and procedures. 
 
When considering topical opioid administration use morphine sulphate injection  
Initially apply morphine 0.125% gel (10 mg/mL morphine sulphate in 8 g IntraSite gel) to the 
wound once daily. This can be increased to twice or three times daily depending on 
response; IntraSite gel should be washed off the wound before reapplying the next dose.  At 
doses greater than 30 mg morphine to avoid an excessively fluid mixture switch to a more 
concentrated morphine preparation. Topical opioids should not be applied to wounds with 
excessive exudates or bleeding because the gel will not adhere to the wound surface. It is 
not recommended in patients under the age of 18 because of the lack of data and in patients 
with a known hypersensitivity to opioids or IntraSite gel. If in doubt seek advice from 
pharmacy, pain, palliative care or tissue viability teams. 
 
12.7 Titrate topically administered morphine starting from 10mg in 5mg steps  
Given the heterogeneity of ulcers a titration process is recommended that is based on a 
regular reassessment at the dressing change where the opioid dose may be either increased 
or decreased. Where pain is well controlled for most of the day but pain consistently returns 
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 prior to the dressing change despite an increase in opioids, increasing the frequency of 
administration to twice or three times daily should be considered. 
 
12.8 Reassessment 
Patients should be re-assessed regularly to determine the efficacy and tolerability of the 
management strategies; inadequate re-assessment may lead to continuance of ineffective 
and inappropriate treatment. If titration fails to identify a successful dose or if adverse 
effects become problematic, treatment should be discontinued. Local adverse effects have 
been reported including pruritus, burning and discomfort. Few systemic adverse effects have 
been reported in the literature; however the potential exists for systemic absorption, 
especially treating ulcers with large surface areas. 
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 Figure 11.1 Algorithm for the topical application of morphine for the management of painful 
cutaneous ulcers  
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 15.1.  Oxford Quality Score
 
 
Source: http://www.medicine.ox.ac.uk/bandolier/Extraforbando/QVS.pdf
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 15.2: Levels of Evidence: Key to evidence statements used by the Scottish Intercollegiate 
Guidelines Network 2008 
 
Level Example 
1++ High quality meta-analyses, systematic reviews of RCTs, or RCTs with a very 
low risk of bias 
1+ Well conducted meta-analyses, systematic reviews, or RCTs with a low risk 
of bias 
1 Meta-analyses, systematic reviews, or RCTs with a high risk of bias 
 
2++ High quality systematic reviews of case control or cohort studies 
High quality case control or cohort studies with a very low risk of 
confounding or bias and a high probability that the relationship is causal 
2+ Well conducted case control or cohort studies with a low risk of confounding 
or bias and a moderate probability that the relationship is causal 
2 Case control or cohort studies with a high risk of confounding or bias and a 
significant risk that the relationship is not causal 
3 Non-analytic studies, e.g. case reports, case series 
4 Expert opinion 
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15.3 Waterlow Score Card 
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15.4 Classification of Eastern Co-operative Oncology Group Performance Status 
 
Score Performance 
0 Fully active, able to carry on all activities without restriction 
1 Restricted in physically strenuous activity but ambulatory and able to carry out 
work of a light and sedentary nature 
2 Ambulatory and capable of all self care; confined to bed or chair 50% of waking 
hours 
3 Capable of only limited self-care; confined to bed or chair 50% or more of waking 
hours 
4 Completely disabled; cannot carry on any self care; totally confined to bed or chair 
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 15.6 Pilot efficacy study: Trial diary of patient number three 
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 15.7 RCT: Trial diary of patient number one 
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